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Abstract 
Both HBV and HIV are hyperendemic in sub-Saharan Africa, and there is a 
correspondingly high incidence of hepatocellular carcinoma (HCC) in this region, 
contributing to a high burden of disease. In regions where HBV genotypes B and C 
prevail, a strong relationship exists between the rapid and more likely development of 
HCC and infection with HBV containing deletions in the preS region. Similar preS 
deletion mutants have been detected in southern African and Indian HCC patients 
infected with subgenotype A1.  Disturbingly in a cohort study conducted in Mpumalanga, 
South Africa by our team, equivalent deletion-mutants were detected in 5 treatment-
naïve HBV-HIV coinfected patients. Thus, the aim of this study was to characterize the 
quasispecies of HBV in these patients and to construct plasmids containing preS 
deletion-mutants in a subgenotype A1 backbone, in order to functionally characterize 
them in vitro.  Such studies may determine how these preS deletions contribute to the 
working model of hepatocarcinogenesis and explain the high hepatocarcinogenic 
potential of subgenotype A1.  
The quasispecies populations of HBV deletion mutants isolated from four HIV-positive 
patients were analysed phylogenetically, using both Neighbor-Joining and Bayesian 
methods. It was found that the preS deletion mutants represented the majority 
population, as 70% or more of clones in each of the four patients were sequentially 
highly similar to the respective parental strains. In addition to the major populations in 
each patient, minor populations were identified in the quasispecies.   
The overlength subgenotype A1 wild-type replication competent plasmid, was 
successfully altered to remove an unwanted XbaI site. This altered construct served as a 
positive control to test whether the removal of this restriction site would affect 
replication and viral protein expression of this construct compared to the original 
plasmid. This plasmid was then successfully used as the backbone to construct three 
overlength deletion mutant constructs.  Using a new strategy a 784 bp fragment flanking 
preS deletions from each of 4 patients, was inserted into the subgenotype A1 backbone.  
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Three fragments were derived from isolates with preS deletion mutants and one 
fragment, without the deletion, was isolated from a patient with occult HBV infection.   
The resulting plasmids together with the appropriate control plasmids were used to 
transfect Huh7 cells in culture.  Viral replication was followed at days 1, 3 and 5 using 
enzyme linked immunosorbent assay (ELISA) for hepatitis B surface antigen (HBsAg) and 
Hepatitis B e antigen (HBeAg). All deletion mutants were shown to express HBsAg and 
HBeAg at levels comparable to the controls, with the highest levels on day 3.   There 
were no significant differences in the expression of HBeAg in Huh7 transfected cells 
between the deletion-mutant constructs and the positive controls.  The HBV viral loads 
(VL) were measured at the same time points, using real-time quantitative PCR (qPCR). 
Both the extracellular (supernatant) and intracellular (lysate) compartment of the Huh7 
cells were tested. Furthermore, to clarify whether encapsidated virus was being secreted, 
an immunocapture technique on the supernatant was employed prior to DNA extraction 
and qPCR. In a similar manner to the ELISA experiments, qPCR measurement of VL 
showed that despite the replacement of the 784 bp fragment with a fragment containing 
deletion mutations, all constructs were producing detectable amounts of HBV DNA 
suggesting that viral replication was occurring. Analogous to the HBsAg results, the 
highest VL was seen in all constructs on day 3 post transfection in both the supernatant 
and lysate experiments.  Cell-associated (lysate compartment) VL was not particularly 
increased when compared to the VL measured in the supernatant, which does not 
indicate an inability to secrete the mature virions, nor an accumulation of viral DNA 
within the cell.  
Negligible HBsAg expression was observed on days 1, 3 and 5 following transfection 
with the overlength construct that contained the 784 bp fragment derived from a patient 
with occult HBV infection.  The VL following transfection with this construct was higher 
than both positive controls at all three time points, in both the supernatant and lysate 
compartment. This is again consistent with the clinical characteristics of the patient, 
which also had high viral loads. This finding is novel, since the in vitro experiments 
mimicked the phenotype of occult infection seen in the patient in vivo.   
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As far as we are aware, we are the first group to have constructed plasmids with deletion 
mutants and an occult mutant in a subgenotype A1 backbone and to show that they 
express viral proteins and viral DNA following transfection into HuH7 cells.  These 
constructs will be important resource for further research into the high 
hepatocarcinogenic potential of subgenotype A1. 
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1 Chapter One: Introduction 
 
Hepatitis B Virus (HBV), the smallest DNA virus known to infect humans, has successfully 
infected a third of the world’s population [1-3]. This literature review will attempt to look 
at the classification, structure and molecular biology of this virus; how this virus impacts 
its human host; and what happens when the genome of the virus is altered by naturally 
occurring deletions. Finally, the rationale for the study will be presented.  
 2 
1.1  The Hepatitis B Virus: Let’s Get to Know Each Other 
 
1.1.1 Classification: What’s in a Name? 
While the virologist V. R. Racaniello neatly summarises that all viruses are “obligate 
intracellular parasites”, and this describes the nature of viruses perfectly, it does not 
give us enough resolution when we are looking at one particular virus [4]. The 
classification of viruses is often confusing or contradictory; one of the reasons for this 
is the difficulty in defining what a virus is. Most leaders in the field of virology seem to 
be satisfied with defining viruses as non-living entities, falling within a certain parameter 
of size that have some of the characteristics of living organisms [4]. However, this 
definition is complicated because it suggests that viruses are then not organisms or 
microbes (as they are not living), and they cannot all be called pathogens, as they do 
not always cause illness or disease [4]. Therefore, we should consider other important 
factors such as which hosts or species the virus infects and affects, which system or 
organ (if any) is targeted by the virus, the viral morphology, and the organisation of the 
viral genome [4]. Nassal et al., (2005) neatly summarised “the fundamental properties of 
a functional virus are the ability to replicate the genome, to form infectious virions, and 
to cope with the host defense in order to establish and maintain infection; a virus 
meeting all these criteria is biologically fit” [5].  
Another source of confusion is that there are a few different systems of classification 
for viruses [4]. The classical system, which is still in use today for the classification of 
animal viruses, is the Linnaean Hierarchical System. The Hierarchy consists of phylum, 
class, order, family, genus and finally species. This system also takes into account the 
kind of nucleic acid present, the symmetry of the capsid or protein shell as well as its 
dimensions and finally the presence or absence of a lipid membrane or envelope [4]. It 
is still the primary system used by the International Committee on Taxonomy of Viruses 
(ICTV), which was established in 1966 and released its latest Virus Taxonomy report in 
2011 [4, 6]. Classification by Genome Type is the second most commonly used system. 
Here viruses are known by their classical term as well as being grouped into one of 
seven genome types that represent all the virus families [4, 6]. Thirdly, the most modern 
system of classification is the Baltimore System. Here viruses are described by the 
relationship of the viral genome to its messenger Ribonucleic Acid (mRNA). Thus the 
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Baltimore System take into account the Francis and Crick central dogma of the flow of 
nucleic acid to protein synthesis in the traditional sense of DNA transcribed into RNA 
and then translated into protein [4]. Table 1.1 summarises the three classification 
systems and illustrates where HBV fits in.  
 
Table 1.1: Virus Classification Systems Summary as Related to HBV 
Viral Classification Systems and Hepatitis B Virus 
 General Hepatitis B Virus 
Li
nn
ae
an
 H
ie
ra
rc
hy
 
Classical system of viral taxonomy by 
assigning a hierarchy based on: 
1. Nature of nucleic acid 
2. Symmetry of Protein Shell 
3. The presence of a lipid envelope 
4. The measurements and symmetry of 
the viral capsid 
 
 
Order - Not assigned 
Family - Hepadnaviridae 
Genus - Orthohepadnavirus 
Species - Hepatitis B Virus 
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 The table was constructed drawing on multiple references [4, 6-9]. 
 
 
Ge
no
m
e 
Ty
pe
 
The viral genome carries the entire blueprint 
of viral propagation and thus survival. All 22 
families of viruses are grouped into seven 
genome types: 
 
 
HBV falls into the seventh genome type as 
the virus has gapped double-stranded DNA, 
and the virus must replicate via an RNA 
intermediate.  
 
 
 
 
 
 
 
 
 
Ba
lti
m
or
e 
Cl
as
si
fic
at
io
n 
All viruses have to generate mRNA to be 
translated into proteins by host ribosomes in 
order to complete their life cycle. The 
pathways to generate these mRNAs are 
dictated by the viral genome type. This 
classification system points out the obligatory 
relationship between viral genomes and the 
mRNA it must produce. 
 
 
 
 
 
 
 
 
 
 
According to the Baltimore scheme, HBV has 
a partially double stranded DNA genome, 
that at one point uses reverse transcriptase 
to replicate this genome via an RNA 
intermediate, and is thus similar to 
retroviruses in animals and pararetroviruses 
in plants. 
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Therefore, when we refer to hepatitis B virus as the prototype of the family 
Hepadnaviridae, we mean that it is the most well-known and understood member of this 
family of viruses, or a model/exemplar of this family. The word Hepadnaviridae is 
constructed from Hepa, from classic Greek meaning liver, and dna referring to the type 
of nucleic acid [3]. In the Hepadnaviridae family, there are two major groups or genera, 
namely Orthohepadnaviridae, which infect mammals and Avihepadnaviridae, which infect 
birds [3, 9-12]. This classification is based on host specificity, similarities in organ 
tropism, ability to cause both acute and persistent infection as well as replication 
strategy. See Table 1.2 [3, 9, 13].  
Table 1.2: The Two Major Genera of the Hepadnaviridae Family 
Hepadnaviridae Family 
Orthohepadnaviruses 
(Infect mammals) 
Avihepadnaviruses 
(Infect birds) 
Human hepatitis B Virus (HBV)* Duck hepatitis B virus (DHBV)* 
Non-human primate HBV: Miscellaneous bird HBV: 
Parrot hepatitis B virus (PHBV) 
Heron hepatitis B virus (HHBV) 
Stork hepatitis B virus (STHBV) 
Crane hepatitis B virus (CHBV) 
Chimpanzee hepatitis B virus (ChHBV) 
Wooly monkey hepatitis B virus (WMHV) 
Gorilla hepatitis B virus (GHBV) 
Orang-utan hepatitis B virus (OuHV) 
Rodent HBV: Geese HBV: 
Snow goose hepatitis B virus (SGHBV) 
Ashy headed sheldgoose HBV (AGSHV) 
Ross goose hepatitis B virus (RGHBV) 
Woodchuck hepatitis virus (WHV) 
Arctic ground squirrel hepatitis B virus 
(AGSHBV) 
Tree shrew (Tupaia Belangeri) hepatitis B virus 
(TSHBV) 
Ground squirrel hepatitis B virus (GSHV) 
Bat HBV (BtHBV): 
New world bats hepatitis B virus (TBHBV) 
Old world bats hepatitis B virus (RB/HBHBV) 
This table was compiled by drawing on a number of literature resources [2, 3, 6, 8, 10, 14-17] to 
illustrate the host range of the Hepadnaviridae family of viruses. The prototype member of each 
genus is indicated with an asterisk (*) [17, 18]. While all Hepadnaviridae show very narrow host 
specificity, some genera have a narrower host range than others, for example; Woodchuck 
hepatitis virus (WHV) occurs naturally in Marmots, but cannot infect Ground Squirrels [3, 17]. Of 
note: Human HBV can experimentally infect Chimpanzees and Chacma Baboons, and only 
transiently infect primary hepatocytes of the Woodchuck, Duck and Tree Shrew [16, 18]. A stable 
animal model for infection includes transgenic animals such as severe combined 
immunodeficiency (SCID) mice, but only where their livers have been humanised [19]. Further, a 
putative third genus of hepadnaviruses, white sucker hepatitis B virus (WSHBV), was recently 
discovered in the genetic material of a White Sucker fish (Catostomus commersonii). This however, 
remains to be confirmed [20]. Endogenous integrated hepadnavirus DNA has also been detected 
in the Zebra finch (Taeniopygia guttata); these kinds of integrated HBV sequences found in host 
genomes are sometimes referred to as “fossilised” viral sequences as they can give clues to the 
origin and deep evolution of the virus [10, 21].  
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HBV has been shown to primarily infect liver cells. However, HBV has also been found in 
other tissues like lymphoid cells, such as bone marrow cells and peripheral blood 
mononuclear cells (PMBCs) as well as spleen and kidney cells [11]. While it has been 
shown that HBV has no disease development in those extrahepatic tissues, viral 
presence and a reservoir of cccDNA in these sites may be important for establishing 
viral persistence [11]. Furthermore, HBV is often grouped together with other viruses that 
also cause liver disease, or have what is referred to as liver tropism, as these viruses 
infect mostly liver cells. These include Hepatitis A, C, D and E the main features of 
which are briefly summarised in Table 1.3 below. 
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Table 1.3: Summary of All Hepatitis Viruses that Affect the Liver 
Virus Virology Clinical Manifestation and  
Route of Transmission 
Hepatitis 
A virus 
Order: Picornavirales 
Family: Picornaviridae 
Genus: Hepatovirus 
Species: Hepatitis A virus 
Structure: 27 nm non-enveloped 
spherical particle 
Genome: +ssRNA  
Acute hepatitis, self-limiting 
 
 
 
 
 
Water-borne, enteral or oro-faecal 
Hepatitis 
B virus 
Order: none 
Family: Hepadnaviridae 
Genus: Orthohepadnavirus 
Species: Hepatitis B virus 
Structure: 42 nm Dane particle, 
enveloped 
Genome: partially dsDNA 
Asymptomatic acute phase, followed by 
possible protracted asymptomatic carrier 
status. Subsequent probable development 
of inflammatory liver disease including 
cirrhosis and liver cancer. Complicated by 
co-infection with HIV 
 
Blood-borne, parenteral 
Hepatitis 
C virus 
Order: none 
Family: Flaviviridae 
Genus: Hepacivirus 
Species: Hepatitis C virus 
Structure: 55-65 nm in diameter, 
enveloped 
Genome: +ssRNA  
Acute phase can be asymptomatic or 
include jaundice. Chronic infection can lead 
to cirrhosis, liver cancer and immune 
disorders. Complicated by co-infection with 
HIV  
 
Blood-borne, parenteral 
Hepatitis 
D virus 
Order: none 
Family: none 
Genus: Deltavirus 
Species: Hepatitis delta virus 
Structure: 36 nm, coated with HBsAg 
Often called a viroid/satellite virus 
Genome: circular –ssRNA, smallest viral 
genome known to infect humans 
Only causes disease in individuals co-
infected with Hepatitis B virus, thus often 
referred to as a satellite virus. Requires to 
be coated in HBsAg for replication to 
occur. Co-infection of HBV and HDV 
increases the likelihood of fulminant 
hepatitis. 
 
Blood-borne, parenteral 
Hepatitis 
E virus 
Order: none 
Family: Hepeviridae 
Genus: Hepevirus 
Species: Hepatitis E virus 
Structure: 27-34 nm, non-enveloped 
spherical particle 
Genome: +ssRNA  
Acute hepatitis, self-limiting 
 
 
 
 
 
Water-borne, enteral or oro-faecal 
Several resources, including textbooks, lecture notes and reports were used to construct the 
following table [2, 4, 22, 23]. (Note size refers to viral diameter, ssRNA stands for single-stranded 
Ribonucleic acid, whereas dsDNA stands for double-stranded ribonucleic acid, the + and – denote 
plus and minus strand) 
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1.1.2 HBV Genome, Structure and Biology:  
All viral classification systems place a lot of importance on the genome; this is because 
the nature of the viral genome predicts how the virus will replicate, which proteins it will 
produce and thus ultimately, how it will interact with its host/s [4]. The HBV genome is 
a very compact genome of ~3200 nucleotides in length and consists of partially double-
stranded DNA [2, 6]. Taken together with the fact that each virion is only 42-47 nm in 
diameter, HBV is the smallest known DNA pathogen to infect humans [1-3, 18, 24-28]. 
Moreover the fact that the genome consists of overlapping reading frames means that 
the HBV has a fairly unique method of replication, which will be discussed below [3]. The 
virions, or infectious particles themselves are named Dane particles after the primary 
author on the paper of HBV’s debut visualisation under the electron microscope [29]. 
 
Figure 1.1: Relative Size of Hepatitis B Virus to Other Viruses 
This picture originates from the ExPASy Viral Zone web-resource [25] and clearly demonstrates 
the relative size of Hepatitis B virus in relation to other well characterised viruses. 
 
This circular genome is organised into four overlapping reading frames (ORFs), located 
on the minus strand of the DNA genome, as the plus strand of the genome DNA is 
roughly only two thirds of the full genome in length, and has a variable size on the 3’ 
end [3, 8, 30]. These ORFs code for the seven viral proteins that are translated from 
five mRNA transcripts, of varying length (Figure 1.3) [9, 13, 26]. The pregenomic RNA 
(pgRNA), consists of an overlength mRNA (3.5 kb) with a polyA-tail and a 5’ cap and 
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serves as the primer for the plus strand during DNA synthesis as well as the transcript 
for the polymerase and core protein [9, 13, 26, 31]. This overlength mRNA is often 
referred to as the major core gene transcript or just the major transcript [13]. A second 
overlength mRNA, called the pre-core/core mRNA, is translated into a precursor 
molecule, which is subsequently post-translationally modified into the enigmatic HBV 
antigen (HBeAg) [9, 13, 26, 31, 32]. Subgenomic mRNAs, which are shorter than 
overlength mRNAs, are the transcripts for the three surface proteins (2.4 kb and 2.1 kb) 
and the X protein (0.7 kb) [9, 13, 26]. Thus the seven viral proteins translated consist of 
the three surface proteins, the X protein, the Hepatitis B e antigen (HBeAg), HBV core 
antigen or nucleocapsid protein (HBcAg) and the polymerase enzyme (see Figures 1.2 
and 1.3) [9, 26]. The gene encoding the polymerase (P) overlaps with all three of the 
other ORFs (covering ≈80% of the entire genome), with complete overlap of the entire 
preS1, preS2 and Surface (S) ORF, and partial overlap of the Core (C) and Hepatitis B X 
(HBx) ORFs [9, 26, 33].  
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Figure 1.2: Representation of the HBV Genome, Transcriptome and Subsequent 
Viral Proteins 
This diagram shows a circular (top) and the linear (bottom) representation of the HBV genome, 
its ORFs and the RNA transcripts. The various mRNA transcripts are from where HBV genes are 
translated, all of which are ‘capped’ with a poly A tail [13, 26]. The linear representation includes 
genome numbering from the EcoRI site; here the numbering is based on Genotype A. For a 
complete reference of numbering for all genotypes, please see Kramvis et al., 2005 [34]. 
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Figure 1.3: Representation of the Viral Proteins in the Mature Virion 
The flat HBV genome layout with numbering relative to the EcoRI site is repeated in the top 
diagram and below is the virion structure with each protein represented in the matching colour. 
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1.1.3 HBV Viral Proteins: Their Translation and Functions 
Surface Proteins 
The overlapping genetic organisation of the HBV genome means it is possible for HBV 
to make use of alternative translation initiation and/or termination sites, allowing for the 
production of multiple proteins from one ORF (Figure 1.3). For example, the multiple 
initiation sites of preS1, preS2 and Surface genes permit the translation of three 
different surface proteins, the Large, Middle and Small hepatitis surface proteins (LHBs, 
MHBs and SHBs respectively) [2, 9, 26, 35, 36] (Table 1.4). Collectively the LHBs, MHBs 
and SHBs are known as the hepatitis B surface antigen (HBsAg) [18]. While the MHBs is 
dispensable, and not required for virion assembly, the SHBs and LHBs are essential to 
the HBV lifecycle [24, 37-39]. The immature virion acquires host-derived lipoproteins from 
either the endoplasmic reticulum (ER) or the Golgi apparatus via the secretory pathways 
during budding [3]. Thus, the budding process allows the viral particle to gain lipoprotein 
envelope encrusted with a mosaic of surface proteins of the virus [36]. The SHBs is also 
known as the major peptide because it is produced in such major excess compared to 
the MHBs and LHBs [35, 40]. A large excess of the HBsAg is also produced, which then 
form spherical (16-25 nm diameter) and filamentous (width of ~20 nm) particles, which 
are visible under the electron microscope [2, 17, 26, 36]. These non-infectious empty 
subviral particles are produced 1000:1 relative to the infectious Dane particle (up to 300 
μg/ml) and accumulate in the blood [13, 17, 26, 36]. They display the T and B cell 
epitopes and thus contribute to antigenemia [13, 40]. This ratio between SHBs and LHBs 
is important for normal viral secretion, and overexpression of the LHBS may lead to 
retention of HBsAg in the ER [28, 41, 42]. 
The primary function of the LHBs is binding to the cellular entry receptor for HBV, the 
bile acid transporter designated sodium taurocholate cotransporting polypeptide (NTCP) 
[11, 40, 43]. While it was known that HBV binds to heparan sulfate for attachment to 
human cells, it was unknown which receptor HBV was binding in order to gain entry into 
hepatocytes (amongst other cells) up until 2012 [43, 44]. Now, however, it has been 
shown that a 75 aa-long domain on the N-terminus the LHBs, which is encoded by the 
PreS1, binds to NTCP with high specificity [3, 18, 43, 45, 46]. 
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Table 1.4: Different Length Transcripts Result in Three Surface Proteins 
Sub Genomic Transcripts for Surface Proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surface 
Protein 
mRNA 
transcripts 
Protein Components Size in Amino 
Acids (aa)* 
 
LHBs 
2.4 kb preS1 
mRNA 
preS1 + preS2 + S 
 
 
400 
 
MHBs 
2.1 kb preS2 
mRNA 
preS2 + S 
 
 
281 
 
SHBs 
2.1 kb preS2 
mRNA with 
alternate 
initiation site 
S 
 
 
226 
Amino acid (aa) size is based on subgenotype A1; variations in the size of these proteins are 
dependent on genotype as well as whether deletions or insertions are present. More exact length 
of the surface proteins for each genotype is reviewed in Kramvis et al., 2005 [26, 34, 35]. 
 
 
This is indicated as the NTCP receptor binding domain in Figure 1.4 below, along with 
other important functional domains. The LHBs is required for the encapsidation of core 
particles, a vital step for budding and secretion of viral particles [13]. It has also been 
shown that this region on the preS1 region has to have a myristoylated residue on the 
second glycine for viral entry to occur, and thus is essential for infectivity [13, 43, 47]. 
preS1 SurfacepreS2
SurfacepreS2
Surface
preS1 SurfacepreS2
SurfacepreS2
Surface
preS1 SurfacepreS2
SurfacepreS2
Surface
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This domain is referred to as the key domain of preS1 and is also crucial in orienting 
the LHB towards the ER or the cytoplasm for budding and nucleocapsid envelopment 
[24]. As seen in Figure 1.4, the T cell epitope is found in the region overlapping the end 
of the preS1 and beginning of the preS2. Mutations in this region are often responsible 
for immune escape and viral breakthrough by reducing T cell reactivity [48]. It is thought 
that vaccine escape mutants may contribute to a rise in horizontal transmission of the 
virus [48]. 
Figure 1.4: Important Functional Domains of the LHBs 
The LHBs of the surface protein of HBV contains a few important functional domains, numbering 
here is from the beginning of the preS1 region for ease of reference. For genotype A, the preS1 
region encodes 119 aas and the preS2 55 aas. Together these two regions make up what is 
known as the infectivity domain as it contains the areas required for hepatocyte entry (NTCP 
receptor). The NTCP receptor has an essential component from aa 9-18 highlighted in bright pink, 
as well an accessory domain from aa 28-48 highlighted here in a dull pink. Myristoylation of the 
N-terminal Glycine on aa 2 is essential for viral entry. Further highlighted in this diagram are 
immune related functional domains including both B and T cell epitopes as well as the areas to 
which neutralising antibodies are targeted [13]. The accompanying table outlines the positions and 
aa sequences of all the above functional domains, and lists aa numbering both relative to the 
start of the LHBs as well as to the preS1 and preS2 regions. 
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A region of the surface protein known as the ‘a’-determinant within the antigenic loops 
(AGL), consists of three central hydrophilic loops, stretching from residues 124-147 
relative to the EcoRI site [13, 49-51]. The exact three-dimensional conformation of the 
“a”-determinant’s loops are as yet unknown, as it consists of 8 conserved cysteines 
connected by disulphide linkages, however the exact linkages have not been discovered 
[13]. It is however proposed that the first loop extends form residues 124-138 and the 
second loop from 139-148 [48]. Most of the immune systems neutralising antibodies are 
targeted at these loops [11, 13, 26, 35, 49, 51]. Thus, these epitopes on the 
immunodominant ‘a’-determinant region of the surface proteins provide the major target 
that ultimately stimulates the production of anti-HBs antibodies and thus underlies the 
efficacy of the Hepatitis B virus vaccine [11, 13, 35, 51]. Finally, these same loops are 
also the target for detection of HBsAg during serological tests [11, 35]. It follows 
therefore, that mutations in this area result in detection and immune escape mutants, 
and importantly, affects the antigenicity of the virus [48, 52]. Mutations may either 
change the conformation of the loops’ structure, or by changing the polarity of the aa 
side chains as a result of substitutions, the ability antibodies to bind the antigenic site 
with high avidity is diminished or even abolished [48, 53].  
The Hepatitis B X Protein 
The last of the viral proteins, HBx is encoded for by the X gene, the viruses’ smallest 
gene [11]. Being a non-particulate or accessory protein, HBx has no role in the structure 
of the Dane particle [18]. With an anti-apoptotic domain on its C-terminus and a pro-
apoptotic domain on the N-terminus, it functions as a transcriptional transactivator or a 
viral regulatory protein, pivotal in the transcription of cccDNA and influencing host as 
well as viral gene expression [9, 11, 18, 24]. It is thought to play a role in 
hepatocarcinogenesis because of its ability to modulate cellular functions that activate 
immune responses [11]. While its exact functions and mechanism of action remain poorly 
understood, we know that X gene mutations have frequently been reported when 
isolated from HCC cases [11].  
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Figure 1.5: Graphic Representation of the ‘a’-determinant Region 
This is a graphical representation of the ‘a’-determinant within its context in the surface protein as a whole. 
The as the exact structure is not known this diagram is hypothetical in nature, but serves to illustrate that 
mutations arising, particularly in the S gene portion, of the surface proteins can lead to various escape 
mutants arising [13]. This is discussed in more depth under the section on HBV mutants and S deletions. 
This figure was reproduced with permission from Copyright © 2009, American Society for Microbiology from 
publications: Le Duff et al., (2009) The Pre-S1 and Antigenic Loop Infectivity Determinants of the Hepatitis B 
Virus Envelope Proteins Are Functionally Independent, Journal of Virology 83(23): 12443–12451 
(http://jvi.asm.org/content/83/23/12443.full.pdf+html) and Copyright © 2012, PLOS One Makondo et al., 
(2012), Genotyping and Molecular Characterisation of Hepatitis B Virus from Human Immunodeficiency Virus-
Infected Individuals in Southern Africa, PLOS One 7(9):e46345 
(http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0046345#pone-0046345-g003) 
 
The Enigmatic HBeAg and Core Proteins 
The pre-Core, Core gene consists of the pre-Core region of 29 amino acid (aa) codons 
and the core section of 181 aa codons [54]. Alternate initiation and termination sites, 
together with post-translational modification, allows the pre-Core (pre-C) and Core (C) 
genes to result in the expression of two proteins, HBeAg and HBcAg [54, 55]. These two 
proteins are translated from separate mRNAS, the pgRNA (the major gene transcript) and 
the pre-Core mRNA, respectively (Table 1.5) [54, 55].  
The pre-Core mRNA stretches from upstream of pre-Core ATG initiation (1814 from the 
EcoRI site) at its 5’ end to the all the way to the Poly A tail, differing from the Core 
gene by only the 29 aa codons on the N terminal end [56]. However, a termination site 
at the end of the core genes 3’ end (2458 from EcoRI) means the immature molecule 
expresses a longer precursor than the pre-core/core gene [54]. This translated precursor, 
which is subsequently post-translationally cleaved at position 19 on the amino end and 
 17 
a variable site on the carboxyl end, results in the mature HBeAg protein [54]. After the 
two proteolytic cleavage events, the mature HBeAg differs from the core protein by ten 
additional residues on the amino or N-terminal end, as well as the lack of a DNA-
binding sequence on the carboxyl or C-terminal end [26, 54]. While the exact role of the 
HBeAg in the viral life cycle is unclear, it appears to have conflicting roles in regulating 
the immune response. It seems to function as an immunogen or target for inflammatory 
responses as well as a viral decoy, or even as a tolerogen; summarily the protein either 
encourages viral persistence or delays the antiviral immune response in some way [13, 
18, 26, 31, 53, 54, 56-59]. Importantly, as it is an extracellular or accessory protein, 
HBeAg is often used as a marker for active replication of HBV and infectivity [9, 56]. 
This is because high viral loads correlate strongly with high HBeAg expression (and 
identify individuals that pose a higher risk of transmitting the virus), and conversely as 
anti-hepatitis B e antibodies (anti-HBe) appear, viremia is significantly reduced [56, 60]. 
Furthermore, while HBeAg is not essential for viral replication or viral assembly, it is 
often observed that with strong immune pressure from anti-HBe over time, expression 
may be reduced or lost altogether [26, 53, 54, 56, 60, 61].  
On the other hand, the 181 aa core protein is translated from the pgRNA gene 
transcript, starting at the core ATG initiation (position 1901 from the EcoRI site) and 
ending at the gene termination site (2458 from EcoRI) [54, 55]. It should be noted that 
in some HBV genotypes, including subgenotype A1, the core protein is 183 aa long. This 
is due to a 6-nt insertion and is the reason for which the subgenotype A1 genome is 
3221 bp in length [54, 55]. This core protein is composed of an assembly domain as 
well as a nucleic acid binding domain, from aa’s 1-149 and 150-183 respectively [55]. 
The translated core protein is essential for the formation of the nucleocapsid [3, 54, 55]. 
Genetic economy dictates that this core protein is repeatedly used to form the 
protective icosahedral protein shell or packaging around the viral genome and 
polymerase that is seen in Dane particles [3, 4, 62, 63]. Thus, the 21 kDa viral core 
protein forms homodimers, which in turn self-assemble into the icosahedral capsids [62]. 
The icosahedral symmetry allows for simultaneous stability of the virion and maximal 
internal volume [4]. The HBV virion’s capsid is icosahedral instead of helical in shape 
because the core proteins are not symmetrical [4]. The core proteins are not always the 
same size, resulting in different sized capsids, ranging from 25nm (small) to 28-30 nm 
(large). The smaller capsids are said to have a T3 icosahedral symmetry and consist of 
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180 copies of the core protein, whereas the larger capsids, resulting in T4 symmetry, 
contains 240 copies [13, 55, 62, 63]. The viability of the T3 virions have however not 
been established [13]. The core proteins will specifically encapsidate the pgRNA as well 
as the viral Polymerase [55]. 
Table 1.5: Different Length Transcripts of the pre-Core and Core Genes  
Sub Genomic Transcripts for Core and HBeAg Proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein mRNA 
transcripts 
Protein Components Size in 
aa 
 
Core 
pgRNA Core Protein 
 
 
181 
 
HBeAg 
pre-Core 
mRNA 
Immature HBeAg 
 
 
210 
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The Polymerase Enzyme 
Another manner in which Hepadnaviridae, and particularly HBV, is unusual is that 
typically smaller viruses do not encode their own polymerase enzymes but use host 
polymerases to replicate their genetic material. Furthermore, the HBV polymerase is 
atypical in that; it is a single enzyme with error-prone RNA-dependent DNA polymerase 
activity as well as reverse transcriptase capability (Figure 1.4). Thus, the replication and 
life cycle of HBV is similar to retroviruses in animals and pararetroviruses in plants [3, 4, 
6, 9, 18].  
 
Figure 1.6: Structure of the HBV Polymerase 
This image is adapted from the study by Das et al., 2001 where they carried out crystal structure analysis 
to achieve this schematic of the enzyme [64]. Copyright was obtained from the journal. The HBV 
endogenous polymerase is comprised of three functional domains (also known as catalytic subdomains) [3, 
13, 18]: 
Polymerase Terminal Protein – a domain located at the N-terminal end of the enzyme; this acts a primer for 
the synthesis of the negative DNA strand. 
A Spacer Region – section in the middle of the enzyme that separates the C and N termini, and allows for 
movement of the enzyme. 
The Polymerase/Reverse Transcriptase (RT) and RNase H Domain – the RT portion is placed after the 
spacer towards the C-terminal end of the enzyme; this section allows the reverse transcription of mRNA into 
negative strand DNA. Finally the RNase H section - immediately adjacent to the RT portion, on the extreme 
end of the C-terminal part of the enzyme; RNase H is a ribonuclease that hydrolytically cleaves RNA 
allowing the removal of the RNA primer and completion of the nascent DNA synthesis. As indicated in the 
image the double-stranded DNA (dsDNA) fits between the ‘thumb’ and the ‘fingers’ of the RT portion of the 
enzyme. 
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1.1.4 The Replication Cycle of HBV 
Despite a good understanding of the endogenous polymerase, the minutia of the HBV 
viral replication cycle has not yet been fully elucidated [3]. This is partly due to the fact 
that the cellular receptor for HBV, NTCP, was only recently discovered [18, 43]. It is also 
partly because finding cell lines that are permissive for HBV infection or suitable animal 
models has been difficult [3, 18]. Figure 1.5 and Table 1.6 below explores the major 
steps of the HBV replication cycle. 
 
Figure 1.7: Stages of the Replication Cycle 
The numbers on the diagram co-ordinate with the steps of the replication cycle as indicated in 
Table 1.6 below. Reprinted from Gastroenterology, 137, F. Zoulim and S. Locarnini, Hepatitis B 
Virus to Nucleos(t)ide Analogues, 1593-1608, Copyright 2009, with permission from Elsevier [65].  
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Table 1.6: Stages of the HBV Replication Cycle 
Life Cycle of HBV in Hepatocytes 
1. HBV binds to heparan sulfate proteoglycans (HSPG) to achieve viral attachment. 
2. The key domain of the preS1 (on the LHBs) binds to the NTCP to gain entry into the 
cell via endocytosis. It has been shown that the first 75 N-terminal amino acids of the 
preS1 domain, as well as an attachment on the on the N-terminal end of a myristic acid 
at the 2nd glycine of preS1, are essential for viral entry to occur. However, the endosomal 
compartment required for endocytosis has not yet been characterised.  
3. The Dane particle is transported/migrated to the nucleus. It is assumed the nucleocapsid 
is disassembled or removed, uncoating the genome, at the nuclear pore, but this has not 
been clearly shown.  
4. The viral genome is discharged into the nucleus, referred to as translocation of the viral 
genome.  
5. The relaxed circular viral DNA (rcDNA) genome is converted into covalently closed 
circular DNA (cccDNA), which is essential to the replication cycle as it is not possible to 
transcribe mRNAs from the gapped rcDNA. All viruses must produce mRNA to replicate. The 
mechanism of this conversion and whether host or viral enzymes carry out this process is 
not well understood, however it is probable that three things must occur: 
• A polymerase (cellular?) or reverse transcriptase (viral?) is required to close the 
gap in the plus strand of the rcDNA 
• Endonucleases should remove the RNA primer on both minus and plus strands of 
DNA as well as remove the short terminally redundant sequence on the rcDNA minus 
strand that was created during DNA synthesis 
• Ligation of both strands to form circular strands is required 
Finally, the cccDNA is complexed with cellular histones forming a minichromosome, also 
referred to as a minicistron, which structurally resembles a plasmid or episomal DNA 
construct. This structure serves as the template for transcription of all the viral genes. 
Because this minichromosome is also similar to the host chromosome in structure, it is 
possible for epigenetic modification to occur. 
At some stage during this step, viral DNA may be incorporated into the host genome as well. 
6. Transcription of the pgRNA and subgenomic mRNAs is carried out by cellular RNA 
polymerase II (the RNA intermediate step of the replication cycle), followed by the 
transcripts being translocated from the nucleus to the cytosol. 
7. Translation and synthesis of the viral proteins occur at the ER; thus, the core particles 
are ready for assembly and encapsidation. 
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8a. Some pgRNA is encapsidated together with the newly 
synthesised viral polymerase, in immature virions. The viral 
particle matures as the viral reverse transcriptase converts 
the pgRNA into -ssDNA inside the nucleocapsid. The +ssDNA 
strand is then synthesised using the –ssDNA as a template, 
and the rcDNA is restored. Thus, the encapsidated pgRNA 
regenerates the partially dsDNA in budding virions after 
reverse transcription. The RNase H activity of the 
polymerase gradually degrades the pgRNA. As the genome 
matures, the virion buds via the ER, the Golgi apparatus 
and finally the cellular membrane (as a part of 
multivesicular particles). As this mature virion buds, it gains 
surface proteins and the host-derived portion of the 
envelope along the way. The subviral particles are similarly 
secreted but via a constitutively active secretory pathway. 
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8b. Some pgRNA will be 
encapsidated, but then, 
some mature genomes 
and core particles (from 
step 8a.) are 
transported back to the 
nucleus, and these are 
used to replenish the 
cccDNA pool to 
continue driving the 
replication cycle. 
This table was compiled using several resources [3, 4, 7, 9, 11, 13, 17, 18, 24, 26, 43, 47, 55, 
66] to best explain the replication cycle of HBV. 
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With the nature of the replication mechanism and the lack of proofreading ability of the 
viral polymerase sequence heterogeneity and quasispecies as well as variants and 
mutations of the virus arise [9, 11, 13, 56, 65]. These will be discussed in detail later, 
but it is important to note that these altered viral genomes arise naturally and 
frequently, and may or may not have functional consequences for the virus regarding 
fitness, replication rates, pathogenicity and immune/drug evasion and/or susceptibility. 
 
1.1.5 HBV Transmission in an African Setting 
Being a blood-borne virus, transmission of HBV is parenteral, meaning percutaneous or 
mucosal exposure to infected blood or body fluids can result in infection [9, 27, 67]. 
Body fluids that can transmit HBV include blood, mucous and saliva, as well as 
menstrual, vaginal and seminal fluids [1, 27]. Further, transmission can either be vertical 
or horizontal (Table 1.7).  
Table 1.7: HBV Routes of Transmission 
Routes of Transmission 
Vertical Transmission Horizontal Transmission 
Vertical transmission of HBV includes: 
Perinatal: 
HBV being passed from mother to child during 
birth or in utero (very rarely)  
Nonsexual transmission: 
Long-term household exposure 
Horizontal transmission includes: 
Iatrogenic or healthcare-related exposure: 
Blood transfusions, needle stick injuries, kidney 
dialysis, organ transplantation and dental 
procedures 
Body fluid transmission: 
Sexual transmission, sharing of contaminated 
needles (as is common with intravenous drug 
users), contact with a bleeding wound, 
tattooing, scarification, acupuncture, traditional 
circumcision, piercing, sharing of toothbrushes 
or razors, exposure to contaminated saliva and 
rough play amongst children, bites and 
scratches  
Indirect transmission:  
Via contaminated objects or surfaces  
Table compiled from resources [2, 9, 26, 27, 67-72]. 
 
In areas where HBV is endemic, the vast majority of persons infected with HBV acquired 
it either at birth or during their early childhood, which is in contrast to low endemicity 
areas where risky sexual behaviour and intravenous drug use are the principal sources 
of infection [1, 26, 61, 70, 73, 74]. Mothers with a high viral load, and thus a high 
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HBeAg seropositivity, will transmit HBV to their offspring 90% of the time [61, 69, 75]. In 
Africa however, the low HBeAg seropositivity amongst pregnant women results in 
horizontal transmission in early childhood being more common than vertical transmission 
[26, 70, 74, 76-78]. Unfortunately, this early stage infection most often results in the 
individual becoming a chronic carrier of HBV, which increases the risk of serious clinical 
sequelae [67, 73, 74]. For a long time, it was thought that there should be a zoonotic 
reservoir to explain high rates of horizontal childhood infection in Africa [1, 79-81]. 
Evidence exists that bats, rodents, a few primates and some species of birds do carry 
hepadnaviruses (orthohepadnaviruses and avihepadnaviruses) that are closely related to 
HBV. Nevertheless, the very narrow host range of these viruses and their limited ability 
to infect human hepatocytes means they may pose minimal threat [4, 15, 19]. While 
tropism studies have shown that bats can be infected with human HBV and that BtHBV 
has the potential to infect human hepatocytes, it remains unclear to what extent bats 
spread HBV in human populations [15, 43, 82]. By the same token, there is as yet no 
convincing evidence to show there is an insect or parasitic vector carrying HBV. 
Although many blood-sucking insects test positive for HBsAg and HBeAg, viral replication 
within these arthropods and actual transmission has not been clearly demonstrated [79-
81]. Thus, maybe traditional practices such as scarification, traditional circumcision, close 
contact and rough play as well as most certainly the substandard clinical practices in 
resource-limited facilities are a more likely source of higher transmission rates in the 
African setting [67, 76, 83]. That said, the failure of maternal health, child health and 
vaccination programmes is probably the biggest contributors to ongoing high 
transmission rates [84]. Unsafe injections have been shown in particular to contribute to 
high rates of HBV transmission in developing countries [72]. It is interesting to note that 
HBV is much more infectious than Human Immunodeficiency Virus (HIV) [72, 85-88]. The 
minimum infectious dose for HBV is as little as 4-10 virions per millilitre whereas HIV 
requires exposure to body fluids containing more than 400 virions per millilitre to 
establish infection [26, 67, 72, 86-90]. One microlitre of HBV-infected blood can contain 
as many as 106 to 109 virions, and these HBV virions are stable in dried blood for up 
to one week [67, 87, 90]. Additionally, body fluids other than blood and serum can 
serve as reservoirs for transmission; fluids such as semen and saliva have also been 
shown to be infectious [67].  
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1.1.6 Epidemiology of HBV – Worldwide and Southern Africa 
The worldwide epidemiology and prevalence are summarised in Figure 1.6. Two billion 
people show evidence in serology of either past or present infection with HBV, that is 
nearly a third of the world’s population [1]. Prevalence rates, measured by the 
seroprevalence of HBsAg in serum, vary extensively across the globe as well as in 
different age categories. Rates are lower than 2% in Central Latin America, North 
America and Western Europe, and are highest (8% and above) in the North Western 
part of Africa [1, 78]. HBV infection is considered chronic if HBsAg has been present for 
six months or more. It is often accompanied by the presence of Ground Glass 
Hepatocytes (GGH) in the liver; and chronic HBV in infection (CHB) is associated with a 
100-fold increased relative risk of developing HCC [1, 65, 91-93]. 
 
Figure 1.8: Facts and Figures of the Global HBV Epidemic 
On the left, this infographic was constructed using the statistics reported in a recent World 
Health Organization Report, and the prevalence images on the right have been presented from 
the same report: Guidelines for the prevention, care and treatment of persons with chronic 
hepatitis B infection 2015 [94] as well as a report compiled by Lozano et al., summarising recent 
global and regional mortality patterns [95]. The infographic depicts the major epidemiological 
facts of HBV concerning burden of disease and morbidity and mortality on a global scale. 	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Underreporting, inefficient data collection resources and general lack of health care 
infrastructure are huge barriers to obtaining accurate prevalence data in Africa [22, 95]. 
However, a paper published in 2007 considered data reported in 111 studies, and 
concluded that 65 million chronically infected individuals reside in Africa, which 
translates to 18% of the global burden of HBV disease [96]. Moreover, it is estimated 
that HBV is the cause of roughly 250 000 deaths per annum in Africa, and we know 
that these deaths result from liver cancer and cirrhosis decades after initial infection [22, 
96]. By measuring population antibodies against hepatitis B core antigen (anti-HBcAg), 
one can show the exposure rate to HBV. In Africa, this ranges from 1.8-98% [76, 96]. 
Here the lower prevalence is associated with blood donors and children, whereas the 
high exposure rates are associated with patients who have chronic liver disease or 
hepatocellular carcinoma (HCC) [76, 96].  
Figure 1.9: Global HBsAg Endemicity (1957-2013) 
This figure clearly shows that Africa has the highest endemicity of HBV drawn from a systematic 
review compiled from studies spanning 56 years. It can be argued that Africa is now the only 
hyperendemic region [78]. Reprinted from the Lancet, 386, Schweitzer et al., Estimations of 
worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published 
between 1965 and 2013, 1546–55. Copyright (2015), with permission from Elsevier.  
 
In sub-Saharan Africa, HBsAg seroprevalence rates suggest that the virus is 
hyperendemic in this region, as 8% of the population or more test positive in the serum 
[96]. There are pockets of sub-Saharan Africa however, that have intermediate endemicity 
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of 2-8%, including Cote d’Ivoire, Kenya, Liberia, Senegal, Sierra Leone and Zambia [96]. 
In most countries in the world, HBsAg carrier status is higher in men than in women, 
and sub-Saharan Africa is no exception to this pattern [97]. Older studies showed that 
while the prevalence of HBsAg carriers ranges from 9-20% in sub-Saharan Africa, in 
South Africa the rate is around 9.6%, so HBV is also considered to be hyperendemic in 
this country [97, 98]. There is a marked increase in prevalence in rural areas as 
compared to urban areas; rural inhabitants are twice as likely to be HBsAg positive as 
their urban counterparts [70, 96]. Thus, roughly 10-15% of rural black children were 
carriers, as opposed to the 1% of urban children who were carriers [70, 77, 97-101]. In 
short, like so many other communicable diseases, HBV hits lower-income and more 
resource-limited settings harder than their socioeconomically more privileged 
counterparts [1, 70, 99].  
 
1.1.7 Phylogeny and the Genotypes and Subgenotypes of HBV 
Phylogenetic analysis and its ability to explain evolutionary theory is a relatively new 
science. As Baldauf states, phylogenetics is the science of estimating the evolutionary 
past based on the comparison of DNA or protein sequences [102]. Modern phylogeny 
thus depends on the numerical calculation of trees using quantitative methods [102-106]. 
Phylogeny represents a potent tool for making previously overwhelming data sets 
comprehensible and allowing the interpretation of trends and relationships [102].  
The system of genotype and subgenotype designation refers to the relative genetic 
relatedness of HBV genome sequences within the family Hepadnaviridae or different 
genera of the family [33]. The description of genotypes and subgenotypes relies on 
sequence alignment, sequence divergence calculations and phylogenetic comparison [6]. 
Considering HBV has such a compact genome with overlapping ORFs, this limits the 
amount of mutation possible without affecting viral viability. Genotypes are identified 
where there is 7.5% or more intergenomic sequence divergence between strains, and 
subgenotypes where there is more than 4% intergenomic sequence divergence [33, 71, 
107, 108]. Phylogenetic analysis of sequences from all over the world have shown that 
there are none confirmed genotypes, designated A-I, and one putative genotype ‘J’, as 
well as 35 or more associated subgenotypes which are linked with all the genotypes 
except for E and G [6, 11, 35, 71, 108, 109]. The distinct geographical distribution of 
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these genotypes (Figure 1.8), and in some cases of subgenotypes, has enabled 
epidemiological and transmission-related studies, furthered understanding of the differing 
prognosis and clinical manifestation of different genotypes, as well as varying response 
to treatment and has contributed the knowledge around the age of HBV infection in 
humans as well as tracing human migrations [10, 11, 35, 71, 76, 108, 110, 111]. 
Furthermore, the study of the geographical distribution of HBV genotypes and 
subgenotypes has cast some light on the long-term evolutionary history, viral mutation 
rate and to some extent the origin of the virus [10, 112]. While it appears that the 
origin of the virus is ancient (potentially as long as 80 million years), the earliest known 
human HBV sequence appears to be between 3000 and 100 000 years old [10, 110]. 
Evidently there are gaps in our knowledge, and while the study of genotypes and their 
evolution has aided in this regard, we still have no consensus on a viral mutation rate 
and many unanswered questions as to the origin and actual age of HBV [10, 112-114].  
 
Figure 1.10: Overview of Geographical Distribution of HBV Genotypes  
The genotypes of HBV have a distinct geographic distribution [108]. The most predominant strains 
in southern Africa are subgenotype A1 (75%) and genotype D (25%) [108]. Picture used here with 
permission from A. Kramvis (from publication title The Clinical Implications of Hepatitis B Virus 
Genotypes in Paediatrics currently submitted to Reviews of Medical Virology). 
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From a more clinical perspective, it has been established that the genotypes and some 
subgenotypes behave differently in terms of clinical manifestation of infectivity, 
susceptibility to antiviral therapy, prognosis, viral antigen expression, relative likelihood of 
developing resistance or escape mutants and relative risk of developing advanced liver 
disease [33, 35, 76, 108, 115-120]. Of course, this may all be complicated in cases of 
infection with recombinants strains or superinfection with more than one genotype [6, 
76].  
A focus on Genotype A: Prevalent in Africa 
Nucleotide divergence shows us that the oldest endemic genotype on the African 
continent is genotype A, and currently still dominates the southern, eastern and central 
parts of Africa [76]. In northern Africa, genotype D prevails and genotype E is most 
prevalent in the central and western parts of Africa [6, 76, 108]. The subgenotypes 
circulating in South Africa are predominantly A1 and D3; however, subgenotype A1 
remains the most widespread at 75% as well as the most studied in South Africa [76]. 
This is largely because of the severe clinical outcomes associated with this subgenotype. 
Genotype A is often coupled with a higher viral load, which results in increased 
infectivity and transmission [35]. The characterisation that has been carried out on 
subgenotype A1 has revealed that it has five very distinct features compared to 
subgenotype A2, which is the subgenotype that predominates outside Africa. Namely, 
subgenotype A1 is associated with low viral loads, early HBeAg seroconversion, high 
transmissibility, which is mostly horizontal and greater hepatocarcinogenic potential [86, 
96, 121-123]. Of these possibly the most important feature is that subgenotype A1 is 
associated with an increased risk of developing HCC in Black Africans, which means 
progression to HCC is accelerated and there may be a different mechanism by which 
HCC develops in the African setting [26, 115, 122, 124, 125]. 
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1.1.8 HBV and HIV Co-Infection: A Dangerous Liaison 
Co-infection occurs when a single individual is concurrently infected with both HBV and 
HIV [1]. These two blood-borne viruses share many common routes of transmission as 
well as sharing similar risk factors. Add to this the reality that Africa has both the 
highest HIV prevalence per capita and high HBV endemicity, it seems evident that high 
rates of co-infection will occur in the African setting [76, 84, 97, 126, 127]. Furthermore, 
while we know there is a significant proportion of co-infection in Africa, it is also likely 
that the number of co-infected individuals is underestimated due to the dependence on 
serological-based screening [84, 97, 128-131]. Again poor systematic surveillance, 
underreporting and limited resources mean we do not have accurate statistics; however 
from examining available data a disturbing pattern emerges [78].  
Of the 34 million HIV-infected individuals worldwide, 5-15% are also chronically infected 
with HBV, (Figure 1.9) [1, 129, 130, 132]. A recent report from the WHO on the state of 
Viral Hepatitis in Africa estimates that 5-20% of HIV-positive individuals are also 
chronically infected with HBV, meaning that of the 24.7 million people living with HIV in 
Africa, between 1.2 and 4.9 million are also HBV-positive [22, 127, 129, 132]. Small 
cohort studies carried out all over the continent, but mostly in South Africa, have 
reported anything from a 1.6% to 83.6% co-infection rate [97, 100, 127, 130, 133-141]. 
A big multinational cohort study, which included African countries, reported a 5.5% co-
infection prevalence [132]. Interestingly, the most common genotype amongst co-infected 
Africans and southern Africans was genotype A and then D, which is reflective of the 
predominant genotypes especially in South Africa [127, 132, 142]. The great variation of 
this co-infection prevalence can be attributed to the fact that these statistics were not 
drawn from population-based studies, and depended heavily on the subpopulation that 
was chosen for the study, and the sample size of the study. It is also worth noting that 
data on complete genome sequences in South Africa (in a predominantly subgenotype 
A1 background) are severely limited, as only a handful of studies have been conducted 
to date [52, 143, 144].  
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Figure 1.11: The Prevalence of HBV and the HIV Globally 
Note the very high rates of prevalence of both diseases especially in Africa and Asia. The 
following diagram was adapted and reproduced with permission, copyright Massachusetts Medical 
Society [84]. 
 
 
 
 31 
Occult HBV Infection 
At this point, it is important to introduce the concept of occult HBV infection. While the 
term was first coined in the late 1970s, prior to the Taormina expert meeting in March 
of 2008 the definition and relevance of occult hepatitis was widely debated [145]. The 
new agreed definition of occult HBV is the presence of HBV DNA in the liver where 
HBsAg is negative, or when HBV DNA is detectable but under 200 IU/ml [145]. False 
occult HBV cases can occur when variants of HBV that affect the S gene, resulting in 
either escape mutants or mutants where a modified and thus unrecognisable HBsAg is 
produced; therefore these cases are not always serologically positive for HBsAg [39, 145]. 
In these false occult cases, the HBV viral load is above 200 IU/ml, and often 
comparable to HBsAg positive cases [145]. Conversely, true occult cases are defined by 
instances in which HBsAg is not detectable in serum (detection escape mutants) and 
additionally HBV viral load is below the 200 IU/ml [145]. Other than the challenge of 
many cases of HBV being missed as they are false serological negatives, clinically, 
occult HBV is important in that the seronegative nature of most occult cases means 
there is a larger risk of HBV transmission resulting from blood transfusions and organ 
transplantations [39, 146, 147]. Further, occult HBV infection is strongly associated with 
HCC development as well as re-emergence of HBV viraemia following immune 
suppression [39, 148]. While extensive studies are required to confirm, occult HBV is 
particularly common in HIV-co-infected patients [97, 128, 138, 146, 147, 149-151].  
Most prevalence studies are based on serological detection of HBV. In the absence of 
nucleic acid testing (NAT), occult HBV would not be detected by these assays, and this 
may result in an underestimate of HBV prevalence in the presence or absence of HIV. 
This means that occult HBV infection itself can be a confounding factor in those studies 
looking at co-infection prevalence [145]. 
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Clinical Outcomes of HBV-HIV Co-infection 
Less obvious than the epidemiology of co-infection is exactly how these two viruses 
interact, and what co-infection means for the individuals who are infected with both 
pathogens. To reiterate, in Europe, North America and Australia, HIV and HBV are 
usually acquired in either adolescence or adult life as a result of sexual transmission or 
intravenous drug use [78, 84, 127]. Conversely, in the African setting HBV is usually 
acquired at a young age, and thus normally precedes infection with HIV [84, 127, 132]. 
Most co-infected individuals in the African setting will, therefore, have an already 
established chronic HBV infection by the time they acquire HIV, which may have 
important bearings on their disease progression and outcome [132]. Adults who acquire 
HBV after HIV are more likely to become chronic HBV carriers compared to HBV mono-
infected adults where the infection is usually acute [97]. A third scenario also occurs 
where individuals who had recovered from or had an effective immune response to an 
HBV infection or even occult HBV infection, then become HIV-infected, the subsequent 
immunosuppression may result in reactivation of the HBV infection [97]. Additionally, it 
should be noted that immune reconstitution inflammatory syndrome (IRIS) or immune 
recovery is likely (in up to 40% of cases) when a patient is placed on anti-retroviral 
treatment (ART) [126, 149, 152]. These individuals will also be more susceptible to 
contracting HBV or having reactivated HBV disease. Thus, the appearance of HBV after 
IRIS is often referred to as either reactivation or unmasking of occult infection [126]. 
There is also increased risk of mother-to-child or perinatal transmission of both 
pathogens, especially since HIV enhances HBV replication and co-infected mothers are 
more likely to be HBeAg-positive and thus more infectious [127]. All these scenarios 
make it clear that acquiring HIV and HBV co-infection is not straightforward and can 
have multiple outcomes; some of these clinical outcomes and complications are 
highlighted in Table 1.8 below.  
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Table 1.8: The Effect of Co-Infection on Disease Outcome for Both HBV and HIV 
Effect of Co-Infection on HBV Disease Effect of Co-Infection on HIV Disease 
Exacerbates liver disease, increased 
inflammation of the liver during IRIS, elevated 
liver enzyme levels, increased jaundice, 
increased hepatotoxicity (3- to 5- fold) due to 
ART and faster progression to cirrhosis and 
HCC. Finally, higher increased cases of liver-
related mortality. 
Where ART has been implemented liver failure 
and end-stage liver disease due to HBV have 
become the leading causes of death in co-
infected individuals.  
Increased proportions of chronicity after acute 
HBV infection has been noted and faster 
progression to chronic disease than in mono-
infection (up to 5 times faster). 
Hyperbilirubinemia, mitochondrial toxicity, 
systemic reactions and hypersensitivity 
reactions are common in combination with 
certain ART medications.  
Less spontaneous clearance of HBV, and 
lower rates of HBeAg clearance, as well as 
increased cases of HBV recrudescence 
subsequent to immune control. 
CD4 T-cell counts were consistently shown to 
be lower in co-infected individuals. 
Increased number of occult HBV infection 
cases.  
Lower body mass index (BMI) was reported 
amongst co-infected individuals. 
Higher replication rates of HBV or higher viral 
loads/viremia have been observed. 
No differences in HIV viral loads have been 
reported. 
Reduced response to treatment especially 
interferons. What's more, immunosuppression 
can cause an accelerated loss of anti-HBs 
antibodies, blunting the immune response 
increasing the risk of HBV reactivation 
episodes. 
Higher chances of treatment interruptions and 
changes in order to accommodate greater 
hepatotoxicity and viral resistance of the two 
pathogens as well as blunted immune 
responses or greater immune deficiency due 
to active HBV replication. 
The development of HBV resistance is 
common, particularly when lamivudine or 
emtricitabine is prescribed in the absence of 
tenofovir. 
Individuals with chronic HBV had a higher 
possibility of experiencing either an AIDS-
defining or death event. Progression to AIDS-
related outcomes, concerning morbidity and 
mortality, is also more likely and more rapid. 
This table was populated with data from multiple studies and reports to show how co-infection 
affects each disease singularly in terms of progression and outcome [1, 84, 127-132, 140, 149, 
153-155]. The effect of HBV on HIV disease is less apparent than the relationship of HIV on HBV 
disease. However, it is thought that HBV may blunt the immune system and cause a greater 
predisposition towards liver toxicity following ART administration than in mono-infected patients 
[130]. It is important to note that the pathogenic and molecular mechanisms for the increase in 
liver disease as a result of co-infection are poorly understood [131]. 
 
Presently neither HBV nor HIV can be eradicated with the therapies we have available to 
us [84]. In the case of HBV, new antiviral therapies have been slow in discovery, 
particularly In comparison to HIV or even hepatitis C virus treatment [156]. Furthermore, 
the challenge of treatment that can remove cccDNA in the nuclei of hepatocytes has 
not yet been overcome [156]. New curative therapies are desperately needed for the 
treatment of HBV if we ever hope to prevent the more than 1 million deaths that occur 
due to end-stage liver disease and HCC associated with HBV [156]. In affluent settings, 
where HBV-HIV co-infection studies were carried out, it was found that simultaneous 
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infection profoundly affected every characteristic of the natural history of HBV and that 
liver disease emerged as the leading cause of death in co-infected patients after the 
initiation of ART [1, 84, 127, 131, 154]. In the African setting, this is not as clearly 
delineated, and it would be wise to assume that other major infectious diseases still 
play a bigger role in morbidity and mortality in HIV-co-infected patients than HBV [1, 84, 
128, 131]. Although ideally all HIV-positive individuals should be screened for HBV and 
occult HBV, the infrastructure and resources to do so are unfortunately severely limited 
[127, 130].  
There are few important factors that that need to be highlighted at this point: 
• In resource-limited settings adequate screening for HBV in HIV patients is scarce 
• The occurrence of occult HBV means that even if screening is carried out there will 
be cases that are missed 
• Co-infected individuals’ lifespans are prolonged by placing them on ART  
• Those that are co-infected are not necessarily placed on HIV treatment regimens that 
are also effective against HBV (especially regimens including Tenofovir, which has 
been shown to be effective treatment of HBV with minimal occurrence of resistance) 
• Co-infection with HIV accelerates advancement of serious HBV-related liver disease 
Taken together it becomes evident that in the African setting this situation is creating 
greater opportunities for chronic liver disease, especially HCC, to take hold in co-
infected patients [97, 130, 131, 138, 151, 153]. Finally, it imperative to note that despite 
a general significant increase in numbers and types of cancers related to HIV infection 
and autoimmune deficiency syndrome (AIDS), liver cancer, and HCC in particular, remains 
the fourth most common cancer in Africa [96, 126, 157].  
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1.1.9 HBV Mutants and preS and S Deletions: What is Missing? 
As mentioned before, variants of HBV arise naturally due to the error-prone nature of 
the polymerase enzyme [9, 13, 24, 31, 114, 158, 159]. As Bouckaert et. al, point out the 
variation that is introduced by these errors is opposed by a conflicting force, namely 
the extreme compactness of the overlapping genome, limiting the degree of variability 
possible [114]. With all HBV mutations, it is important to remember that because of the 
overlapping genome, a mutation can affect more than one gene at a time. Thus, even a 
single point mutation can affect many aspects of the virus [9, 11, 31, 65]. Particularly, 
for the purposes of this study, its important to remember the S ORF is completely 
overlapped by the Polymerase ORF and thus mutants that have drug resistance and/or 
altered replication fitness can simultaneously be vaccine-escape or HBsAg mutants [24]. 
Due to the high replication rate of HBV, and the polymerase being error-prone, it is 
reasonable to assume that each person infected with HBV harbours a virus population 
of quasispecies [9, 11, 24, 31, 56]. In virology, when we refer to quasispecies, we mean 
“a population of viruses that share a common origin but which have distinct genomic 
sequences as a result of mutation, drift and the impact of selection” (Smith et al., 1997) 
[160]. Consequently, any infected individual may be infected with several variants at any 
one time, and not all of these variants will be viable [9, 159]. Nassal et al., 2005 above, 
summarise the requirements for viability of the virus. While viable variants will replicate 
autonomously, partially defective virus strains can be ‘rescued’ by trans-complementation 
with a wild-type (WT) or viable strain [28, 37, 159, 161-165]. Some of the mutants may 
arise within an infected individual as de novo mutations, but there are variants that have 
been found to be transmissible [24, 91]. Thus, these transmissible variants circulate as 
the predominant viral population [166]. There are several kinds of variants that arise in 
HBV, and they may arise from immune or drug pressure as well as the error-prone 
polymerase. All are shown in Table 1.9. While it is not yet clear, another selection 
pressure exerted on the HBV genome may be co-infection with HIV, as a relatively high 
incidence of variants have been seen in co-infected patients [52, 97, 138, 151], but the 
mechanism by which this occurs is unclear.  
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Table 1.9: HBV Variants and Their Relevance 
HBV Variants 
Type of 
Variant 
Cause of 
Mutation 
Location of Mutation Result 
Vaccine 
Escape 
Mutants 
Host 
immune 
pressure 
The ‘a’-determinant of 
HBsAg, where B and T 
cell epitopes are found 
The immune system is primed by the vaccines, 
but the circulating HBV does not display the 
same epitopes, thus, HBs antibodies will be 
ineffective 
Immune 
Escape 
Mutants 
Host 
immune 
pressure/ 
vaccine 
pressure 
The ‘a’-determinant of 
HBsAg, where B and T 
cell epitopes are found 
The immune system no longer recognises the 
virus, as epitopes are either deleted or 
obscured, lower HBsAg titers are common 
Surface 
Protein 
Deletion-
mutants 
Not explicitly 
known 
The preS1 and preS2 
regions 
These deletions are usually in-frame and are 
common in CHB and are associated with 
necro-inflammation, fulminant hepatitis, 
cirrhosis, progressive liver disease and 
increased HCC development 
Host 
immune 
pressure 
The ‘a’-determinant of 
HBsAg 
Occult infection; HBsAg is not serologically 
detectable due to the deletion or decreased 
HBsAg secretion  
Reduced binding of HBsAg to anti-HBs, thus 
immune escape as well as reduced virion 
secretion 
Drug 
Resistance 
Mutants 
Drug 
pressure 
The polymerase gene Resistance to Nucleos(t)ide Analogues  
Pre-Core 
Mutant 
Host 
immune 
pressure 
The HBeAg protein Higher rates of fulminant hepatitis and 
exacerbation of clinical outcomes of CHB, stop 
codon mutations can lead to the complete 
blockage of HBeAg production 
Core 
Promoter 
Mutations 
Error-prone 
polymerase, 
shown to 
accumulate 
over time 
In the promoter section of 
the pre-core 
The most common of the naturally occurring 
variants 
Decreased HBeAg production and increased 
seroconversion, escape of anti-HBe antibody 
mediated immunity, increased severity of 
disease prognosis as well as HCC development  
X Gene 
Mutants 
Error-prone 
polymerase 
Usually point mutations, 
often close to the C-
terminus of the HBx 
protein 
HCC development  
This table was populated using numerous resources [11, 26, 31, 35, 37, 40, 51, 56, 65, 166-170]. 
 
Owing to the research focus here being deletion-mutants in the S gene, its important to 
remember that alterations of this gene may affect infectivity, virion binding to and 
secretion from hepatocytes, virus transmission, response to vaccine-primed immunity as 
well as pathogenesis of liver disease [31, 65]. It is still not clear exactly how HBV 
causes HCC, as the virus is not cytopathic [171]. It is thought to be largely due to the 
interplay of the viral replication and the host immune system that causes continuous 
liver injury and regeneration and ultimately leads to tumorigenesis [11, 26, 31, 73, 166]. 
While HBV DNA integration was previously thought to be a possible culprit, it has since 
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been shown that integration is both random and does not have a cis-effect on flanking 
genes, so it is unlikely to be an HCC-causative mechanism [91]. However, some studies 
have shown that when integrated into specific sites of the host genome, the S and X 
genes can possibly contribute to genomic instability and mutagenesis [170]. Certain 
genotypes have a stronger link with HCC development than others; subgenotype A1, 
predominant in sub-Saharan Africa, for example, is known to be the cause of most 
cases of HCC in that region [26]. There is a growing body of work showing an 
association between variants that contain preS deletions or produce truncated envelope 
proteins and the development of advanced liver disease, including cirrhosis and HCC [24, 
26, 40, 51, 119, 166-168, 170, 172-178]. Of particular note, a meta-analysis that 
scrutinised nearly 12 000 patients involved in 43 different studies found that preS 
deletion-mutants were associated with a 3.77-fold increased risk of developing HCC [167]. 
While the S region of the genome is moderately well conserved, the preS1 and preS2 
are much more variable and tend towards mutation, and we now know that preS 
variants frequently arise in patients with chronic HBV [24, 35, 170, 179]. Furthermore, 
preS deletion-mutants become more likely the older the HBV-infected individual becomes 
[24, 167, 172]. In-frame preS deletions are most commonly deletions in the C-terminal 
end of the preS1, central deletions in the preS2, the start codon of preS2 or 
miscellaneous point mutations [24, 91]. Not surprisingly, because the MHBs protein is not 
essential for virion assembly, infectivity or viral secretion, mutants where MHBs is 
severely truncated or not synthesised at all are frequently selected [24, 91]. This said, 
balanced production of the surface proteins seems to be important for normal viral 
secretion [24, 164]. Where preS1 mutants contain deletions towards their C-terminal ends 
and preS2 mutants contain deletions towards their N-terminal ends the likelihood of 
defective or no MHBs production rises, and correspondingly these mutants are more 
commonly seen in HCC [24]. Moreover, the preS2 region overlaps with the spacer 
domain of the HBV polymerase; thus large deletions in this region are tolerated as they 
do not always negatively affect replication fitness [24, 180]. Infection with preS/S 
mutants is associated with low circulating and supernatant HBsAg levels, retention and 
accumulation of surface proteins in the ER of GGH cells, impaired secretion of virions 
and increased amounts of cccDNA building up in hepatocyte nuclei [24, 91, 93, 166, 
170].  
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The hypotheses or viral model for hepatocarcinogenesis where S deletion-mutants are 
concerned include the following cellular occurrences: 
• It has been shown by several studies that preS deletion-mutants are incompetent for 
secretion, because the LHBs is truncated and the transmembranous section required 
for cytosolic directionality and budding is missing or defective [24, 166]. The preS1 
deletion-mutants tend to aggregate more centrally causing the appearance of ‘classic’ 
or inclusion-like type I GGH cells, whereas preS2 deletion-mutants will accumulate in 
the periphery or margin causing the appearance of type II GGH cells [24, 91, 166, 
170, 181-183]. This is important because we can infer that the deletion-mutants 
produce two different kinds of truncated surface proteins and may even have differing 
oncogenic mechanisms [91]. For this reason, subsequent identification of the GGH type 
could be a diagnostic and prognostic tool for detection of precursor lesions of HCC 
[24, 91]. 
• A strong ER stress response occurs as a result of the cellular defence response 
triggered by the accumulation of unfolded proteins, leading to increased recruitment 
of cellular chaperones like Grp78 and Grp94 [91, 182, 183]. These chaperones will 
prevent apoptosis and increase tolerance to hypoxia thus creating a favourable 
environment for tumour growth [91, 182]. ER stress also leads to an accumulation of 
reactive oxygen species, which will damage host DNA; in due course this leads to 
destabilisation of the host genome in hepatocytes and mutagenesis [24, 91, 182]. 
• Several cellular pathways crucial for normal growth are affected by abnormal S 
protein accumulation and ER stress, and together they lead to hepatocyte 
hyperproliferation. The first of these is the augmented production of cyclin A protein; 
by increasing centrosome duplication this increased cyclin A leads to cell aneuploidy 
and may exacerbate ER stress [24, 91, 170, 182]. The second process is the 
induction of the cyclooxygenase-2 (COX-2) enzyme; ordinarily important for 
anchorage-independent growth, here COX-2 allows cells to proliferate abnormally [91]. 
Similarly, retinoblastoma (RB) protein becomes hyperphosphorylated, resulting in 
abnormally increased cell cycling conditions [24, 91]. In analogy, over-expression of 
the mammalian target of the rapamycin (mTOR) signal cascade, the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-ΚB) protein, and mitogen-activated 
protein kinases (MAPK) pathways similarly lead to abnormal cell cycling and 
hyperproliferation [24, 91, 170, 182]. Importantly NF-ΚB also upregulates COX-2 [182]. 
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• Mutants affecting the MHBs specifically have been shown to upregulate human 
telomerase reverse transcriptase (hTERT); where it normally regulates telomerase 
activity, overexpression promotes carcinogenesis [24]. 
• In mouse models, it has been shown that where very high viral loads are reached the 
HBV can become directly cytopathic and can burst hepatocytes after the extreme 
accumulation of LHBs [24, 91, 166, 170, 182, 184]. 
Ultimately the retention of truncated surface proteins leads to ER stress resulting in 
oxidative damage to host DNA, genome instability and mutagenesis and the induction of 
cell cycle disturbances and hepatocyte hyperproliferation [24, 91, 170]. It is thus very 
important to keep studying the incidence of these S deletion-mutants as they can be 
strong prognostic tools; but more importantly, it is possible with a better understanding 
of the carcinogenesis model of HBV that we would be able to identify novel drug targets 
[91, 182]. 
 
1.1.10 The Cell Culture Systems Available for HBV Study 
It is important to remember in a study like this where the aim is to functionally 
characterise mutant strains of Hepatitis B virus, there are two major limiting factors. 
Firstly HBV has a very narrow range of species that it can readily infect; and secondly 
because of this; there is only a handful of in vitro systems available in which to carry 
out functional studies. The four core in vitro model systems that can be employed when 
studying the Hepatitis B Virus and their main advantages and disadvantages are 
summarised in Table 1.10. Transient transfection of human hepatic cell lines provides a 
readily available and relatively cost-effective model that adequately simulates the liver 
microenvironment [5, 60, 185-187]. As the cell lines can be transiently transfected with 
overlength clones, they can be used to study the replication competence of these HBV 
clones as well as carry out other experiments towards the functional characterisation 
and prediction of the clinical phenotype of such clones [5, 60, 65, 187-189]. Of course 
transient transfection systems have shortcomings too, including inter-experimental 
variability where a stably transfected cell line is not employed, variable transfection 
efficiencies are frequent and the peak of viral expression being reached prematurely due 
to incomplete transfection of all cells [5]. Establishing a stably transfected cell line is not 
always feasible if the time frame in which to do the study is limited. 
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Table 1.10: Comparison of Cell Lines Used for HBV  
Primary Hepatocytes 
Primary Human Hepatocytes (PHH) 
Origin: derived from surgically resected liver pieces 
Advantages: 
Most closely represent average human hepatocytes, 
naturally susceptible to infection and thus can be 
used for infection and viral entry studies 
These cells allow for the study of the entire 
replication cycle 
Disadvantages: 
Differences arising from donor heterogeneity mean 
infection efficiencies vary; cells are only viable for a 
few days post-infection as they lose liver-specific 
function and de-differentiate back to fibroblast-like 
cells. It is expensive and difficult to acquire these 
cells, ethics clearance is required, donors may not 
be suitable due to liver disease, requires surgery on 
a live person 
Primary Tupaia Belangeri Hepatocytes (PTH) 
Origin: derived from surgically resected liver pieces of the Northern Tree shrew 
Advantages: 
These cells are immediately susceptible to infection 
and infection has been shown to be specific, entire 
replication cycle of the virus is possible. 
As Tree shrews can be kept in captivity, these cells 
are easier to obtain than human hepatocytes, and 
often the cells obtained are more homogenous for 
the same reason 
Disadvantages: 
Only transient infection can be achieved  
Will also lose hepatic phenotype if not maintained by 
chemical induction 
Human Hepatic Cell Lines  
HepaRG  
Origin: A hepatoma cell line isolated from a female patient with both HCC and hepatitis C infection 
Advantages: 
Unlike the other hepatoma cell lines, HepaRG is 
susceptible to HBV infection, and thus, the entire 
replication cycle, viral attachment, entry, drug 
metabolism as well as viral uncoating can be studied 
in this cell line 
Disadvantages: 
Requires constant supplementation of DMSO and 
hydrocortisone to keep cells from de-differentiating 
and losing NTCP expression 
Requires both DMSO and polyethylene glycol for 
efficient infection;ß despite supplements it is still 
likely that only a subpopulation of the cells remains 
susceptible to infection 
Low HBV replication is seen in this cell line 
Huh7 and HepG2 
Origin of Huh7: A hepatoma cell line obtained from a 57-year-old Japanese male with HCC 
Origin of HepG2: A human hepatoblastoma cell line isolated from a 15-year-old Caucasian American male 
with HCC 
Advantages: 
Can be transfected with overlength genome plasmids, 
which then support viral replication, viral gene and 
protein expression, viral assembly and production of 
infectious virions, which can be stably maintained for 
extended periods of continuous study and can be 
propagated in a purely chemically defined media. 
HBV replication is high in this cell line, continuous 
study lasting up to nine months in passaged 
transfected cells is possible, they retain functional 
hepatocyte activity to a large degree 
If constitutive expression of NTCP can be achieved 
both these cell lines are susceptible to HBV infection 
Can be propagated into a stable cell line, which can 
overcome inter-experimental variability 
Disadvantages: 
Not susceptible to direct HBV infection 
Susceptible to mycoplasma infection 
Low drug metabolizing capability  
The mutated p53 gene in Huh7 cells results in an 
increased half-life as well as increased expression of 
p53 in these cells 
Both cell lines do not allow for study of the 
oncogenic potential of HBV as they are already 
derived from cancerous cell lines  
Transfection efficiencies may vary 
This table was constructed using a number of resources to summarise the main features of 
several popular cell culture systems. [5, 16, 45, 60, 185, 186, 188-191] 
 41 
1.1.11 Study Rationale: Why Carry Out Functional Characterisation on 
S Deletion-mutants 
It is apparent that preS deletion-mutants play an integral role in the rapid development 
of HCC [91, 124, 170]. HIV co-infection is not just another risk factor for HCC 
development, but may lend an opportunity for HBV occult infection going unnoticed and 
probably untreated [126-132, 138, 157]. While much work has been done in genotypes 
other than genotype A, limited work on molecular characterisation has been undertaken 
and as yet no functional characterisation of preS deletion-mutants in subgenotype A1 
has been performed to date in the African context [39, 100, 117, 133, 134, 137, 138, 
140, 142, 147, 153, 179].  
The cohort from which this current study draws, enrolled 298 treatment-naïve and HIV-
positive patients from Mpumalanga in South Africa, of which 23.8% were co-infected with 
HBV (Figure 1.10 below) [153]. It was found that out of a pool of 71 HIV-co-infected 
patients, 43 (63%) of those had occult HBV infection (Figure 1.10) [153].  
 
Figure 1.12 Shongwe Cohort Outcomes on Co-Infection and Occult HBV 
The numbers reported here are from the Bell et. al., 2012 Shongwe cohort study, which was 
carried out in Mpumalanga South Africa, highlighted in red on the map [153]. The red pie chart 
represents the number of individuals who were HIV-positive, and either mono- (76%) or co-
infected (24%). The number appearing above the percentage represents actual participants, the 
total of which was 298. The yellow pie chart shows the proportions of participants from the co-
infected group who were classified as either overt or occult infection cases.  
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When sequencing of the S region of 29 of these patients was carried out, isolates from 
five patients were found to have deletions in either the preS1, preS2 or both [52]. Four 
of these isolates were from HBsAg-positive participants, but one was a case of occult 
HBV infection [52]. The deletions were in-frame and ranged from 30-66 nt deletions 
which are mapped in Table 1.11 and depicted in Figure 1.13 [52]. One additional patient 
sequence, SHH193A was chosen as it was a full-length sequence and could thus be 
employed as a full-length cloning control. Notably, this patient was confirmed to have an 
occult infection, as this patient had undetectable HBsAg in serum and had a viral load 
above 200 IU/ml [52, 145].  
Importantly, in other studies carried out in southern Africa and India it was found that a 
very high percentage of patients, infected with subgenotype A1 strains and having 
developed HCC, harboured HBV with the same deletions in the preS region [118, 192]. 
 
Table 1.11: Summary of Patient Sequences Selected from the Shongwe Study 
No. Patient Subgenotype Deletion 
Region No of 
nucleotides 
Positions from 
the EcoRI site 
1. SHH011A A1 preS1  
and  
preS2 
30 nt  
and  
66 nt 
2900 to 2929 
and 
3211 to 3255 
2. SHH045A A1 preS2 33 nt 23 to 55 
3. SHH167A A1 preS2 45 nt 9 to 54 
4. SHH274A A1 preS2 54 nt 2 to 55 
5. SHH300A A1 preS2 54 nt 3 to 56 
   Point Mutations (Positions from the EcoRI site). 
6. SHH193A A1 Full-length 
It should be noted that while the sequence from patient SHH193A was a full-length sequence, 
and a WT relative to the deletion-mutants. This patient sequence was the most similar to the 
HBV backbone into which it would be cloned, and could thus be used as a cloning control. This 
patient was confirmed to have a false occult infection [52]. Thus HBsAg was undetectable in 
serum however viral load was above 200 IU/ml at baseline [52, 145].  
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Figure 1.13: Graphical Representation of Sequences Selected from the Shongwe 
Study 
Each participant was identified by the SHH denoting the Shongwe study as well as a number 
indicating the order in which they entered the cohort study. In each case, the deletion size and 
relative positions are indicated on the grey dotted area. The deletions are outlined in this figure 
relative to the WT subgenotype A1 S gene of the A12C15_OL 1.28 MER construct and the full-
length SHH193A patient sequence. 
 
The primary aim of this study is to construct a plasmid with the preS1 and preS2 
deletion-mutants discovered in the Shongwe study in a subgenotype A1 backbone and 
to establish whether these deletion-containing constructs are replication-competent. The 
objectives for this study include: 
• Amplification of the complete S region from DNA extracted from Shongwe patient 
samples 
• Cloning of the S region into pTZ57R/T plasmid for a quasispecies analysis of the 
viral population in each of these patients. 
• Subcloning deletion sequences closest to parent sequence isolated from patients 
into an overlength, replication-competent, WT subgenotype A1 backbone (originally 
constructed by Nimisha Bhoola [158, 193]) using restriction and ligation enzymes.  
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• Transfecting the WT replication-competent clone (as a control and basis of 
comparison) as well as the newly constructed deletion-mutant and occult clones into 
Huh7 cells, which simulate the liver microenvironment.  
• To establish replication competence by following viral replication using the 
expression of viral proteins using enzyme-linked immunosorbent assay (ELISA) as well 
as viral load (VL) quantification using quantitative Real-Time PCR (qPCR) [51]. 
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2 Chapter Two: Materials and Methods 
Overview and Workflow of the Study: 
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2.1  List of Materials and Equipment 
All experimental procedures were performed according to standardised protocols either 
set out by manufacturers or published methods as described [194]. For detailed 
protocols, and the composition of reagents and solutions, electrophoresis gels, as well 
as other related compounds, please refer to Appendices A and B respectively. 
 
2.1.1 Complete List of Materials Used for This Study: 
Primers and synthesised DNA:  
Integrated DNA Technologies (IDT) of Whitehead Scientific (Cape Town, South Africa) was 
the preferred supplier for the following: 
1. Forward and reverse primers for the complete S-gene (refer to Figure 2.2 and Table 
5.1 in Appendix A) 
2. HBV Primers for Real-Time PCR (refer to Table 5.10 in Appendix A)  
3. Two synthesised genes, within pIDTBlue plasmids (Figures 5.6 and 5.7 in Appendix C).  
Enzymes: Some Mung Bean Nuclease, DNaseI and some restriction enzymes and their 
respective buffers, as well as 100x BSA buffer, were obtained from New England Biolabs 
(Ipswich, USA).  The large majority of restriction enzymes and T4 DNA ligase was 
acquired from Thermo Fisher Scientific Inc. (Renfrew, Scotland). HotStarTaq® Polymerase 
was supplied by Qiagen GmbH (Hilden, Germany), and Roche (Mannheim, Germany) 
supplied the Taq/Tgo Polymerase mix in the High Fidelity Expand Kit. The PCR 
Terminator® End Repair Enzyme was acquired from Lucigen (Middleton, USA). Remaining 
DNaseI recombinant, RNase-free was obtained from Roche (Mannheim, Germany). 
SsoFast™ EvaGreen® Supermix for Real-Time PCR was obtained from BioRad (California, 
USA). 
Molecular Weight Markers:  Ladders for nucleic acids, such as the O’GeneRuler™ 1kb 
DNA Ladder, GeneRuler™ 1kb DNA Ladder, 1kb DNA Plus GeneRuler™ Ladder and 
O’GeneRuler DNA Ladder Mix were acquired from Thermo Fisher Scientific Inc. (Renfrew, 
Scotland). The 1 kb DNA Ladder was supplied by Promega (Madison, USA). 
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Gel Electrophoresis: Molecular Grade Agarose was supplied by White Scientific (Cape 
Town, South Africa). Ethidium Bromide was from Bio Basic Inc. (Ontario, Canada). Novel 
Juice Gel Staining Reagent was obtained from GeneDireX (Gueishan, Taiwan). 
Kits: The NucleoBond® PC 500 Kit, NucleoBond® XtraMidi EF, NucleoSpin® Plasmid 
QuickPure and NucleoSpin® Gel & PCR Cleanup Kit were supplied by Machenerey-Nagel 
GmbH & Co (Düren, Germany). Qiagen GmbH (Hilden, Germany) was the preferred 
supplier of the following: HotStarTaq® Mastermix PCR Kit, QIAprep® Spin Miniprep Kit, 
QIAamp®DNA Blood Mini Kit. ZymoResearch (California, USA) supplied the DNA 
Clean&Concentrator Kit.  The High Fidelity Expand PCR Kit was procured from Roche 
(Manheim, Germany). PCR Terminator® End Repair Kit was acquired from Lucigen 
(Middleton, USA). The Murex® HBsAg Version 3 ELISA and ETI-EBK PLUS HBeAg Kits 
were obtained from DiaSorin (Sallugia, Italy). Monolisa™ HBsAg ULTRA Kit for 
immunocapture was obtained from BioRad (California, USA).  
Antibiotics and Bacterial Strains: Kanamycin and Ampicillin were acquired from Melford 
Laboratories (Ipswich, UK). For the bacterial strains, DH5α Escherichia coli was obtained 
from Invitrogen Life Technologies (Paisley, Scotland), and the SCS110 Escherichia coli 
was obtained from Stratagene-Agilent Technologies (California, USA). 
Dry Chemicals: Peptone/Tryptone, Yeast Extract and Piperazine-1,2-bis(2-ethanesulfonic 
acid) (PIPES) were obtained from Merck (Darmstadt, Germany). Merck (Wadeville, South 
Africa), supplied Bacteriological Agar, Sodium Chloride and 
Tris(hydroxymethyl)aminomethane. Both Magnesium Chloride and Calcium Chloride were 
supplied by Saarchem (Krugersdorp, South Africa).  
Liquids: Alcohols such as Absolute Ethanol, Methanol, Propan-2-ol and Glycerol we 
supplied by Merck (Darmstadt, Germany), which was also the preferred supplier of the 
cleaning agent Extran. Acids such as Hydrochloric Acid were obtained from Saarchem 
Merck (Krugersdorp, South Africa). Sterile saline water (used as best-quality water in PCR, 
was supplied by Adcock Ingram (Johannesburg, South Africa), and ULTRAPure Water was 
supplied by GibCo by Life Tech Technologies (Paisley, Scotland). 
Plasticware and other consumables: Lab coats were obtained from Supreme Workwear 
(Johannesburg, South Africa). All nitrile and latex gloves were acquired from Lasec (Cape 
Town, South Africa). 5, 10, 20 and 50 ml pipettes were acquired from Techno Plastic 
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Products® (Trasadingen, Switzerland). 15 ml falcon tubes and 50ml tubes were obtained 
from Greiner Bio-One (GmbH, Austria). Minisart 0.2 µm Filter units were obtained from 
Sartorius (Goettingen, Germany). All 1,5 and 2,0 ml tubes were supplied by Eppendorf 
(Barkhausenweg, Hamburg). Thin wall PCR* tubes were acquired from QSP Hoffman-
LaRoche (Basel, Switzerland). Petri dishes 47 mm for bacterial work were supplied by 
Merck Millipore (Darmstadt, Germany). MicroAmp™ Optical 96-Well reaction plates for 
Real-Time PCR were supplied by Applied Biosystems (Singapore, Republic of Singapore). 
Microseal® ‘B’ film to seal 96-well plates was obtained from BioRad (California, USA). 
Tissue Culture: Hyclone Foetal Bovine Serum was acquired from Thermo Scientific 
(Northumberland, UK). Gibco™ Phosphate Buffered Saline tablets, Gibco™ 0.25% Trypsin 
EDTA (10x), DMEM GlutaMAX™ media and 100x Pen Strep Glutamine were supplied by 
GibCo™ by Life Tech Technologies (Paisley, Scotland). 75 cm2 cell culture flasks were 
obtained from Sigma (St. Louis, USA). Tissue culture 12-well plates, as well as 5, 10, 20 
and 50 ml pipettes, were acquired from Techno Plastic Products® (Trasadingen, 
Switzerland). Minisart 0.2 µm filter units were obtained from Sartorius (Goettingen, 
Germany). TransIT® Transfection reagent was obtained from Mirus Bio (Madison, USA). 
Polyethylenimine linear (PEI) was supplied by Polysciences Inc. (Pennsylvania, USA). 
Protease Inhibitor Cocktail tablets cOmplete Mini was obtained from Roche (Manheim, 
Germany). 
2.1.2 Complete List of Equipment Used for This Study: 
Pipettes either from Gilson Inc. (Middleton, USA), or from Finnpipette made by Thermo 
Fisher Scientific Inc. (Renfrew, Scotland).  The Eppendorf Easypet 4221 was supplied by 
Eppendorf (Barkhausenweg, Hamburg). Other Eppendorf acquired equipment included 
centrifuges S810R, 5424, 5417C and 5453, the Mastercycler gradient 5331 PCR machine 
as well as the Thermomixer Comfort with 1.5ml adaptor (Barkhausenweg, Hamburg). The 
Hettich Universal II centrifuge in the tissue culture area was obtained from DJB Labcare 
Ltd. (Buckinghamshire, UK). Transilluminators used to visualise non-ethidium bromide 
electrophoresis results included the Kodak Electrophoresis Documentation and Analysis 
System supplied by Panavision (Midrand, South Africa) and the DarkReader 
Transilluminator DR-45M from Clare Chemical Research (Dolores, US). The gel 
electrophoresis workstations including the Sub-Cell® GT electrophoresis tanks and the 
PowerPac™ Basic power packs were supplied by BioRad (California, USA). For visualising 
 49 
and recording gel electrophoresis results the BioRad Geld Doc system and the 
accompanying software; Quantity-One v4.6.9 from BioRad (California, USA) was used. 
Also from BioRad: the Microplate Reader Model 680, the Plate Washer PW40, the T100™ 
Thermal Cycler PCR machine, as well as the CFX96™ Real-Time System with C100™ 
Thermal Cycler (California, USA). The NanoDrop ND 1000 spectrophotometer was from 
NanoDrop Technologies-Thermo Fisher Scientific Inc. (Waltham, USA). The heating block 
used was the Accublock Digital Dry bath and vortex machine used was the VX10 as well 
as the Prism microcentrifuges were all supplied by Labnet International Inc. (Edison, USA). 
The Heidolph MR1 magnetic stirrer was obtained from Heidolph (Schwabach, Germany). 
The -70°C chest freezer, fume hood without UV light, the water baths and the 37°C 
shaking incubator were all acquired from Labcon Air and Vacuum Technologies (Midrand, 
South Africa). The Esco Ascent ductless fume hood was obtained from Esco® 
(Pennsylvania, USA). The Biosan DNA/RNA UV cleaner hood for PCR and extraction was 
procured from BioSan Medical-Biological Research and Technologies (Riga, Latvia). The 
Labotec Bio-Flow laminar flow fume hood in the tissue culture room was supplied by 
Labotec (Midrand, South Africa). The stationary 37°C incubator, Jouan EB 53, was 
obtained from Labexchange® (Burladingen, Germany). The tissue culture incubators 
included the Heal Force HF90 CO2 Incubator from Heal Force (Shanghai, China) and the 
Forma™ Scientific™ Water Jacketed CO2 Incubator supplied by Thermo Fisher Scientific 
Inc. (Renfrew, Scotland). A number of upright and chest fridges and freezers were 
obtained from Defy Appliances (Pty) Ltd (Durban, South Africa). The Orion Star™ A111 
pH benchtop meter was acquired from Thermo Fisher Scientific Inc. (Renfrew, Scotland). 
The Olympus CK2 inverted microscope was obtained from Olympus Optical Co., Ltd. 
(Tokyo, Japan). Two autoclaves were used; the Erma Optical Works autoclave was 
acquired from Optical Works Inc. (Tokyo, Japan) and the SteriLClav-28 from Raypa® 
(Barcelona, Spain). The UltraSonic Cleaner – Memory Quick was obtained from EUMAX 
(Shenzhen, China). Refrigerated Microfuge SIGMA 1-14K (Osterode am Harz, Germany). 
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2.1.3 Complete List of Bioinformatics Tools, Suites and Software Used 
for This Study: 
• CLC Main Workbench v6.6 and CLC Sequence Viewer v6.6 from CLC Bio (Aarhus, 
Denmark http://www.clcbio.com) 
• Unipro UGENE v1.10.1 from UniPro (Novosibirsk, Russia http://ugene.unipro.ru) 
• Finch v1.4.0 from Geospiza Inc. (Seattle, USA www.geospiza.com/finchtv)   
• MEGA v5.05, Molecular Evolutionary Genetics Analysis version 5 from the Institute of 
Molecular Evolutionary Genetics (Pennsylvania, USA http://www.megasoftware.net/) [195, 
196]  
• EnzymeX v3.1 by Nucleobytes.com Software (Amsterdam, The Netherlands 
http://nucleobytes.com/index.php/enzymex) 
• Fragment Merger Tool by Trevor Graham Bell (Johannesburg, South Africa 
http://hvdr.bioinf.wits.ac.za/fmt/) [197]  
• Pipeline: TreeMail by Trevor Graham Bell (Johannesburg, South Africa 
http://hvdr.bioinf.wits.ac.za/treemail/) {unpublished data} 
• Babylon Tool by Trevor Graham Bell (Johannesburg, South Africa 
http://hvdr.bioinf.wits.ac.za/SmallGenomeTools/) [198]  
• Mutation Reporter Tool by Dr Trevor Graham Bell (Johannesburg, South Africa 
http://hvdr.bioinf.wits.ac.za/mrt/) [199] 
• Quantity One 1-D Analysis Software from BioRad (California, USA http://www.bio-
rad.com/en-us/product/quantity-one-1-d-analysis-software) 
• GeneDoc: Analysis and Visualisation of Genetic Variation by Karl B. Nicholas, Hugh B. 
Nicholas Jr. and David W. Deerfield II. (San Francisco, USA 
http://www.nrbsc.org/gfx/genedoc/ebinet.htm) [200] 
• RANDOM.ORG - True Random Number Service by Dr Mads Haahr of the School of 
Computer Science and Statistics at Trinity College (Dublin, Ireland 
http://www.random.org/sequences/) 
• MEGA 5: Molecular Evolutionary Genetics Analysis by Sudhir Kumar, Koichiro Tamura, 
Daniel Peterson and Glen Stecher (Tokyo, Japan http://www.megasoftware.net/) [196] 
• jModelTest v2.1.4 by D. Darriba, G.L. Taboada, R. Doallo and D. Posada of the 
Department of Biochemistry, Genetics and Immunology at the University of Vigo and 
the Department of Electronics and Systems at the University of A Coruna (Vigo, Spain 
https://code.google.com/p/jmodeltest2/) [105] 
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• PAUP* v4.0a142 by David L. Swofford at Duke University (Durham, USA 
http://paup.csit.fsu.edu/) [201] 
• GARLI: Genetic Algorithm for Rapid Likelihood Inference by Derrick J. Zwickl (Austin, 
USA http://www.bio.utexas.edu/faculty/antisense/garli/garli.html) [202] 
• BEAUti: Bayesian Evolutionary Analysis Utility v1.8.0 by Alexei J. Drummond, Andrew 
Rambaut, Marc A. Suchard and Walter Xie of the Institute of Evolutionary Biology, 
University of Edinburgh (Edinburgh, Scotland http://beast.bio.ed.ac.uk/) [104] 
• BEAST: Bayesian Evolutionary Analysis Sampling Trees v1.8.0 by David Geffen and 
Andrew Rambaut of the Institute of Evolutionary Biology, University of Edinburgh 
(Edinburgh, Scotland http://beast.bio.ed.ac.uk/) [104] 
• Tracer v1.6.0 by Andrew Rambaut, Marc A. Suchard, Walter Xie and Alexei J. 
Drummond of the Institute of Evolutionary Biology, University of Edinburgh (Edinburgh, 
Scotland http://beast.bio.ed.ac.uk/) [103, 104]  
• Tree Annotator v1.8.0 by Andrew Rambaut and Alexei J. Drummond of the Institute of 
Evolutionary Biology, University of Edinburgh. 
(Edinburgh, Scotland http://beast.bio.ed.ac.uk/treeannotator) [104] 
• FigTree: Tree Figure Drawing Tool v1.4.0 by Andrew Rambaut of the 
Institute of Evolutionary Biology, University of Edinburgh. 
(Edinburgh, Scotland http://tree.bio.ed.ac.uk/) [104] 
• R Studio – open-source commercial statistics package by R Studio. (Boston, USA 
https://www.rstudio.com/products/rstudio/) 
• Bio-Rad CFX Manager v2.1.1 Real-Time Software System by developed by BioRad 
Laboratories (California, USA https://bior-rad.com/pcrsoftware)  
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2.1.4 List of Plasmids Generated and Util ised During This Study: 
Table 2.1: Constructs Generated and Utilised During This Study 
Plasmid Name: Description: Source/Reference  
pIDTBlue A high-copy vector of 2951 bp in size. Based on 
the pBluescript II SK (+) phagemid; originally 
designed for cloning, sequencing and in vitro 
transcription. Used here as a backbone for 
synthesised gene products 
Integrated DNA 
Technologies (IDT) 
Gene Products (Alting-
Mees, 1989 [203]) 
pIDTBlue_S011A-1 A 3710 bp plasmid containing a 709 bp 
synthesised segment of SHH011A plus flanking XbaI 
sites with Ampicillin resistance gene 
Generated for this 
work by IDT Gene 
Products 
pIDTBlue_S045A-1 A 3773 bp plasmid containing a 772 bp 
synthesised segment of SHH045A plus flanking XbaI 
sites with Ampicillin resistance gene 
Generated for this 
work by IDT Gene 
Products 
pTZ57R/T TA cloning vector that allows for blue-white 
screening and has an ampicillin resistance gene 
Thermo Scientific/ 
Fermentas 
pEGFP-C3  A mammalian expression vector containing a 
fluorescent tag (Green Fluorescent Protein) under 
the control of the CMV promoter. Contains a 
Kanamycin resistance gene. Used here to calculate 
transfection efficiency 
Addgene/Clonetech 
pcDNA™4/TO 
Vector 
pcDNA™4/TO is a 5.1 kb expression vector 
available from Invitrogen. The vector allows 
expression of the gene of interest in transfected 
mammalian host cells  
Invitrogen Life 
Technologies 
A12C15_OL 
A1WTSA1.281MER 
1.28 overlength replication-competent Hepatitis B 
Virus genome of subgenotype A1 within pcDNA4_TO 
backbone 
Bhoola, N.H., et. al., 
2014 [193] 
A12C15_OL 
A1WTSA1.281MER  
Altered 9.3 
1.28 overlength replication-competent Hepatitis B 
Virus genome of subgenotype A1 within pcDNA4_TO 
backbone, where the third XbaI site present in the 
backbone was removed and is thus 32 bp shorter 
than the parent plasmid 
Present study 
OL _DELMUT 
SHH011A-F 
The 1.28 overlength replication-competent 
subgenotype A1 backbone containing the SHH011A 
deletion-mutant in the correct orientation 
Present study 
OL _DELMUT 
SHH045A-F 
The 1.28 overlength replication-competent 
subgenotype A1 backbone containing the SHH045A 
deletion-mutant in the correct orientation 
Present study 
OL _DELMUT 
SHH167A-F 
The 1.28 overlength replication-competent 
subgenotype A1 backbone containing the SHH167A 
deletion-mutant in the correct orientation 
Present study 
OL _OCFL 
SHH193A-F 
The 1.28 overlength replication-competent 
subgenotype A1 backbone containing the S region 
of patient SHH193A, which is a occult full-length, 
sequence in the correct direction 
Present study 
For complete plasmid maps of all plasmids used in this study, please refer to Appendix C.  
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2.1.5 List of Bacterial Strains and Cell Culture Lines Util ised in This 
Study: 
Table 2.2: Summary of the Bacterial Strains and Cell Lines Used for This Study  
Bacterial Strain 
or Cell Line: 
Description: Supplier and 
Reference: 
Escherichia coli 
DH5α 
This bacterial strain is used for routine cloning Invitrogen Life 
Sciences [204] 
Escherichia coli 
SCS110 
This is a Dam and Dcm methylation-free strain 
used for cloning when DNA needs to be restricted 
with methylation-sensitive enzymes 
Stratagene-Agilent 
Technologies [205] 
Escherichia coli 
XLBlue 
Host strain for routine cloning, allows for blue-white 
screening 
Stratagene-Agilent 
Technologies [205] 
Huh7 human 
hepatic cell line 
A human hepatic cell line generated from the 
explant of the hepatocellular carcinoma of a male 
patient in Japan in 1982 
Dr Abdullah Ely from 
the AGTRU  
 
2.2  Overview of Statistics Employed in This Study 
Where appropriate statistical analysis was done using the student T-test to establish 
significant relationships in the data. This was done in a pairwise fashion using the R 
Studio software. Only where the p-values were equal to or below 0.05 was it considered 
significant. 
2.3  Study Participants and Ethical Clearance 
A cohort was established the Shongwe Hospital, in Malelane, a rural area in the 
Mpumalanga province of South Africa [52]. All patient sera were anonymised using a 
number referring to the order in which they were enrolled in the cohort from July 2009 
to December 2010 [133, 153]. Biomedical and clinical data were matched to the number 
in a database. During a previously completed Masters project, it was found that five HIV-
infected patients were co-infected with HBV with deletions in the PreS1 and PreS2 
regions [52].  Isolates from these five patients were chosen for the present study. 
Furthermore, an isolate from a sixth patient, SHH193A, was chosen as it had no 
deletions (i.e. full-length) however the patient was classified as having false occult HBV 
infection [52, 153]. The quasispecies population of HBV isolated from the patients, at 
baseline, before the initiation of antiretroviral therapy, was analysed. Table 2.3 below 
outlines some key clinical data for the selected patients. 
 
 54 
 
Table 2.3: Key Clinical Data for Selected Shongwe Patients 
 
Patient Gender Age BMI HBsAg HBeAg Viral Load 
copies/ml 
Viral Load 
IU/ml 
SHH011A F 25 27.1 + - 6.53e x 03 1.39e + 03 
SHH045A F 18 26.3 - - 2.98e + 04 6.33e + 03 
SHH167A M 38 16.7 + - 1.35e + 05 2.86e + 04 
SHH274A F 52 21.2 + + 5.16e + 04 1.10e + 04 
SHH300A M 33 20.9 + - 1.55e + 03 3.30e + 02 
SHH193A F 23 18.7 - - 2.06e + 04 4.93e + 03 
 
The medical arm of the Human Research Ethics Committee of the University of the 
Witwatersrand was consulted for ethical clearance for this study. The study received 
unconditional approval from the committee on the 11th of May in 2012, certificate 
number M1204106 (Appendix D). 
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2.4  Quasispecies Analysis – General Recombinant Nucleic 
Acid Manipulation, Cloning and Phylogenetic Analysis  
 
2.4.1 DNA Extraction 
To obtain purified DNA from patient sera, the QIAamp® DNA Blood Mini Kit was used 
(full protocol refer to Appendix A). 200 µl of serum from patients, as well as from 
controls was used (Figure 2.1). The HBV isolated from SHH193A had no deletions in the 
S gene region and thus served as a full-length cloning control. DNA was eluted into 75 
µl of best-quality water (BQW) and then used as template for amplification by PCR. 
 
Figure 2.1: Algorithm for DNA Extraction 
Each round of extraction required 200 µl of serum; DNA was eluted into 75 µl of BQW. 
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2.4.2 PCR Amplification 
The complete S region was amplified using a nested PCR with specific primers [86], 
(Figure 2.2). 
Figure 2.2: Nested PCR Strategy, Primers and Amplicons 
Nested PCR, strategy, where S1F and S1R are the primers for the first round and S2F and S2R 
for the second round. Primer sequences are represented in light blue and amplicons in pink. Note 
the position of the EcoRI site, which is important in the numbering of the HBV genome. 
 
Initially, a Hot Start Taq polymerase was used, just to confirm that DNA extraction was 
successful, and the desired amplicons were being produced (HotStarTaq® MasterMix PCR 
kit). Subsequently, the Roche Expand High Fidelity PCR System was employed as it 
provides TA overhangs, which assists in easy cloning into a vector. Also, this system 
contains an enzyme blend of both thermostable Taq Polymerase and Tgo Polymerase. 
The Tgo enzyme possesses proofreading ability and thus provides high specificity of PCR 
products. The final dNTP concentration was 200 µM of each dNTP in both PCR protocols, 
(see content detail in Table 5.2, Appendix A). In both PCR protocols, the positive control 
consisted of DNA extracted from an HBV-positive serum sample and the negative 
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controls included DNA extracted from an HBV-negative serum samples, as well as BQW 
only where no DNA was added.  
Both PCR processes were optimised using the Taguchi method [206] and the cycling 
conditions are detailed (Figure 2.3). To confirm the size of the PCR products, 5 µl of the 
PCR product was run on a 1% agarose gel using a current to separate products by size. 
The BioRad GelDoc system was used to visualise and capture the images of the PCR 
products on the gel for analysis and confirmation of PCR success.  
 
Figure 2.3: The PCR Cycling Conditions for Amplification of the Entire S Region 
The cycling conditions for the first round and the second round of the two PCR reactions are 
identical, except for the difference in time during the initial denaturation step. The HotStart 
protocol requires a 10-minute initial denaturation, whereas the High Fidelity protocol only needs a 
1-minute initial denaturation.  
 
2.4.3 Cloning and Sequencing 
The PCR products that were the correct size were carefully excised from the gel. The 
amplified DNA was extracted and purified from the gel slice using the Zymo Research 
DNA Clean&Concentrator Kit (Appendix A 5.1.2). Where it was intended to use DNA for 
downstream cloning, gels were stained with Novel Juice instead of ethidium bromide so 
as to avoid damage to the DNA. T and A overhangs were added by Taq, thus the 
purified DNA segments were directly ligated into a cloning vector. In this case, the 
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InsTAclone™ PCR Cloning Kit with the pTZ57R/T cloning vector was employed. Once the 
PCR products were ligated into the pTZ57R/T, these circular constructs were transformed 
into DH5α competent cells (Appendix A; 5.1.4 - 5.1.8 for details). White colonies were 
then screened for clones using the cracking method and restriction digestion with XbaI 
(see Appendix A; 5.1.5 and 5.1.9). After mini-prep (Appendix A 5.1.6), DNA from selected 
clones was sent to the Stellenbosch Sequencing Unit for Sanger sequencing. Figure 2.4 
below shows the details of the sequencing primers. After chromatograms had been 
carefully checked and any wobble bases disambiguated, the DNA Fragment Merger Tool 
[197] was used to merge the three overlapping sequences into the complete S sequence 
fragment (Figure 2.4). These sequences were used to identify clones that were suitable 
for subcloning into the overlength subgenotype A1 backbone, as well as being used for 
analysis of the quasispecies via phylogenetic analysis. 
 
Figure 2.4: Graphical Representation of Sequencing Primers Used for Determining 
DNA Sequence of Quasispecies. 
Each primer is likely to give a read of 800 bp of good quality sequence; the overlapping 
fragments were merged in the correct order using the Fragment Merger Tool. These merged 
sequences could then be aligned and used for phylogenetic analysis. 
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2.4.4 Phylogenetic Analysis 
For phylogenetic analysis 30 HBV clones from each patient were chosen randomly out 
of the total pool of clones for phylogenetic analysis using the free online random 
number generator:  
RANDOM.ORG (http://www.random.org/sequences/)  
The random selection process ensured that the quasispecies analysis was not skewed or 
biased by manual selection of clones. Using ClustalW alignment in CLC Main Workbench, 
the sequences of the selected clones were aligned with the preS1/S2/Surface region of 
6 subgenotype A1 sequences and a genotype F sequence as the root, from GenBank, 
[102]. For purposes of comparing the preS1/S2/Surface region of representatives from 
each genotype of HBV, 100 sequences were selected from Genbank. These are listed in 
Appendix G (Table 5.12).  Three phylogenetic trees were constructed:  
1. Neighbor-Joining Phylogenetic tree with bootstrapping of 1000 data sets – the 
multiple sequence alignment was submitted as a PHYLIP file to Pipeline: TreeMail 
(http://hvdr.bioinf.wits.ac.za/treemail/). The resulting tree was annotated in FigTree 
(http://tree.bio.ed.ac.uk/).  
2. Maximum likelihood tree with bootstrapping of 1000 data sets – the multiple 
sequence alignment was submitted as a Nexus file (http://www.megasoftware.net/) 
to Garli (http://www.bio.utexas.edu/faculty/antisense/garli/garli.html). The resulting 
tree was annotated in FigTree (http://tree.bio.ed.ac.uk/).  
3. Maximum Clade Credibility tree using BEAUti and BEAST programs 
(http://beast.bio.ed.ac.uk/). Model testing was carried out using the 
programmes jModelTest v2.1.4 (https://code.google.com/p/jmodeltest2/) and 
PAUP* (http://paup.csit.fsu.edu/). The tree was then analysed using Tracer 
v1.6.0 (http://beast.bio.ed.ac.uk/) and finally annotated in FigTree 
(http://tree.bio.ed.ac.uk/).  
The complete algorithms for producing all trees are included in Appendix F.  
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2.5  Generation of Overlength Clones Containing PreS1 
Mutations 
 
2.5.1 Cloning Strategy Design 
The A12C15_OL A1WTSA1.281MER was chosen as the backbone for cloning the deletion-
mutants. This construct is a 1.28 overlength replication-competent HBV genome of 
subgenotype A1 within pcDNA4_TO backbone that was constructed using a novel method 
described by Bhoola et al. [193]. XbaI restriction sites were identified in the S region of 
HBV that flanked the preS deletions, and these sites were present in the same genomic 
position in the HBV overlength genome inserted into pcDNA4_TO vector (Figures 2.5 and 
2.6).   
Thus, the genomic region containing the mutations could be restricted and ligated into 
the overlength backbone in the equivalent position, to replace the WT. However, in 
addition to the two suitable XbaI sites in the HBV, the vector contained a third XbaI site. 
The latter XbaI site was removed by restriction with ApaI and NotI (Figure 2.6). The ends 
were blunted using the Lucigen End Repair Kit; the modified plasmid was re-ligated to 
become circular again and transformed to SCS110-competent cells. Full restriction 
mapping was carried out to confirm the integrity of this resulting plasmid. 
 
Figure 2.5: Layout of the Overlength A12C15_OL A1WTSA1.281MER Backbone 
and the ORFs of HBV Including Identified Restriction Sites 
This image shows a scale representation of how the overlength genome of HBV is oriented. The 
black line above represents a two times the full genome and all the relevant restriction sites. 
Note the position of the two central XbaI sites, which were the sites that flank the Pres1 and 
PreS2 regions where deletions were identified. These were the XbaI sites that were used for 
inserting fragments containing deletions into the overlength backbone.  
 
Polymerase ORF
1.28 MER Overlength Subgenotype A1 HBV
preS1 SurfaceS2 XX preCore & Core preCore & Core
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Figure 2.6: Algorithm to Alter the Backbone of the Plasmid for Subcloning 
Purposes 
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Clones of the deletion-mutants that were identical to those of the major population of 
HBV isolated from each patient (i.e. homologous to the parent strain) were chosen for 
subcloning into the modified plasmid using the identified XbaI sites (Figure 2.7 and 2.8). 
The resultant clones were transformed into SCS110-competent cells (See Appendix A 
5.14). Colonies were screened by cracking and restriction for clones that contained the 
insert in the correct orientation (see Appendix A 5.1.5 and 5.1.9 respectively). Complete 
restriction mapping and sequencing were used to confirm correct insertion and 
orientation.  
 
Figure 2.7: Algorithm for 784 bp Fragment Generation 
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Figure 2.8: Identification of Suitable Restriction Sites and Cloning Workflow 
Initially, a multiple sequence alignment was used to check whether all PCR amplified fragments 
contained the XbaI sites in the same genomic positions as the plasmid overlength backbone. 
Once it was confirmed that the XbaI sites were a suitable enzyme to use for cloning purposes, a 
cloning workflow was established. First PCR amplicons were cloned into pTZ57R/t plasmid, and 
once confirmed, the XbaI to XbaI fragment was restricted out of the appropriate clone (A), and 
similarly the fragment was removed from the A12C15_OL A1WTSA1.281MER Alt 9.3 backbone (B). 
Finally, the fragment identified in a patient isolate was ligated into the A12C15_OL 
A1WTSA1.281MER Alt 9.3 backbone (C), to produce an overlength clone containing the mutant 
fragment. 
 
2.5.2 Replication Capacity of Clones  
The nucleic acid sequences of the cloned final constructs were translated using 
GeneDoc and the Babylon tool [198], to determine whether the start and stop codons 
were still in-frame and to ensure correct expression of the viral proteins and to prevent 
the transfection of clones with artefactual mutations. Those constructs that were 
homologous to the parent strains were transiently transfected into an Huh7 cell line. 
These cells were grown in complete Dulbecco’s Modified Eagle’s Medium (DMEM) which 
contains 10% Foetal Calf Serum (FCS), L-Glutamine (2.92 mg/ml) with antibiotics 
Streptomycin (1 mg/ml) and Penicillin (1000 units/ml). Huh7 cells were grown in 75 cm2 
culture flasks until they were at 90% confluent, then they were either frozen for stocks, 
split/passaged or seeded into 12-well plates for transfection (detailed protocols in 
Appendix A 5.1.11, details for solutions Appendix B). Transfections were carried out in 
12-well plates in triplicate, when cells were 90% confluent, with 2 µg of DNA and 5 µl of 
Polyethylenimine (PEI) transfection reagent.	   Transfection efficiency was calculated by 
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determining the percentage of cells successfully transfected with the pEGFP-c3 plasmid in 
a separate well. This plasmid contains Green Fluorescent Protein, which is self-
fluorescent under 395 nm light, emitting light at a 509 nm wavelength (Figure 2.8). The 
percentage of cells transfected was calculated by counting the number of fluorescent 
cells, relative to the total number of cells.  
 
Figure 2.9: The GFP-Containing Plasmid Used to Determine Transfection Efficiency 
 
Supernatant as well as the cells were collected on days 1, 3 and 5 post-transfection. 
For supernatants, a proteinase inhibitor cocktail (PIC) was added to preserve proteins 
and viral particles and then frozen at -70°C. For harvesting of cells, a protocol was 
followed that allowed for the disruption of cell membranes and the addition of PIC for 
storage at -70°C. The frozen samples were then thawed and used for ELISA and DNA 
extraction to be followed by qPCR quantification of VL. For DNA extraction, both 
supernatants and cell lysates were treated with DNaseI and RNaseA to remove any 
plasmid DNA, as this would falsely inflate VL detection. (Appendix A 5.1.11 - 5.1.17). 
ELISA was used to measure HBsAg and HBeAg expression after transfection. A plate was 
prepared where 75-100 µl of a 1:20 dilution of the supernatant was loaded into each 
well, in each case two biological replicates were added to the plate. The plate was only 
considered valid if it passed all the internal quality control specifications, and ODs were 
read at 620 and 450 nm. Samples were considered negative if the OD measure was 
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below the cut-off values, which was calculated by adding 0.05 to the mean of the kit 
provided negative control replicates. To analyse the data, the 620 nm reading was 
subtracted from the 450nm reading to get a ‘blanked’ result, and the average readings 
were normalised to the WT control. Furthermore, VL testing was done on the DNA 
extracted from both the supernatants and cell lysates via a SYBR Green qPCR strategy 
using primers designed for a conserved area of the BCP region of HBV. A serial dilution 
of plasmid pCH-9/3091 DNA was prepared from 109 copies decreasing to 103 copies to 
establish a standard curve. Only values with an R2 value of 0.92 and above were 
considered significant, and efficiency of the run should be between 95% and 105%. For 
qPCR a sample was considered negative if the Sq values were lower than the threshold 
and/or the water negative control. Each qPCR plate was prepared with three biological 
replicates from three independent transfections as well as three technical replicates for 
each sample. Finally, an immunocapture technique using a Monolisa™ HBsAg ULTRA 
ELISA plate to capture secreted virions from the supernatant on day 3 post-transfection 
and then extracting DNA for qPCR was employed. Thus, this technique developed by 
Samal et al., allows a method for the rapid quantification of VL of encapsidated DNA 
present in secreted virions only [207].  
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3 Chapter Three: Results 
Overview and Workflow of the Study: 
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3.1  Quasispecies Analysis - General Recombinant Nucleic 
Acid Manipulation, Cloning and Phylogenetic Analysis 
 
3.1.1 PCR Amplification of the Envelope (preS1/pre2/S) Region and 
Sequencing 
Specific S region primers were used to amplify the complete S region from extracted 
DNA. Once amplification was successful with a Hot Start Taq protocol, the Roche Expand 
High Fidelity PCR System was used to obtain amplicons of high fidelity. These amplicons 
were used for downstream cloning (Figure 3.1). SHH011A and SHH045A failed to amplify 
despite multiple attempts using both the Hot Start and High Fidelity protocols, and 
serum for these samples was depleted. Thus, it was decided to use synthetic nucleotide 
fragments, with the deletions, for downstream cloning (refer to Figure 5.6 and 5.7 in 
Appendix C).  
  
Figure 3.1: High Fidelity PCR of the S Region 
PCR results of the second round of nested PCR with Roche Expand High Fidelity PCR System. The 
figure shows a 1% Agarose gel stained with ethidium bromide. Here templates from the first 
round of PCR were diluted 1 in 100 and expected band size is 2055 bp. Primers were S2F 3’ 
AAT GTT AGT ATT CCT TGG ACT CAT AAG GTG GG 5’ and S2R 3’ AGT TCC GCA GTA TGG ATC 
GGC AGA GGA 5’. All controls were as expected. SHH011A and SHH045A were not amplified. This 
gel is representative of the High Fidelity PCR experiment, which was repeated a number of times 
to attain enough DNA for sequencing and cloning. 
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Before proceeding with purification and cloning, the amplicons were sent for Sanger 
sequencing to confirm the correct sequences for cloning (Figure 3.2). 
 
 
Figure 3.2: Alignment of PCR product against parent sequence 
This small segment of the overall alignment shows that the Roche High Fidelity PCR has 
reproduced the sequences identically, and thus these sequences were taken forward to cloning. 
This section shows the results obtained when the 3188F sequencing primer was used and similar 
results were obtained with both the 2497F and 519F primers. Note the figure shows both a 1 in 
50 and a 1 in 100 dilution product of the second round of the nested PCR. 
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3.1.2  Cloning Amplicons and Sequencing Clones  
Following transformation with pTZ57R/T containing the amplicons, white colonies were 
picked randomly from plates and screened. Cracking and restriction digest were used to 
identify positive clones (see Figure 3.3). In total 257 clones were produced 75 for 
SHH167A, 78 for SHH193A, 43 for SHH274A and 61 for SHH300A. All of these clones 
represent the pool from which quasispecies were analysed by phylogenetic comparison. 
 
 
Figure 3.3: Screening for clones using restriction by XbaI 
This gel is representative of screening by restriction digestion with XbaI. For pTZ57R/T+SHH193A 
the bands indicating a clone are 3935 bp, 783 bp and 244 bp; for pTZ57R/T+SHH274A the 
bands indicating a clone are 3916 bp, 739 bp and 244 bp; for pTZ57R/T+SHH300A the bands 
indicating a clone are 3916 bp, 730 bp and 244 bp. Not shown here, bands for 
pTZ57R/T+SHH167A would be 3916 bp, 739 bp and 244 bp. On this gel, all lanes marked with 
an asterisk show the correct bands and thus were counted as clones. This figure depicts a 1% 
Agarose gel, stained with ethidium bromide. 
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3.1.3  Phylogenetic Analysis: 
Using a random number generator (https://www.random.org/), 30 clones of HBV from 
each patient were sequenced. Fragments produced by the three sequencing primers were 
curated and then merged using the Fragment Merger tool [197]. A multiple sequence 
alignment was constructed containing the 4 parent sequences, sequences of the 120 (4 
x 30) clones. HBV subgenotype F was used as an outlier to root for the tree, and 19 
subgenotype A1 sequences for comparison. Both inter- and intra-group nucleotide 
divergences were calculated for the clones and their parental sequences (Table 3.1). A 
summary of molecular characteristics of the cloned sequences from the multiple 
sequence alignment is detailed in Table 3.2. While the parental sequence was found to 
represent the majority population within the quasispecies sequences, subpopulations of 
different sequences were identified. 
  
Table 3.1: Inter- and Intra- Group Divergence Within Quasispecies and the 
Parental Strains 
 
 
 
Mean nucleotide divergence in percentage was calculated using DAMBE (Data Analysis in 
Molecular Biology and Evolution) software [208]. Sequence divergence is reported as percentages 
of the mean divergence ± the standard deviation where intra-group divergence is shaded in 
yellow. The smaller the divergence, the more similar sequences are to each other. 
 
 
 SHH167A SHH193A SHH274A SHH300A 
SHH167A 11±0.07    
SHH193A 11±0.05 4±0.03   
SHH274A 12±0.05 10±0.01 2±0.02  
SHH300A 12±0.05 10±0.01 10±0.01 4±0.01 
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Table 3.2: Molecular Characteristics of Clones Relative to the Parental Strain 
Molecular Characteristics of Quasispecies 
Sequence Sequence characteristic Position of Indel Region 
Frequency 
no., (%) in 30 
clones 
Parent SHH167A 45 nt deletion 9 - 54 PreS2 N/A 
SHH167A 1.70 
30 nt & 66 nt deletions 
overlapping the 45 nt 
deletion 
2899 – 2929 & 
3212 -56 PreS1 1 (3.3%) 
SHH167A 1.77 63 nt deletion overlapping the 45 nt deletion 2 - 64 PreS1 1 (3.3%) 
SHH167A 2.134 19 nt deletion instead of 45 nt deletion 3201 - 3219 PreS1-PreS2 1 (3.3%) 
SHH167A 1.121 183 nt deletion instead of 45 nt deletion 3021 - 3209 PreS1 1 (3.3%) 
SHH167A 1.12 224 nt deletion instead of 45 nt deletion 127 - 350 Surface 1 (3.3%) 
SHH167A 1.3 134 nt deletion instead of 45 nt deletion 3020 - 3154 PreS1 1 (3.3%) 
SHH167A 1.133 
SHH167A 2.22 
SHH167A 1.69 
No 45 nt deletion 
 
- 
 
 
- 
 
 
3 (10%) 
Remaining 
Clones 45 nt deletion 9 - 54 PreS2 21 (70,2%) 
Parent SHH193A Full-length - - N/A 
SHH193A 1.147 
SHH193A 2.143 1 nt deletion 
608 
2911 
Surface 
PreS1 
1 (3.3%) 
 
SHH193A 2.141 
SHH193A 1.121 
SHH193A 1.150 
SHH193A 2.146 
SHH193A 2.144 
SHH193A 2.122 
54 nt deletion 
 
 
 
3 - 56 
 
 
Surface 
 
6 (20%) 
 
Remaining 
Clones Full-length - - 23 (76.7%) 
Parent SHH274A 54 nt deletion 2 - 55 PreS2 N/A 
SHH274A 2.21 96 nt deletion 3120 - 3215 PreS1 1 (3.3%) 
SHH274A 1.11 101 nt deletion overlapping the 54 nt deletion 3167 - 46 PreS1-PreS2 1 (3.3%) 
SHH274A 1.25 1 nt deletion 322 Surface 1 (3.3%) 
Remaining 
Clones 54 nt deletion 2 - 55 PreS2 27 (90%) 
Parent SHH300A 54 nt deletion 3 - 56 PreS2 96.6% 
SHH300A 2.14 21 nt deletion instead of the 54 nt deletion 35 - 56 PreS2 1 (3.3%) 
SHH300A 2.109 1 nt deletion 733 Surface 1 (3.3%) 
SHH300A 1.125 1 nt deletion 286 Surface 1 (3.3%) 
Remaining 
Clones 54 nt deletion 3 - 56 PreS2 27 (90%) 
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Initially, the sequences of the clones were compared using a Neighbor-Joining tree, and 
a few reference sequences to establish how the major and minor populations would 
cluster (Figure 3.4). Reference sequences were obtained from GenBank, and were 
trimmed and aligned such that only the PreS1/PreS2/Surface section is shown.  
The grouping and relative close relatedness of these sequences suggest that the 
deletion-mutants represent the major population of viral quasispecies circulating in each 
of the patients. Only one of the quasispecies, SHH167A 2.134 showed no deletion 
whereas the parental strain showed a 45 nt deletion. However, it also contained a 
separate 19 nt deletion in a different location. Interestingly, six clones derived from 
patient SHH193A (with the full-length parental strain) showed a novel deletion of 54 nt 
in a similar position as the parental strains from patients SHH274A and SHH300A. 
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Figure 3.4: Neighbor-Joining Phylogenetic Tree 
This tree demonstrates the phylogenetic similarity of complete PreS1/PreS2/Surface sequences of 
cloned quasispecies from four patients, established using the Neighbor-Joining method. Bootstrap 
statistical analysis was included to 1000 replicates, values above 65% are considered significant, 
some values are indicated as a percentage. All sequences obtained from GenBank are designated 
by their genotype, accession number and an acronym for the country of origin. Genotype F was 
used as the outlier to root the tree (light purple), and 19 Subgenotype A1 sequences from South 
Africa (dark purple) were included for comparison (detailed in Table 5.12, Appendix F). Branch 
lengths represent the amount of genetic change over time to scale of substitutions per site. Most 
sequences from patient SHH167A cluster together in group I, including four clones (SHH167A 
2.134; SHH167A 1.133; SHH167A 2.22; SHH167A 1.69) that have no deletion. The SHH167A_1.77 
displayed a 63 nt deletion which more closely resembled the deletion pattern of the SHH300A 
parent, and thus clustered with group III. SHH167A_1.70 contained extra novel deletions of 30 nt 
and 66 nt, which resulted in this sequence not clustering with any of the others. Most of the WT 
group from patient SHH193A clustered together in group II except 6 clones that had a novel 54 
nt deletion which cluster with SHH300A patient sequences in group III. Refer back to Table 3.2 for 
the complete list of novel mutations. 
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Once it was established how the quasispecies relate to each other and the reference 
PreS1/PreS2/Surface sequences, it was decided to carry out additional phylogenetic 
analysis of the quasispecies to the PreS1/PreS2/Surface sequences representative of all 
9 HBV genotypes. This tree was again constructed using Neighbor-Joining statistical 
methods and thus depicts evolutionary relatedness of the PreS1/PreS2/Surface 
sequences by minimum evolution, or maximum parsimony (Figure 3.5) [209]. 
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Figure 3.5: Neighbor-Joining Phylogenetic Tree with all the Genotypes  
Phylogenetic analysis of complete PreS1/PreS2/Surface sequences of cloned quasispecies from 
four patients to 105 complete PreS1/PreS2/Surface sequences representative of all 9 HBV 
genotypes. This analysis was established using the Neighbor-Joining method. Bootstrap statistical 
analysis was included to 1000 replicates, values above 65% are considered significant, these are 
indicated on the branches as a percentage. All sequences obtained from GenBank are designated 
by their genotype, accession number and country of origin, a full list of the sequences used are 
available in Table 5.12, Appendix F. Genotype F_DQ823092 from Argentina was used as the 
outlier to root the tree; the tree is presented in descending order. This tree was generated using 
the Pipeline Treemail tool, the tree was viewed in FigTree [104]. 
 
While the Neighbor-Joining method is known for its efficiency in obtaining a correct tree, 
it also assumes the smallest amount of total evolutionary change and constant rate of 
nucleotide substitution [209]. For comparison, a Maximum Clade Credibility Tree using 
Bayesian Markov Chain Monte Carlo (MCMC) inference method was also constructed, to 
see whether using this statistical model would show a different evolutionary relationship 
between the PreS1/PreS2/Surface sequences (Figure 3.6) [210]. This method uses prior 
knowledge (phylogeny distribution, statistical models and substitution rates) to evaluate 
the likelihood of a given tree [210]. Therefore, this method infers whether a tree is likely, 
based on the observations made [210]. The posterior probability is calculated by 
measuring the proportion of times that a tree is visited by the inferential chain [210]. 
Thus the closer to 1 the posterior probability, the better the evidence is for the 
placement of each node [210]. 
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Figure 3.6: Maximum Clade Credibility Tree with all the Genotypes 
Bayesian Markov Chain Monte Carlo (MCMC) inference method, comparing complete 
PreS1/PreS2/Surface sequences of cloned quasispecies from four patients to 105 complete 
PreS1/PreS2/Surface sequences representative of all 9 HBV genotypes. The genotype, accession 
number and country of origin for all designated sequences was obtained from GenBank, a full list 
of the sequences used are available in Table 5.12, Appendix F. A relaxed molecular clock was 
used for analysis and the generalised time-reversible (GTR) substitution model and a gamma 
distribution model was employed. The MCMC analysis was run for 100 000 000 states, the 
Effective Sample Size (ESS) was 190, and their uncertainties were represented in the 95% Highest 
Posterior Density intervals. Branch lengths represent a 2% divergence as per the scale. The tree 
is presented in descending order. The tree was generated using BEAUti and BEAST; and analysis 
was conducted in Tracer and FigTree [103-106, 201, 210]. 
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3.2  Generation of Overlength Replication-Competent 
Constructs with PreS Mutations 
 
3.2.1 Initial Restriction Mapping of the A12C15_OL A1WTSA1.281MER 
Construct 
This construct was originally generated by Dr. N. Bhoola [193]. To confirm the integrity 
of this plasmid, full restriction mapping was carried out (Figures 3.7 and 3.8 plus Table 
3.3) 
 
Figure 3.7: Plasmid Map of the A12C15_OL A1WTSA1.281MER Vector  
This plasmid map shows the organisation and relevant restriction sites in this construct. 
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Table 3.3: Summary of Restriction Enzymes Utilised and Expected Band Sizes 
Enzyme No of cuts Size of expected fragments for correct orientation 
PvuI 1 8211 bp linear 
NotI 1 8211 bp linear 
BamHI 1 8211 bp linear 
EcoRI 1 8211 bp linear 
SalI  2 6026 bp and 2185 bp 
XhoI 2 5895 bp and 2316 bp 
XbaI 3 5769 bp, 1658 bp and 784 bp 
BglII 3 5411 bp, 2776 bp and 24 bp 
StuI 7 3257 bp, 2607 bp, 1119 bp, 587bp, 587 bp. 27 bp and 27 bp 
 
 
Figure 3.8: Restriction Mapping of A12C15_OL A1WTSA1.281MER Vector 
The resulting restriction map is considered successful as all expected bands were present and 
were also confirmed to be the correct size using a standard curve graph. Distance travelled was 
plotted against the log of the molecular weight; band distances from the well were substituted 
back into the line equation and compared to actual sizes. The uncut plasmid and a no DNA 
control were included to show enzyme activity was as expected. This figure represents a 1% 
Agarose gel, stained with ethidium bromide. 
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3.2.2 Alteration of the A12C15_OL A1WTSA1.281MER 
The A12C15_OL A1WTSA1.281MER was successfully altered for the purposes of cloning. 
After removing the third unwanted XbaI site with ApaI and NotI, the ends were blunted 
using the Lucigen End Repair Kit (Figure 3.9). 
 
Figure 3.9: Restriction of A12C15_OL A1WTSA1.281MER with ApaI and NotI 
Restriction with these enzymes removed the undesired XbaI site from the vector backbone. After 
restriction, the total length is 8189 bp as opposed to the 8211 bp it was before the restriction, 
as 22 bp were removed around the undesired XbaI site. This restriction also eliminated a second 
XhoI site. The uncut plasmid and a no DNA control were included to show enzyme activity was 
as expected. This figure represents a 1% Agarose gel, stained with Novel Juice. 
 
After blunting the restricted ends and recircularising the altered plasmid, full restriction 
mapping was carried out on the resulting plasmid (Figures 3.10 and 3.11 as well as 
Table 3.4). 
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Figure 3.10: Plasmid Map of A12C15_OL A1WTSA1.281MER Altered 9.3 Vector  
This plasmid map shows the organisation and relevant restriction sites of the now altered 
construct. Thus, in this construct, there is one less XbaI site and one less XhoI site as result of 
the restriction with ApaI and NotI. Also as a result of the restriction with ApaI and NotI, this 
construct is 22 bp shorter than the A12C15_OL A1WTSA1.281MER. The two remaining XbaI sites 
were used for subcloning. 
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Table 3.4: Summary of Restriction Enzymes Utilised and Expected Band Sizes 
Enzyme No of cuts Size of expected fragments for correct orientation 
PvuI 1 8189 bp linear 
NotI 0 8189 bp circular (NotI site was removed with alteration) 
EcoRI 1 8189 bp linear 
BamHI 1 8189 bp linear 
SalI  2 6004 bp and 2185 bp 
XhoI 1 8189 bp  
XbaI 2 7427 bp, 784 bp 
BglII 3 5389 bp, 2776 bp and 24 bp 
StuI 7 3257 bp, 2607 bp, 1097 bp, 587bp, 587 bp. 27 bp and 27 bp 
 
 
Figure 3.11: Restriction Mapping of A12C15_OL A1WTSA1.281MER Altered 9.3 
The resulting restriction map is considered successful as all expected bands were present and 
were also confirmed to be the correct size using a standard curve graph. Distance travelled was 
plotted against the log of the molecular weight; band distances from the well were substituted 
back into the line equation and compared to actual sizes. The uncut plasmid and a no DNA 
control were included to show enzyme activity was as expected. This figure represents a 1% 
Agarose gel, stained with ethidium bromide. 
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3.2.3  Production of Final Overlength Constructs 
A small subset of pTZ57R/T clones were identified for subcloning; this was done on the 
basis that the sequences spanning the two XbaI sites were most homologous to the 
parental sequence. Thus, the fragment containing the mutations could be ligated into the 
A12C15_OL A1WTSA1.28 MER Altered 9.3 overlength backbone for functional analysis. All 
final constructs had to be screened carefully to ensure the section fragment containing 
the deletion was oriented in the forward direction. The sequences of the final constructs 
were confirmed by complete restriction mapping and by Sanger Sequencing (Figures 3.12 
– 3.19 and Tables 3.5 – 3.8). 
 
Figure 3.12: Plasmid Map of the OL_DELMUT SHH011A- F Construct  
This plasmid map shows the organisation of the deletion-mutant, amplified from the patient 
SHH011A, inserted in the correct orientation within the OL backbone and the relevant restriction 
sites.  
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Table 3.5: Summary of Restriction Enzymes Utilised and Expected Band Sizes 
Enzyme No of cuts Size of expected fragments for correct orientation 
PstI 0 8093 bp circular 
EcoRI 0 8093 bp circular 
XhoI 1 8093 bp linear 
BamHI  2 7256 bp and 837 bp 
XbaI 2 7405 bp and 688 bp 
SalI 2 5908 bp and 2185 bp  
BglII 3 5389 bp, 2680 and 24 bp 
 
 
Figure 3.13: Restriction Mapping of the OL_DELMUT SHH011A- F Construct 
The resulting restriction map is considered successful as all expected bands were present and 
were also confirmed to be the correct size using a standard curve graph. Distance travelled was 
plotted against the log of the molecular weight; band distances from the well were substituted 
back into the line equation and compared to actual sizes. The uncut plasmid and a no DNA 
control were included to show enzyme activity was as expected. This figure represents a 1% 
Agarose gel, stained with ethidium bromide. 
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Figure 3.14: Plasmid Map of the OL_DELMUT SHH045A- F Construct  
This plasmid map shows the organisation the deletion-mutant, amplified from the patient 
SHH045A, inserted in the correct orientation within the OL backbone and the relevant restriction 
sites.  
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Table 3.6: Summary of Restriction Enzymes Utilised and Expected Band Sizes 
Enzyme No of cuts Size of expected fragments for correct orientation 
PstI 0 8156 bp circular 
XhoI 0 8156 bp circular 
EcoRI 1 8156 bp linear 
BamHI  2 7256 bp and 751 bp 
XbaI 2 7405 bp and 688 bp 
SalI 2 6001 bp and 2185 bp  
BglII 3 5419 bp, 2743 and 24 bp 
 
 
Figure 3.15: Restriction Mapping of the OL_DELMUT SHH045A- F Construct 
The resulting restriction map is considered successful as all expected bands were present and 
were also confirmed to be the correct size using a standard curve graph. Distance travelled was 
plotted against the log of the molecular weight; band distances from the well were substituted 
back into the line equation and compared to actual sizes. The uncut plasmid and a no DNA 
control were included to show enzyme activity was as expected. This figure represents a 1% 
Agarose gel, stained with ethidium bromide. 
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Figure 3.16: Plasmid Map of the OL_DELMUT SHH167A- F Construct  
This plasmid map shows the organisation of the deletion-mutant, amplified from the patient 
SHH167A, inserted in the correct orientation within the OL backbone and the relevant restriction 
sites.  
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Table 3.7: Summary of Restriction Enzymes Utilised and Expected Band Sizes 
Enzyme No of cuts Size of expected fragments for correct orientation 
PstI 0 8144 bp circular 
XhoI 0 8144 bp circular 
EcoRI 1 8144 bp linear 
BamHI  1 8144 bp linear 
XbaI 2 7405 bp and 739 bp 
SalI 2 5959 bp and 2185 bp  
BglII 3 5389 bp, 2731 and 24 bp 
 
 
Figure 3.17: Restriction Mapping of the OL_DELMUT SHH167A- F Construct 
The resulting restriction map is considered successful as all expected bands were present and 
were also confirmed to be the correct size using a standard curve graph. Distance travelled was 
plotted against the log of the molecular weight; band distances from the well were substituted 
back into the line equation and compared to actual sizes. The uncut plasmid and a no DNA 
control were included to show enzyme activity was as expected. This figure represents a 1% 
Agarose gel, stained with ethidium bromide. 
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Figure 3.18: Plasmid Map of the OL_OCFL SHH193A- F Construct  
This plasmid map shows the organisation of full-length cloning control, amplified from patient 
SHH193A, inserted in the correct orientation within the OL backbone and the relevant restriction 
sites.  
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Table 3.8: Summary of Restriction Enzymes Utilised and Expected Band Sizes 
Enzyme No of cuts Size of expected fragments for correct orientation 
PstI 0 8188 bp circular 
XhoI 0 8188 bp circular 
EcoRI 1 8188 bp linear 
BamHI  1 8188 bp linear 
XbaI 2 7405 bp and 783 bp 
SalI 2 6003 bp and 2185 bp  
BglII 3 5389 bp, 2775 and 24 bp 
 
 
Figure 3.19: Restriction Mapping of the OL_OCFL SHH193A- F Construct 
The resulting restriction map is considered successful as all expected bands were present and 
were also confirmed to be the correct size using a standard curve graph. Distance travelled was 
plotted against the log of the molecular weight; band distances from the well were substituted 
back into the line equation and compared to actual sizes. The uncut plasmid and a no DNA 
control were included to show enzyme activity was as expected. This figure represents a 1% 
Agarose gel, stained with ethidium bromide. 
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3.2.4 Sequence Analysis of Overlength Clones  
Sequences of the final overlength constructs were aligned and translated using the 
Babylon Tool [198]. The three deletion mutant and one full-length occult constructs, that 
were the most homologous to the parental strains were selected for transfection [52].  
The sequences of these four selected constructs, their parental strains and the two WT 
control constructs, A12C15_OL A1WTSA1.281MER and A12C15_OL A1WTSA1.281MER ALT 
9.3, were aligned against a WT subgenotype A1 reference (GenBank number AY233274) 
for comparison. Each reading frame was checked to see whether the translated 
sequence was in-frame, and whether any unwanted start and/or stop codons were 
introduced as a result of ligating the 784 bp fragment into the A12C15_OL 
A1WTSA1.281MER ALT 9.3 backbone. Moreover the functional domains were inspected to 
determine whether they were conserved (Table 3.9). All amino acid changes reported 
here include those present the parental strains, as well as any novel changes observed 
in the final constructs [52]. This same analyses was also carried out on the Polymerase 
gene, however, this is not included as there were no amino acid changes in the final 
constructs.  
 
Table 3.9: Functional Domains of the LHBs 
Functional Domain Indicator Region Amino Acid 
Position  
(Number of aa) 
Amino Acid Sequence 
Myristoylated N-
Terminal Glycine è 
PreS1 ps1G2  
(1) 
G 
NTCP Receptor 
Binding Site è 
PreS1 ps1R9-I48  
(39) 
RKGMGTNLSVPNPLGFFPDHQLDP
AFGANSNNPDWDFNPI 
T Cell  
Epitope è 
PreS1/2 ps1S109-ps2L12  
(23) 
SPPLRDSHPQAMQWNSTAFHQAL 
B Cell Epitope è PreS2 ps1Q132-ps2G25  (13) 
QDPRVRGLYFPAG 
Neutralising Antibody 
Target 1 è 
PreS1 ps1V18-ps1D50 
(33) 
VPNPLGFFPDHQLDPAFGANSNNP
DWDFNPIKD 
Neutralising Antibody 
Target 2 è 
PreS2 ps2M1-ps2I45 
(45) 
MQWNSTAFHQALQDPRVRGLYFP
AGGSSSGTLNPVPNTASHISPI 
The colour of the indicator arrow correlates with each functional domain as represented Figures 
3.20-3.22.  
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Figure 3.20: Translated aa Sequence of the preS1 Region  
This alignment depicts the translated sequences as compared to a WT subgenotype A1 reference 
sequence (GenBank Accession AY233274). Functional domains are indicated by coloured arrows 
that corresponding to Table 3.9 above, and deletions are indicated by plain X letters. All 
mutations observed are detailed below. A base change compared to the WT is not reported as a 
mutation if it is present in all the constructs. 
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Figure 3.21: Translated aa Sequence of the preS2 Region  
This alignment depicts the translated sequences as compared to a WT subgenotype A1 reference 
sequence (GenBank Accession AY233274). Functional domains are indicated by coloured arrows 
that corresponding to Table 3.9 above, and deletions are indicated by plain X letters. All 
mutations observed are detailed below. A base change compared to the WT is not reported as a 
mutation if it is present in all the constructs. 
 
 
 95 
 
Figure 3.22: Translated aa Sequence of the Surface Region of All Constructs 
This alignment depicts the translated sequences as compared to a WT subgenotype A1 reference 
sequence (GenBank Accession AY233274). Functional domains are indicated by coloured arrows 
that corresponding to Table 3.9 above, and deletions are indicated by plain X letters. All 
mutations observed are detailed below. A base change compared to the WT is not reported as a 
mutation if it is present in all the constructs. 
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Only 784 bp fragment, from position 2684 bp to position 252 bp from the EcoRI siteof 
the A12C15_OL A1WTSA1.281MER ALT 9.3 backbone was replaced. This fragment only 
extends 92 aa into the Surface region, and only the first the first 23 aa contained 
deletions (Figure 3.22). 
 
Table 3.10: Missense Mutations in the preS1, preS2 and S Regions of the Final 
Overlength Constructs: 
 
All translated sequences were compared to a WT subgenotype A1 reference sequence (GenBank 
accession number AY233274). The underlined mutations represent the aa changes already in the 
parental strain [52]. In plain text are the inadvertent aa changes not found in the parental strain 
but only in the final construct.  
 
 
  
Construct Region in Which aa Changes Were Observed 
preS1 preS2 S 
A12C15_OL 
A1WTSA1.281MER 
pS1I48V ps2A7T  
A12C15_OL 
A1WTSA1.281MER ALT 9.3 
pS1I48V ps2A7T  
OL_DELMUT SHH011A - F pS1del15-25, 
pS1I48V  
pS1T90A 
ps2del1-22, 
ps2T48K 
 
OL_DELMUT SHH045A - F pS1I48V 
pS1W4P, pS1G35R, 
pS1T90A 
ps2del12-22,   
ps2L1I, ps2Q2K, 
ps2A11T 
sL21S 
OL_DELMUT SHH167A - F pS1F25L, pS1V88L 
pS1L85M 
ps2del8-22, 
ps2R48T 
 
OL_OCFL SHH193A - F pS1F25L, pS1V88L 
pS1F45L, pS1N98K, 
pS1L112I 
ps2Q10R, psR48T, 
ps2A53V 
ps2N33H, ps2R48T 
sN3S, sG10R 
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3.3  Determination of the Replication Competence of 
Overlength Clones 
The A12C15_OL A1WTSA1.281MER, which is replication-competent [193] was used as the 
backbone for the generation of the deletion-mutant constructs and as a positive control. 
In order to insert the subgenomic fragment, containing the deletions, two XbaI sites 
spanning the 784 bp fragment were utilized. However, because the vector contained 
three XbaI sites, the redundant site had to be removed. This removal resulted in a 
backbone, which was 22 bp shorter than A12C15_OL A1WTSA1.281MER. The shorter 
plasmid was named A12C15 ALT 9.3. The restricted 22 bp fragment was in the multiple 
cloning site of the pcDNA™ 4/TO plasmid vector, which is not functionally important. 
The fragments containing the deletion-mutants were all inserted into this A12C15 ALT 
9.3 backbone. Thus transfection experiments with A12C15 ALT 9.3 were used for the 
normalisation and comparison of the replication of the deletion mutant constructs.  
An additional control was constructed in which the S region of HBV, without deletions, 
was amplified from the serum derived from patient SHH193A and inserted into A12C15 
ALT 9.3. This resulted in the full-length cloning control OL_OCFL SHH193A.  
The negative controls included mock-transfected Huh7 cells, with and without the 
transfection agent PEI as well as cells transfected with the eGFP-C3 plasmid, a 
mammalian expression vector, containing a GFP fluorescent tag under the control of the 
CMV promoter and used here to measure transfection efficiency. 
 
3.3.1 Expression of HBsAg and HBeAg 
HBsAg and HBeAg are both expressed extracellularly, thus were harvested at day 1 (24 
hours), day 3 (72 hours) and day 5 (120 hours) after transfection. The quantitative 
measurements were repeated 3 times with 2 biological replicates each. The expression of 
these proteins indicates that a construct is producing virus in cell culture. Samples were 
considered negative if the OD measure was below the cut off values, which was 
calculated by adding 0.05 to the mean of the kit provided negative control replicates. 
The results of HBsAg expression in transfected Huh7 cells are shown Figures 3.23 – 3.27 
and the significant differences when measuring HBsAg expression is summarized in Table 
3.11. 
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Figure 3.23: Detection of Mean HBsAg Expression in Culture Supernatant of 
Transfected Huh7 Cells 
This bar graph presents the observed HBsAg expression in supernatant of transfected Huh7 cells 
as measured by ELISA. Error bars represent the standard deviation of the mean. Expression was 
tested at a dilution 1:20 of supernatant, unless OD measures were out of the linear scale. In 
which case those samples were re-measured at 1:80 dilution, and multiplied by 4.  
 
 
Figure 3.24: Normalised HBsAg Expression in Culture Supernatant of Transfected 
Huh7 Cells  
The observed HBsAg Expression in supernatant of transfected Huh7 cells was normalized against 
the A12C15 ALT 9.3 construct to show relative expression. 
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Table 3.11: Significant Differences in HBsAg Expression  
 A12C15_OL 
1.28MER 
DAY 1 
DAY 3 
DAY 5 
A12C15 
ALT 9.3 
DAY 1 
DAY 3 
DAY 5 
OL_OCFL 
SHH193A 
DAY 1 
DAY 3 
DAY 5 
DELMUT 
SHH011A 
DAY 1 
DAY 3 
DAY 5 
DELMUT 
SHH045A 
DAY 1 
DAY 3 
DAY 5 
DELMUT 
SHH167A 
DAY 1 
DAY 3 
DAY 5 
DAY 1       
A12C15_OL 
1.28MER 
      
A12C15 
ALT 9.3 
é 
(p = 0.014) 
 é 
 (p = 0.001) 
é 
 (p = 0.007) 
é 
(p = 0.040) 
é 
 (p = 0.002) 
OL_OCFL 
SHH193A 
    ê 
 (p = 0.040) 
 
DELMUT 
SHH011A 
   ê 
(p = 0.039) 
ê 
(p = 0.015) 
  
DELMUT 
SHH045A 
    ê 
(p = 0.025) 
 
DELMUT 
SHH167A 
     ê 
(p = 0.010) 
DAY 3       
A12C15_OL 
1.28MER 
      
A12C15 
ALT 9.3 
      
OL_OCFL 
SHH193A 
ê 
(p = 0.029) 
ê 
(p = 0.048) 
 ê 
(p = 0.028) 
ê 
(p = 0.039) 
ê 
(p = 0.007) 
DELMUT 
SHH011A 
      
DELMUT 
SHH045A 
      
DELMUT 
SHH167A 
     ê 
(p = 0.013) 
DAY 5       
A12C15_OL 
1.28MER 
      
A12C15 
ALT 9.3 
      
OL_OCFL 
SHH193A 
ê 
(p = 0.033) 
ê 
ns: 
(p = 0.075) 
 ê 
(p = 0.010) 
ê 
(p = 0.014) 
ê 
(p = 0.008) 
DELMUT 
SHH011A 
      
DELMUT 
SHH045A 
      
DELMUT 
SHH167A 
      
Arrows indicate a significant relationship where experimental samples on the left column are 
compared relative to controls and experimental samples in the top row. Significance was 
determined to be any p-value below 0.05 by employing a student t-test. Any blank cell indicates 
there is no significant difference. 
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Figure 3.25: Detection of HBeAg Expression in Culture Supernatant of 
Transfected Huh7 Cells 
This bar graph presents the observed HBsAg expression in supernatant of transfected Huh7 cells 
as measured by ELISA. Error bars represent the standard deviation of the mean. Expression was 
tested at a dilution 1:20 of supernatant, unless OD measures were out of the linear scale. In 
which case those samples were re-measured at 1:80 dilution, and then the OD was multiplied by 
4. 
 
 
Figure 3.26: Normalised HBeAg Expression in Culture Supernatant of Transfected 
Huh7 Cells 
HBeAg expression in supernatant of transfected Huh7 cells was normalized against the A12C15 
ALT 9.3 construct to show relative expression. 
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There were no significant differences in the expression of HBeAg in Huh7 transfected 
cells between the deletion-mutant constructs and the positive controls. Furthermore, 
there was no significant difference in HBeAg expression between days 1, 3 and 5. 
 
 
 
Figure 3.27: Expression of HBsAg Relative to HBeAg  
This figure shows the mean values of HBsAg were divided by mean values of HBeAg to show 
extracellular protein expression as a ratio.  
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3.3.2 Viral Load Quantification of Overlength Constructs 
Samples for qPCR were collected on day 1 (24 hours), day 3 (72 hours) and day 5 (120 
hours) after transfection. Supernatant, lysate and immunocaptured virions were collected 
in order to analyse extracellular, intracellular (cell-associated) and secreted/encapsidated 
virion DNA levels, respectively. Immunocapture was carried out only on day 3 (72 hours) 
after transfection.  Secreted hepatitis B virions were estimated in undiluted supernatants 
of transfected cells by using an immunocapture ELISA strategy before isolating the DNA. 
Three biological replicates were employed for the Real-Time plates from three 
independent transfections as well as three technical replicates for each sample. For 
qPCR, a sample was considered negative if the Sq values were lower than the threshold 
and the negative water control. qPCR results are shown in Figures 3.28 to 3.33.  
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Figure 3.28: Box and Whisker plot of HBV DNA Expression in Culture Supernatant 
of Huh7 Cells 
The central value or median is shown by the black horizontal line through the bar. The vertical 
lines on the upper and lower extremes of each bar represent the upper and lower quartiles, 
meaning that the coloured bar itself represents the interquartile range. 
 
Figure 3.29: Normalised HBV DNA Expression in Culture Supernatant of Huh7 
Cells 
Represented here is the normalised data for quantified VL in the supernatant of transfected Huh7 
cells. Normalisation was carried out against the A12C15 ALT 9.3 construct.  
Table 3.15 summarises all the significant differences when measuring HBV DNA in the 
supernatant of Huh7 transfected cells. 
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Table 3.12: Significant Differences in Supernatant Viral Loads  
 A12C15_OL 
1.28MER 
DAY 1 
DAY 3 
DAY 5 
A12C15 
ALT 9.3 
DAY 1 
DAY 3 
DAY 5 
OL_OCFL 
SHH193A 
DAY 1 
DAY 3 
DAY 5 
DELMUT 
SHH011A 
DAY 1 
DAY 3 
DAY 5 
DELMUT 
SHH045A 
DAY 1 
DAY 3 
DAY 5 
DELMUT 
SHH167A 
DAY 1 
DAY 3 
DAY 5 
DAY 1       
A12C15_OL 
1.28MER 
ê 
(p = 0.008) 
é 
(p = 0.006) 
   é 
(p = 0.005) 
é 
 (p = 0.015) 
A12C15 
ALT 9.3 
 ê 
(p = 0.000) 
é 
(p = 0.000) 
  é 
(p = 0.003) 
é 
 (p = 0.021) 
OL_OCFL 
SHH193A 
  é 
(p = 0.011) 
é 
 (p = 0.039) 
é  
(p = 0.003) 
é 
 (p = 0.007) 
DELMUT 
SHH011A 
   ê 
(p = 0.001) 
é 
(p = 0.000) 
é 
(p = 0.022) 
DELMUT 
SHH045A 
    ê 
(p = 0.000) 
ê 
(p = 0.003) 
DELMUT 
SHH167A 
     ê 
(p = 0.020) 
DAY 3       
A12C15_OL 
1.28MER 
é 
(p = 0.000) 
  é 
(p = 0.029) 
  
A12C15 
ALT 9.3 
 é 
(p = 0.000) 
 é 
(p = 0.032) 
  
OL_OCFL 
SHH193A 
  é 
(p = 0.001) 
   
DELMUT 
SHH011A 
   é 
(p = 0.000) 
  
DELMUT 
SHH045A 
    é 
(p = 0.000) 
 
DELMUT 
SHH167A 
     é 
(p = 0.001) 
DAY 5       
A12C15_OL 
1.28MER 
      
A12C15 
ALT 9.3 
ê 
(p = 0.006) 
 ê 
(p = 0.003) 
ê 
(p = 0.012) 
ê 
(p = 0.000) 
ê 
(p = 0.005) 
OL_OCFL 
SHH193A 
    é 
(p = 0.044) 
 
DELMUT 
SHH011A 
      
DELMUT 
SHH045A 
      
DELMUT 
SHH167A 
      
Arrows indicate a significant relationship where experimental samples on the left column are 
compared relative to controls and experimental samples in the top row. Significance was 
determined to be any p-value below 0.05 by employing a student t-test. Any blank cell indicates 
there is no significant difference. 
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Immunocapture VL were measured only on day 3 post transfection. 
 
Figure 3.30: Box and Whisker Plot of Immunocaptured Supernatant HBV DNA 
Expression of Huh7 Cells 
This figure represents the distribution of data for quantified VL following immunocapture. The 
central value or median represented by the black horizontal line through the bar. The vertical 
lines on the upper and lower extremes of each bar represent the upper and lower quartiles, 
meaning that the coloured bar itself represents the interquartile range. 
 
 
 
Figure 3.31: Normalised Secreted Virion HBV DNA Expression in Immunocaptured 
Supernatant of Huh7 Cells 
Depicted here is the normalised data for quantified VL in immunocaptured virions found in 
supernatant of transfected Huh7 cells. Normalisation was carried out against the A12C15 ALT 9.3 
construct to show relative HBV DNA measurement.  
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Table 3.13: Significant Differences in Immunocapture Viral Loads  
 A12C15_OL 
1.28MER 
DAY 3 
A12C15 
ALT 9.3 
DAY 3 
OL_OCFL 
SHH193A 
DAY 3 
DELMUT 
SHH011A 
DAY 3 
DELMUT 
SHH045A 
DAY 3 
DELMUT 
SHH167A 
DAY 3 
DAY 3       
A12C15_OL 
1.28MER 
  ê 
(p = 0.000) 
ê 
(p = 0.029) 
ê 
(p = 0.000) 
ê 
(p = 0.000) 
A12C15  
ALT 9.3 
  ê 
(p = 0.000) 
ê 
(p = 0.001) 
ê 
(p = 0.001) 
ê 
(p = 0.000) 
OL_OCFL 
SHH193A 
   ê 
(p = 0.000) 
é 
(p = 0.000) 
é 
(p = 0.000) 
DELMUT 
SHH011A 
    é 
(p = 0.000) 
é 
(p = 0.000) 
DELMUT 
SHH045A 
     ê 
(p = 0.000) 
DELMUT  
SHH167A 
      
Arrows indicate a significant relationship where experimental samples on the left column are 
compared relative to controls and experimental samples in the top row. Significance was 
determined to be any p-value below 0.05 by employing a student t-test. Any blank cell indicates 
there is no significant difference. 
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Figure 3.32: Box and Whisker Plot of HBV DNA Expression in Culture Lysates of 
Huh7 Cells 
Quantification of the VL in the lysates, and thus cell-associated virus. The central value or 
median represented by the black horizontal line through the bar. The vertical lines on the upper 
and lower extremes of each bar represent the upper and lower quartiles, meaning that the 
coloured bar itself represents the interquartile range. 
 
 
Figure 3.33: Normalised HBV DNA Expression in Culture Lysates of Huh7 Cells 
This figure represents the normalised data for quantified VL in lysates, thus cell-associated virus. 
Normalisation was carried out against the A12C15 ALT 9.3 construct to show relative HBV DNA 
measurement. 
All significant differences for the lysate or cell-associated qPCR results are highlighted in 
Table 3.17. 
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Table 3.14: Significant Differences in Lysate Viral Load  
 
 A12C15_OL 
1.28MER 
DAY 1 
DAY 3 
DAY 5 
A12C15 
ALT 9.3 
DAY 1 
DAY 3 
DAY 5 
OL_OCFL 
SHH193A 
DAY 1 
DAY 3 
DAY 5 
DELMUT 
SHH011A 
DAY 1 
DAY 3 
DAY 5 
DELMUT 
SHH045A 
DAY 1 
DAY 3 
DAY 5 
DELMUT 
SHH167A 
DAY 1 
DAY 3 
DAY 5 
DAY 1       
A12C15_OL 
1.28MER 
ê 
(p = 0.016) 
ê 
(p = 0.000) 
     
A12C15 
ALT 9.3 
      
OL_OCFL 
SHH193A 
      
DELMUT 
SHH011A 
   ê 
(p = 0.003) 
  
DELMUT 
SHH045A 
    ê 
(p = 0.030) 
 
DELMUT 
SHH167A 
     ê 
(p = 0.011) 
DAY 3       
A12C15_OL 
1.28MER 
ê 
(p = 0.028) 
 ê 
(p = 0.026) 
   
A12C15 
ALT 9.3 
  ê 
(p = 0.038) 
   
OL_OCFL 
SHH193A 
      
DELMUT 
SHH011A 
   é 
(p = 0.013) 
  
DELMUT 
SHH045A 
      
DELMUT 
SHH167A 
      
DAY 5       
A12C15_OL 
1.28MER 
   é 
(p = 0.002) 
 é 
(p = 0.050) 
A12C15 
ALT 9.3 
ê 
(p = 0.000) 
 ê 
(p = 0.043) 
   
OL_OCFL 
SHH193A 
   é 
(p = 0.030) 
  
DELMUT 
SHH011A 
      
DELMUT 
SHH045A 
      
DELMUT 
SHH167A 
      
Arrows indicate a significant relationship where experimental samples on the left column are 
compared relative to controls and experimental samples in the top row. Significance was 
determined to be any p-value below 0.05 by employing a student t-test. Any blank cell indicates 
there is no significant difference. 
 
 109 
4 Chapter Four: Discussion 
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Both HBV and HIV are hyperendemic in sub-Saharan Africa, and there is a 
correspondingly high incidence of HCC in this region [1, 22, 78, 97, 151, 157], 
contributing to a considerable burden of disease in this region. In regions where HBV 
genotypes B, C and D prevail, a strong relationship exists between the rapid and more 
likely development of HCC and infection with preS deletion mutants of HBV [24, 35, 37, 
39, 40, 51, 91, 117, 118, 159, 166-168, 172, 178, 183, 211, 212]. Similar preS deletion 
mutants have been detected in southern African and Indian HCC patients infected with 
subgenotype A1 [52, 118, 192]. Disturbingly, in a cohort study conducted in Mpumalanga, 
South Africa by our team, equivalent deletion-mutants were detected in 5 treatment-
naïve HBV-HIV coinfected patients [52]. Thus, the aim of this study was to characterise 
the quasispecies of HBV in these patients and to construct plasmids containing preS 
deletion-mutants in a subgenotype A1 backbone, in order to functionally characterize 
them in vitro.  Such studies may determine how these preS deletions contribute to the 
working model of hepatocarcinogenesis and explain the high hepatocarcinogenic potential 
of subgenotype A1 [115, 192]. 
 
4.1  Quasispecies and Phylogenetic Analysis 
Sequence variability is a feature of HBV because of the error-prone nature of the HBV 
polymerase. Thus, in infected individuals, HBV exists as a quasispecies population [171, 
213], which can be shaped by pressures exerted by host immunity, co-infection with 
other pathogens, vaccination or antiviral therapies [9, 155, 171]. The deletion mutants 
detected in the 5 treatment-naïve HBV-HIV coinfected patients by direct sequencing [52] 
represent the major population because only sequences comprising at least 20% of 
quasispecies can be detected by direct sequencing [24, 159, 171, 213]. In order to 
determine whether the parental sequences are the only strains in the quasispecies 
population, or whether they co-circulate with other variants or WT HBV, 30 clones of the 
complete S region of HBV isolated from each of 4 patients (SHH167A, SHH193A, 
SHH274A and SHH300A) were analysed. 
Both inter- and intra-group nucleotide divergence were calculated in order to determine 
the diversity of quasispecies and to compare how the clones differed from the parental 
sequence, obtained by direct sequencing (see Table 3.1) [52]. The clones of HBV from 
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patient SHH167A showed the highest intra-group divergence of 11% (Table 3.1). A total 
of 9 of the 30 clones (26,7%) were distinct from the parent sequence, including 5 
deletion patterns that were different from that of the parental strain (Table 3.2). These 
additional deletion mutants are the reason for the high intra-group divergence. On the 
other hand, the intra-group divergence of the complete S region of HBV isolated from 
the 4 remaining patients ranged from 2% to 4%. Studies characterising quasispecies in 
genotypes other than subgenotype A1, report similar intra-group divergences [39, 177, 
213, 214] and also found that the preS2 is the most variable region of the complete S 
[37, 119, 213]. 
Sequencing of the clones of the S region amplicons from patients SHH167A, SHH193A, 
SHH274A and SHH300A, revealed that the majority of the clones (70% or more) were 
similar to their respective parental strains (Table 3.2). This corresponds with other 
studies, which found that the mutant population isolated from the patient sera was the 
predominating species [37, 39, 166]. For patient SHH167A, three clones (10%) had 
sequences with WT sequence (with no deletion). This is similar to the findings of others 
who investigated preS deletion-mutants of genotype B and C in patients with advanced 
liver disease [40]. Similarly, Melegari et. al., found a majority population of preS deletion-
mutants with a small proportion of a WT population being simultaneously present [162]. 
However, this was the case in a patient that was infected with genotype D following 
interferon therapy and followed-up at several time points, thus drug pressure was 
present which not the case in our study [162]. It is possible these WT strains are trans-
complementing the deletion mutants, thus rescuing the major population, if replication 
and/or protein expression are compromised by the deletion/s [28, 37, 161-165].  
In all four patients, minority populations, which differed from the major population, were 
detected. Five clones of HBV from SHH167A had deletion patterns, which differed from 
that of the parental strain. Three percent of the HBV clones from patients SHH274A and 
SHH300A showed deletion patterns different to the deletion pattern in the parental strain. 
The reverse was observed in the HBV isolates from patient SHH193A. The majority 
population of HBV clones had preS regions without deletions (i.e. full-length) and were 
homologous to the parental strain. However, one clone had a 1 nt deletion, and 5 
clones had a 54 nt deletion that was not detected by direct sequencing. These results 
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demonstrate that deletion-mutants can co-circulate with WT or full-length virus in various 
proportions, representing either a major or minor population of the quasispecies.  
The opposing forces of the error-prone polymerase and the compactness of the 
overlapping HBV genome can be factors that influence the dynamic nature of the 
quasispecies population within a patient [9, 114, 171]. However, the human immune 
system and drug pressure can act to positively select for mutations that allow evasion 
of detection and elimination [9, 171, 215]. As all patients selected for this study were 
HBV-HIV co-infected and treatment naïve, it is likely they were immunosuppressed at the 
time of serum collection. This may mean the immune system was not exerting selective 
pressure on the quasispecies population [9], which could explain why so little variation is 
seen in the quasispecies sequences presented here [97, 149, 152]. This is supported by 
the fact that CD4 counts at the time of serum collection from these patients were low 
(SHH167A CD4 = 49; SHH193A CD4 = 12; SHH274A CD4 = 182; SHH300A = 98) [52]. 
Moreover, in the African context, we know that HBV transmission often occurs at a 
young age, with a competent immune system at the time of infection [26, 70, 74, 77, 78, 
107]. Assuming that the HIV infection occurred later than the HBV infection, and as it is 
known that HIV alters the natural history of HBV, immunosuppression as a result of HIV 
co-infection may exert the little or no selection pressures on the quasispecies, explaining 
the minimal variation [9, 84, 127, 128, 130, 132, 140, 149, 153-155]. Only 2 of the 4 
patients, SHH167A and SHH193A, had mixed populations of deletions and full-length 
strains, which contrasts with a study where a very high proportion of patients had a 
quasispecies population comprised of various deletion mutants and WT strains, all 
belonging to genotype C [40]. In another study all five patients, infected with genotype C, 
had mixed populations [212]. However, in another this study where limited clones were 
sequenced (only 5 to 10 clones per patient), the deletion mutants were found to be the 
major population [37, 39]. Our findings have clinical relevance, as the severity of disease 
has been shown to be increased in patients infected with a quasispecies where escape 
mutants represent the major population [9].  
Phylogeny allows the comparison of sequences in such a way that evolutionary past, 
relatedness, and trends can be established [102]. Thus, we used Neighbor-Joining and 
Bayesian inference phylogenetic methods to analyse the relationship of the S regions of 
clones to each other. The Neighbor-Joining phylogenetic method is based on the least 
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squares estimation of branch length and assumes a constant rate of nucleotide 
substitution [209]. Thus, this method assumes minimum evolution or maximum parsimony, 
minimizing the sum of the branch lengths at each clustering of an operational taxonomic 
unit, or sequence [209]. The resulting ‘true’ tree is made up of the most pairs of 
neighbors with the shortest branch length [209]. Although the trees constructed using 
this method may not be the most accurately representative of evolutionary pathways, 
this method is highly efficient in producing a tree that groups the sequences with 
highest similarity to each other [209]. 
As expected, the tree comparing the 4 groups of 30 clones, the clustering of parental 
sequences and subgenotype A1 references sequences, reflects the sequence variation 
seen in the nucleotide divergence calculations (Tables 3.1 and 3.2). The major 
populations clustered together in four main groups, each set of clones grouping with its 
parental sequence, except where significant sequence variation was present (Figure 3.4). 
For example, SHH167A 1.70, clustered separately from any of the clones in the 
Neighbor-Joining tree. This can be attributed to the deletion pattern present that was 
unlike any other sequence in the group, namely a 33 nt as well as a 66 nt deletion 
overlapping the region where the 45 nt deletion was present in the parental strain. 
Furthermore, clone SHH167A 1.77 contained a 63 nt deletion similar to the deletion 
pattern seen in SHH274A, and thus this clone clustered with the SHH274A group. The 5 
clones of SHH193A, with the 54 nt deletion distinct from the parent sequence, clustered 
with SHH300A group, which also has a 54 nt deletion in the same position. The relative 
clustering of the strains from SHH167A, SHH193A, SHH274A and SHH300A, to each 
other was the same as seen in our previous analysis of the sequences obtained by 
direct sequencing [52].  
In addition to the Neighbor-Joining method, the sequences were analysed 
phylogenetically using Bayesian inference. The Bayesian inference approach has become 
progressively popular as it estimates maximum posterior probability allowing more 
accurate estimations of evolutionary pathways compared to Neighbor-Joining and 
Maximum Likelihood trees [103, 113]. It is a hierarchical approach that requires 
specification of priors; such as evolutionary model, molecular substitution rate, selection 
of a molecular clock, accurate sampling dates, to infer the most likely tree by 
coalescent algorithms [103, 104, 113, 114]. In this study, we found there were essentially 
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no differences between the two trees (Fig 3.5 and 3.6). The clustering pattern was the 
same for both trees and the four groups of clones clustered in the corresponding 
pattern as in the previous Neighbor-Joining tree where only subgenotype A1 sequences 
were included as references. Upon investigation of the literature in this regard, it was 
found that there are some challenges with Bayesian inference analysis of data. The first 
of which being that Bayesian analysis is time-consuming compared to Neighbor-Joining 
methods, and while it has the power to elucidate virus evolution accurately, all priors 
have to be known for an accurate outcome [103, 112, 113, 215-218]. In the case of 
HBV, these priors are not always available. HBV demonstrates rapid evolutionary 
dynamics, and there is controversy over the HBV nucleotide substitution rate [112-114, 
217]. This is because it is affected by the overlapping viral genome (where different 
ORFs may evolve at different rates), substitutions can occur in both directions, 
recombination events are not accounted for and finally calculation of the substitution 
rate affects the selection of the molecular clock [112, 113, 216]. Furthermore, the model 
requires accurate sampling dates and times before it can precisely extrapolate the 
evolution of viruses like HBV [112, 113, 216-218]. The optimum use of the Bayesian 
inference method in the present study was limited. Accurate sampling date and time 
data were not available for all the reference sequences, which were obtained from 
GenBank. As we only sequenced HBV isolated at baseline, we did not have multiple 
longitudinal time points to follow up for each patient over a long period of time. Finally, 
Bayesian analysis is most accurate when the sample group is large, and we only had 30 
clones sequences for the four patients, which did not represent a powerful enough 
sample size [114, 215, 216]. This meant that an evolutionary rate or time of origin 
estimation of quasispecies could not be determined using Bayesian inference on this 
data set in the present study. 
 
4.2  Generation of Overlength Constructs for Transfection 
Experiments 
The most cost-effective method to establish whether the deletion mutants would be 
replication competent and how the deletions would affect virus protein expression and 
viral loads, is to construct overlength clones that can be transfected into a cell-line like 
Huh7 for functional characterisation. The replacement of the WT 784 bp region 
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corresponding to the fragment flanking the preS deletions, with those sequences from 
patients with variations in this region, minimised the confounding effects of any other 
variations in other regions of the genome. Thus, once the constructs were generated, it 
was important to confirm that the deletions were present and in the correct genomic 
context, that there was high sequence similarity to the respective parental strain, that 
the backbone sequence was not altered and finally that no unwanted start or stop 
codons were introduced in the HBV overlength sequence.  
After carrying out restriction mapping, it was confirmed that the constructs were correct 
regarding the position and size of deletions (Figures 3.7 – 3.19 and Tables 3.3 – 3.8). 
Sequencing of a number of clones allowed for the selection of the sequences with the 
least nucleotide divergence compared to the parental strain. Bioinformatic analyses of 
both the nucleotide and amino acid sequences revealed that no unwanted start and 
stop codons, nor lethal missense mutations were introduced by the introduction of the 
784 bp fragment into the subgenotype A1 replication competent clone. Some inadvertent 
aa changes were introduced. However, none of these mutations were in functionally 
important domains in the ‘a’-determinant region or polymerase ORF, where such 
mutations could impact on antigen presentation and/or replication, respectively (Figures 
3.20 – 3.22 and Tables 3.9 - 3.10). The removal of the XbaI restriction site and 22 
nucleotides from the vector in the replication competent clone did not compromise viral 
replication and protein expression significantly.   
As far as we are aware, we are the only group to have adopted this cloning strategy 
for the functional characterisation of preS deletion mutants. Studies that have carried 
out functional characterisation in other genotypes and subgenotypes have employed 
overlength clones constructed from the entire original patient sequence [24, 28, 37, 39, 
117, 164, 166, 183, 219, 220]. However, the strategy employed here may provide more 
specificity in exploring the effect of the deletions themselves as the chance of 
introducing additional changes in the remainder of the HBV genome sequence is 
minimised. 
4.3  Extracellular Protein Expression After Transfection  
Expression of extracellular proteins is an important marker of viral replication and 
function. The ELISA used for HBsAg detection employs numerous monoclonal mouse 
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antibodies with slightly different antigen binding sites to ensure high specificity when 
binding the antigenic loops of the ‘a’-determinant region [11, 35]. However, it should be 
noted that while ELISA is a quantitative assay for HBsAg, it cannot distinguish between 
virion-associated or subviral particle HBsAg [36]. This said, detection of HBsAg in vitro 
indicates that subviral particles are expressed, and/or virions are being assembled, and 
thus suggests that viral replication is occurring [36]. Moreover, the cloning strategy used 
here, where the 784 bp fragment flanking the mutations was replaced, did not affect the 
conformation of the antigenic loop structure, and thus should not affect HBsAg 
detection.  
While HBeAg is not essential for viral replication, it is used as an indicator of viral 
replication [56]. Again, as the cloning strategy employed in the present study only 
replaced a 784 bp fragment flanking the mutations in the preS region, the pre-core ORF 
was unaffected and therefore HBeAg expression should not be disturbed at the 
transcriptional and translational levels [56, 60].  However, if the preS deletions interfere 
with the expression of HBsAg in the endoplasmic reticulum/endoplasmic reticulum Golgi 
intermediate compartment (ER/ERGIC), this may interfere with the secretion of HBeAg at 
that level. The ratio of SHBs to LHBs, where SHBs vastly outnumbers SHBs is important 
for viral assembly. Thus, if this ratio is disrupted by the preS deletions, it may negatively 
affect HBsAg secretion, increase retention of HBsAg in the ER and decrease virion 
secretion [28, 37, 41, 42, 162]. This, in turn, may block HBeAg secretion from the ER 
and cause considerably higher amounts of cccDNA accumulating within the cell and its 
nucleus [37]. It has been shown that accumulation of cccDNA can lead to HBV being 
directly cytopathic [184]. 
The ELISA experiment it was found that the deletion mutant constructs; DELMUT 
SHH011A, DELMUT SHH045A and DELMUT SHH167A expressed HBsAg at levels 
comparable to the positive controls (Figures 3.23 and 3.24 and Table 3.11). HBeAg 
expression was not affected by the introduction of deletions in the preS region (Figures 
3.25 and 3.26), and no significantly different expression levels of HBeAg were noted 
across all the constructs; meaning that HBeAg expression was comparable to the 
positive controls for all constructs at all time points. Functional studies carried out on 
other genotypes of HBV, concurred with the findings of the present study that deletion 
mutants expressed both HBsAg and HBeAg in tissue culture [28, 37, 39, 117, 162]. The 
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relatively lower levels of HBeAg expressed by the deletion mutants compared to the WT 
constructs, was also observed in several other studies investigating genotypes other than 
subgenotype A1 [28, 37, 39, 117, 162]. 
The negligible HBsAg expression by the full-length cloning control OL_OCFL SHH193A 
was initially surprising, because it had been assumed that the full-length construct, which 
was chosen because of its sequence similarity to wild-type HBV, would behave much like 
the WT controls. After subsequent closer examination of the clinical data for patient 
SHH193A, it was discovered that the HBV-HIV co-infected patient had occult HBV 
infection [145]. Thus, the finding, that the subgenotype A1 occult OL_OCFL SHH193A 
construct produced very low HBsAg levels at all three time points (Figure 3.23), is novel, 
since the in vitro experiments mimicked the phenotype of occult infection seen in the 
patient in vivo [145, 153]. This result also indicates that the 784 bp fragment from 
patient SHH193A that was replaced in the WT A12C15 ALT 9.3 backbone was sufficient 
to drastically reduce HBsAg expression, and to produce the occult phenotype. 
When HBsAg was analysed as a ratio of HBeAg, it was found that HBsAg is generally 
expressed earlier and HBeAg later (Figure 3.27). HBsAg expression was retarded on day 
1 post transfection for the DELMUT SHH011A construct, but then increased amply on 
day 5. This retardation may be because this construct has an additional deletion as 
compared to the other two deletion mutant constructs. The additional deletion is in the 
preS1 region as opposed to the preS2 region, which encodes for MHBs, which is 
dispensable for HBV replication whereas SHBs is necessary for HBsAg secretion [24, 37-
39, 162]. The negative effect of this additional preS1 deletion on HBsAg expression was 
also observed in another study, which characterised a preS1 deletion mutant in a 
genotype D overlength construct [162].  
 
4.4  HBV Viral Loads Following Transfection 
Real-Time PCR used to measure VL is a quantitative assay for the amount of HBV DNA 
present. To establish whether replication occurs and whether viral particles were being 
secreted, both the extracellular (supernatant) and intracellular (lysate or cell-associated) 
compartment of the Huh7 cells were tested. Furthermore, to clarify whether the 
encapsidated virus was being secreted, an immunocapture technique was employed on 
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the supernatant prior to DNA extraction and qPCR. Thus, qPCR was employed in all 
three compartments to establish whether the full-length cloning control and the deletion-
mutant constructs would replicate once transfected into an Huh7 tissue culture model.  
In a similar manner to the ELISA experiments, qPCR measurement of VL of showed that 
despite the replacement of the 784 bp fragment with a fragment containing deletion 
mutations, all constructs were producing detectable amounts of HBV DNA suggesting 
that viral replication was occurring (Figures 3.28, 3.29, 3.32 and 3.33 and Tables 3.12 
and 3.14). Analogous to the HBsAg results, the highest VL was seen in all constructs on 
day 3 post transfection in both the supernatant and lysate experiments.  Most notably, 
the VL of the occult construct, OL_OCFL SHH193A, was higher than both positive 
controls at all three time points and in both the supernatant and lysate compartment. 
This is again consistent with the clinical characteristics of false occult HBV infection 
where viral loads are higher than 200 IU/ml [145, 153]. Cell-associated (lysate 
compartment) VL was not particularly increased when compared to the VL measured in 
the supernatant, which indicates the ability to secrete the mature virions with no 
accumulation of viral DNA within the cell.  
The immunocapture VL method measures the HBV DNA that is encapsidated in virions 
and have been secreted into the supernatant, and not any free DNA [207].  
Incongruously, where the deletion mutants expressed lower levels of HBsAg and lower VL 
(in the supernatants or lysates) compared to the positive controls, a significantly higher 
VL was observed as compared to the positive controls following immunocapture (Figures 
3.30 and 3.31 and Table 3.13). The occult construct (OL_OCFL SHH193A) also showed a 
significantly higher VL than the positive controls. These results would indicate that the 
changes made by replacing the 784 bp fragment in the S region were sufficient to alter 
the encapsidation and secretion of virions. This effect was more pronounced when the 
double deletion mutant construct DELMUT SHH011A was transfected. The reason for the 
increased VL in encapsidated virions needs further investigation. 
 
4.5  The Way Forward 
In terms of assessing whether the mutations studied here are directly linked to the 
development of HCC and other advanced liver disease, it would be necessary to 
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determine whether the mutations precede the manifestation of disease. The only way to 
establish this convincingly would be to implement a long-term longitudinal prospective 
study [91, 169, 172, 221] and to collect additional clinical data from liver biopsies 
and/or examination using a Fibroscan. The prospects of such studies are limited 
because of both financial and human resource constraints in the South African setting, 
where these are already overburdened by the largest ARV roll-out programme in the 
world.  Moreover, many patients are lost to follow-up either due to their inability to 
attend the clinic or succumbing to illness. A shorter follow-up study is currently 
underway where 40 patients from the original Shongwe cohort are being followed-up at 
3, 6, 12 and 18 months after the commencement of ARV treatment.  One of the 
objectives of the follow-up study is to analyse the quasispecies population at follow-up 
time points using next generation sequencing, which should also yield a big enough 
sample group for more accurate analysis by Bayesian inference methods and follow the 
evolution of the deletion mutants following the initiation of ARV treatment. 
The functional characterization of the preS deletion mutants is being continued.  This 
will include Southern hybridization to characterize the replication intermediates and to 
convincingly show viral replication in the Huh7 cells following transfection with the 
deletion mutants. The expression of the envelope proteins will be studied by Western 
blotting as well as by immunohistochemistry combined with confocal microscopy [24, 37-
39, 117, 166, 219, 220]. These experiments will shed light on whether HBV DNA and/or 
surface proteins of the deletion-mutants accumulate inside Huh7 cells, whether they 
cause apoptosis, and thus whether they are likely to cause ER stress which has been 
implicated in the development of HCC [24, 91, 166, 170, 181-183]. Further, it may prove 
useful to carry out qPCR with primers specifically to amplify up cccDNA in the 
lysate/cell-associated compartment of transfected cells to confirm whether there is a 
significant increase in the HBV DNA pool within the hepatocyte nucleus [37, 184]. It may 
be prudent to repeat the transfection experiments in a different cell line, such as HepG2, 
to establish whether the present findings are reproducible in alternative cell lines [37]. 
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4.6  Conclusion 
The quasispecies circulating in treatment naïve HBV-HIV co-infected patients infected with 
HBV preS deletion mutants, have been molecularly characterised. It was found that the 
preS deletion mutants represented the majority population, as 70% or more of clones in 
each of the four patients were sequentially highly similar to the respective parental 
strains. In addition to the major populations in each patient, minor populations were 
identified in the quasispecies. It appears we are the first group to characterise the 
quasispecies in patients who are co-infected with HIV and HBV, where the patients are 
infected with subgenotype A1. 
The overlength subgenotype A1 WT replication competent plasmid [193], was successfully 
altered to remove an unwanted XbaI site. This altered construct served as a positive 
control to test whether the removal of this restriction site would affect replication and 
viral protein expression of this construct compared to the original plasmid. This plasmid 
was then successfully used as the backbone to construct three overlength deletion 
mutant constructs, which were shown to be replication competent. Finally, the altered 
backbone was used to successfully construct an overlength construct that contains the 
784 bp fragment derived from a patient with occult HBV infection and transfection with 
this construct mimicked the phenotype seen in vivo. As far as we are aware, we are the 
first group to have constructed plasmids with deletion mutants and an occult mutant in 
a subgenotype A1 backbone and to show that they express viral proteins and viral DNA 
following transfection into Huh7 cells. These constructs will be an important resource for 
further research into the high hepatocarcinogenic potential of subgenotype A1, the 
genotype A strain predominating in Africa.   
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5 Appendices 
5.1  Appendix A – Detailed Protocols 
5.1.1 DNA Extraction Protocol 
•  Care was taken to follow the manufacturers’ instructions. When carried out correctly, 
this kit should yield purified total DNA (genomic + viral + any other DNA present in the 
sample), which does not contain proteins, nucleases or other contaminants. There are 
elements of serum that can act as inhibitors to the amplification process of PCR; this kit 
should also strip away such elements 
•  Aliquot out appropriate volumes of each solution. Equilibrate all necessary solutions to 
room temperature and set heating block to 56°C 
•  Pipet 20 µ l  Qiagen Proteinase K into the bottom of a 1.5 ml microcentrifuge tube 
•  Add 200 µ l  serum sample to the microcentrifuge tube, if you want to rid the sample of 
RNA, add 4 µ l  of RNase A stock solution (100 mg/ml) to the sample before adding 
buffer AL 
•  Add 200 µ l  buffer AL to the sample, mix contents thoroughly using a pulse vortex for 15 
seconds  (Do not add Qiagen Proteinase K directly to buffer AL) 
•  Incubate the mixture at 56°C for 10 minutes and then briefly centrifuge the 1.5 ml tube 
to remove drops from the inside of the lid 
•  Add 200 µ l  Ethanol (96-100%) to the sample and mix again by pulse-vortexing for 15 
seconds. Again briefly centrifuge the 1.5 ml tube to remove drops from inside the lid 
•  Carefully apply the mixture from step 5 to the QIAamp spin column (in a 2 ml collection 
tube) without wetting the rim, close the cap and centrifuge at 6 000 x g or 8 000 RPM 
for 1 minute. Discard the collection tube containing the fi ltrate and place column in a 
new collection tube 
•  Carefully open the column and add 500 µ l  of buffer AW1 without wetting the rim, close 
the cap and spin for 1 minute at 6 000 x g or 8 000 RPM. Discard the collection tube 
containing the fi ltrate and place column in a new collection tube 
•  Carefully open the column and add 500 µ l  of buffer AW2 without wetting the rim, close 
the cap and spin at full speed (20 000 x g or 14 000 RPM) for 3 minutes, replace column 
into a new collection tube and spin again at full speed for 1 minute (to prevent any 
carryover of buffer AW2) 
•  Place the QIAamp spin column in a new sterile 1.5 ml microcentrifuge tube. Carefully 
open the column and add 75 µ l  of buffer AE, warmed in the water bath. Incubate at 
room temperature for 1-5 minutes and the centrifuge at 6 000 x g or 8 000 RPM for 1 
minute. Measure DNA concentration by NanoDrop and then store at -20°C   
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1.1.1. PCR Amplification  
•  For all PCR reactions the hood was first prepared by wiping the surfaces with bleach and 
then 70% ethanol, then all remaining DNA was destroyed using the UV lamp in the hood 
for 15 minutes 
•  All required PCR tubes were autoclaved beforehand and any necessary racks were 
cleaned in a diluted bleach solution  
•  For the Hot Start PCR reactions, the Qiagen HotStarTaq® Mastermix was used, thus 
there was no need to add dNTPs separately. However this Mastermix ensures that the 
final dNTP concentration is 200 μM of each dNTP. In both PCR protocols the positive 
control consisted of DNA extracted from a sera sample that was known to be HBV 
positive. Whereas, the negative controls would include the DNA extraction from a known 
HBV negative serum sample, as well as a best quality water only control where no DNA 
whatsoever was added. In both cases they were added instead of template DNA. 
•  A 20 μmol/l primer solution was prepared by adding 5 μ l  of the 200 μmol/l stock to 45 μ l  
of Best Quality Water 
•  For the Roche High Fidelity Expand kit the 50 μ l  aliquot of 10mM dNTP solution had to 
be prepared as follows: 
o  In a 1.5ml (Eppendorf) tube, mix the following to get 2.5x dNTP 
stock:  
o  250ul 100 mM dATP  
o  250ul 100 mM dTTP  
o  250ul 100 mM dGTP  
o  250ul 100 mM dCTP.  
o  Aliquot 500 μ l  into two 1.5 ml tubes.  
o  Add 750 ul ddH2O to each of the two tubes to dilute to 10mM.  
o  Aliquot 10 mM dNTP into 50 tubes, 50 μ l  per tube.  
(Note: Small aliquots are made in order to reduce the number of 
times that dNTP mixes are thawed and frozen, which degrade the 
nucleotides.)  
o  Store @ -20°C.  
•  The Roche High Fidelity Expand kit’s buffer includes MgCl2 in 25 mM concentration, thus 
final concentration of MgCl2 in PCR reactions was 1.5 mM 
•  See Table 5.1 below for details on primer sequences, which were originally designed by 
Vermeulen et al.,  [86]. See Table 5.2 for detailed content of PCR reactions for both Hot 
Start and High Fidelity Expand protocols 
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Table 5.1: Complete S Gene Primer Sequences 
 Primer  Primer sequence 
(3’-5’) 
Region in HBV 
genome 
Amplicon 
size 
1st 
round 
S1F TCA ATC GCC GCG TCG CAG AAG ATC 
TCA ATC 
2401 -2439 2113 bp 
S1R TCC AGA CCK GCT GCG AGC AAA ACA 1314 – 1291 2113 bp 
2nd 
round 
S2F AAT GTT AGT ATT CCT TGG ACT CAT 
AAG GTG GG 
2451 – 2482 2055 bp 
S2R AGT TCC GCA GTA TGG ATC GGC AGA 
GGA 
1286 - 1254 2055 bp 
The region in the genome refers to the relative position of the primers to the EcoRI site 
within the HBV genome. These primers were originally designed for the purposes of 
amplifying the complete S region by Vermeulen et al.,  [86] 
 
Table 5.2: Master Mixes used for Qiagen HotStart PCR reactions and subsequent Roche 
High Fidelity PCR reactions for amplification of the entire S region 
Qiagen HotStart PCR 
First Round PCR Reaction Second Round PCR Reaction 
Sample Content Quantity in μ l  Sample Content Quantity in μ l  
Forward primer (S1F) 0.375  Forward primer (S2F) 0.75  
Reverse primer (S1R) 0.375  Reverse primer (S2R) 0.75  
Qiagen Master Mix 12.5  Qiagen Master Mix 25  
Template DNA 2.5  Template DNA 5  
Best Quality Water 9.25  Best Quality Water 18.5  
T o t a l  V o l u m e  2 5   T o t a l  V o l u m e  5 0   
 
Roche Expand High Fidelity PCR System 
First Round PCR Reaction Second Round PCR Reaction 
Forward primer (S1F) 0.375  Forward primer (S2F) 0.75  
Reverse primer (S1R) 0.375  Reverse primer (S2R) 0.75  
Roche Expand Enzyme 0.125  Roche Expand Enzyme 0.25  
Roche Expand Buffer 2.5  Roche Expand Buffer 5.0  
dNTPs 0.5  dNTPs 1.0  
Template DNA 2.5  Template DNA 5.0  
Best Quality Water 18.625  Best Quality Water 37.25  
T o t a l  V o l u m e  2 5   T o t a l  V o l u m e  5 0   
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Figure 5.1: PCR ThermocyclingCconditions  
All PCR product were visualised by running them on a 1% (w/v) agarose gel for 1.5 hours at 
75 V. 5 μ l  1 kb DNA Ladder was run alongside. They were then visualised and captured on 
the Gel Doc system. 
 
5.1.2 Gel Electrophoresis and DNA Amplicon Purification from Gel  
•  Agarose gels were usually prepared to be 1 % Agarose, they were run at 70-80V for 2 
hours, depending on whether the DNA had travelled far enough the length of the gel. 
Mostly gels were stained with ethidium bromide. However when DNA was intended to be 
used for downstream cloning, gels were stained with Novel Juice instead of ethidium 
bromide as to avoid damage to the DNA. This is because ethidium bromide intercalates 
with DNA, and is not easily removed upon purification. 
•  To Prepare a 1 % Agarose Gel 
o  Add 1 g of Agarose for every 100ml of 1x TAE Buffer, heat in microwave until 
Agarose is completely dissolved. Allow to cool. Prepare gel tray and select 
desired comb, place comb in the tray. Add 3 µ l  of ethidium bromide to every 
100 ml of Agarose solution. Pour into tray and allow to set. Similarly a 2% gel 
would be 2 g Agarose for every 100ml of 1x TAE Buffer. 
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•  Gel Purification Protocol 
o  Excise the DNA fragment from the agarose gel using razor blade or scalpel 
and transfer it into a sterile Eppendorf tube. Note: The amount of agarose 
excised from the gel should be as small as possible and should not exceed 
150 µl (150 mg) per tube. 
o  Add 3 volumes of ADB to each volume of agarose excised from the gel (e.g. 
for 100 µl (mg) of agarose gel slice add 300 µl of ADB). Not For DNA 
fragments <8 kb, following the incubation step, add one additional volume 
(equal to that of the gel slice) of water to the mixture for better DNA recovery 
(e.g. 100 µl agarose, 300 µl ADB and 100 µl water).  
o  Incubate at 37-55 °C for 5-10 minutes until the gel slice is completely 
dissolved. 
o  Transfer the melted agarose solutions to the wells of the Zymo-Spin™ Column 
and place within the collection tube 
o  Centrifuge for 1 minute at 10 000 RPM until the sample mixtures have been 
completely fi ltered. Discard the flow-through  
o  Add 200 µl of DNA Wash Buffer to each tube. Centrifuge for 1 minute at 10 
000 RPM. Repeat the wash step, but centrifuge for 1.5 minutes.  
o  Add ≥15 µl preheated DNA Elution Buffer or water directly to the column 
matrix in each well. Transfer the Zymo-Spin column into a fresh Eppendorf 
tube, incubate at 60°C for 1 minute and centrifuge for 3 minutes to elute the 
DNA. 
o  Ultra-pure DNA is now ready for use. 
 
5.1.3 Preparing Chemically competent cells  
It is important to choose a strain of Escherichia coli (E. coli) that will lend itself to the needs 
of your cloning protocols.  
After doing a comparison of the strains of E. coli according to genotype, it was decided to 
use SCS110 this project as it is a strain which is has dam (DNA adenine methylase) and dcm 
(DNA cytosine methylase) mutations which allows cleavage with methylation sensitive 
enzymes. This was important during this project because XbaI was the enzyme primarily 
employed for cloning as well as screening during the cloning processes employed during 
this project, and XbaI is a methylation sensitive enzyme.  
This strain also allows blue/white screening due to the N-terminal deletion (lacZΔM15), 
which permits the α-complementation segment present on pUC-based plasmids, to make a 
functional lacZ protein. Thus empty vectors will appear to have a blue colour, whereas those 
containing a cloned insert will be white.  
Finally SCS110 cells are easily transformed by electrochemical methods, and will produce 
relatively high transformation efficiency even with large plasmids. 
Table 5.3 below outlines genotypes of commercially available used E. coli strains that were 
considered for this study. 
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Table 5.3: Choosing Escherichia coli strain by Genotype 
Strain 
Name 
Stockist Genotype 
XL1-BLue Stratagene recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)] 
XL1-Blue 
MR 
Stratagene Δ (mcrA)183 Δ (mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 
gyrA96 relA1 lac 
XL1-Blue 
MRF 
Stratagene Δ (mcrA)183 Δ (mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 
gyrA96 relA1 lac {F´ proAB lacIqZΔM15 Tn10 (Tetr)} 
XL2-Blue Stratagene recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac {F´ proAB 
lacIqZΔM15 Tn10 (Tetr) Amy Camr}* 
SCS110 Stratagene rpsL (Strr) thr leu endA thi-1 lacY galK galT ara tonA tsx dam 
dcm supE44 Δ ( lac-proAB) {F´ traD36 proAB lacIqZΔM15} 
JM110 Stratagene rpsL (Strr) thr leu thi-1 lacY galK galT ara tonA tsx dam dcm 
supE44 Δ ( lac-proAB) [F´ traD36 proAB lacIqZΔM15] 
Top10  Invitrogen F– mcrA Δ (mrr-hsdRMS-mcrBC) Φ80 lacZΔM15 Δ lacX74 recA1 
araD139 Δ (ara	  leu )  7697 galU galK rpsL (StrR) endA1 nupG 
Top10F Invitrogen F´{lacIq Tn10 (TetR)} mcrA Δ (mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
Δ lacX74 recA1 araD139 Δ (ara-leu)7697 galU galK rpsL endA1 
nupG 
DH5α  Invitrogen F- φ80lacZΔM15 Δ ( lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, 
mk+) phoA supE44 thi-1 gyrA96 relA1 tonA (confers resistance to 
phage T1) 
SURE Stratagene e14–(McrA–) Δ (mcrCB-hsdSMR-mrr)171 endA1 supE44 thi-1 
gyrA96 relA1 lac recB recJ sbcC umuC::Tn5 (Kanr) uvrC [F´ proAB 
lacIqZΔM15 Tn10 (Tetr)] 
 
PIPES Protocol for Preparing Chemically Competent E. coli: 
•  Inoculate 10 ml of LB medium with 100 µ l  of untransformed DH5α/SCS110/XLBlue E. coli 
stock, or previously prepared competent bacteria of the necessary strain and shake 
overnight in a bacterial incubator at 37°C (120 RPM).  OR spread stock the required strain 
on an appropriate LB plate, grow at 37°C overnight, and inoculate 10ml of media with 
one colony 
•  Split the overnight culture into two 50ml tubes and make up to 50ml with fresh LB 
medium, culture bacteria for 90 minutes (@ 37°C, 120 RPM) until bacteria are in mid log 
phase (OD600 of 0.3-0.5) OR Innoculate 50 ml of SOB with 50 µ l  of the overnight culture, 
grow at 37°C, shaking at 120 RPM til l  cells are in mid-log phase (OD600 of 0.3-0.5), thus 
±5hours 
•  Pellet the bacteria (4x25 ml per 50 ml falcon tube) by centrifuging at 4500 RPM for 15 
minutes at 4°C and remove supernatant 
•  Gently resuspend the bacterial pellet from each 25 ml tube in 2.5 ml PIPES buffer and 
place on ice for 15-30 minutes. Note: the bacteria in PIPES buffer are extremely fragile 
and should be treated gently making sure not to keep them on ice for too long 
•  Pellet the bacteria (4x25 ml per 50 ml falcon tube) by centrifuging at 2500 RPM for 10 
minutes at 4°C and remove supernatant 
•  Gently resuspend each bacterial pellet in 1ml PIPES buffer, aliquot 100 µ l  of the now 
competent bacteria into 2 ml capped sterile tubes. The PIPES buffer contains 15% 
glycerol thus enabling storage at -70 to -80°C for up to 6 months 
•  Test transformation efficiency using a standard high replication plasmid such as pTZ57R 
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5.1.4 Transformations  
Using the InsTAclone Kit: Transformation Protocol from Overnight Bacterial Culture  
This protocol is sufficient for 2 transformations; if more are required the protocol should be 
adjusted accordingly. 
•  The day prior to the transformation, seed an overnight culture (of the required bacterial 
cell l ine either SCS110 of DH5α )  by inoculating 2 ml of C-medium with a single bacterial 
colony. Make sure to use freshly streaked bacterial colonies (not older than 10 days). 
Incubate the culture overnight at 37°C in a shaker. 
•  2 ml of overnight culture is sufficient for 26 transformations. The culture can be kept at 
4°C for one week and used for preparation of competent cells. 
•  The day of transformation ensure culture tubes are pre-warmed and contain the 
required amount of C-medium (1.5 ml for each 2 transformations) at 37°C for at least 20 
min. Pre-warm LB agar plates in a 37°C incubator for at least 20 min before plating. 
These should be supplemented with ampicill in, X-Gal and IPTG.  
•  Prepare the T-solution by thawing T-solution (A) and T-solution (B), and mixing contents 
thoroughly. Combine 250 μ l  of T-solution (A) and 250 μ l  of T-solution (B) in a separate 
tube and keep on ice. 
•  Add 150 μ l  of the overnight bacterial culture to 1.5 ml of pre-warmed C-medium and 
incubate with shaking for 20 min at 37°C. 
•  Pellet bacterial cells from this overnight culture by centrifugation for 1 min at 5000 RPM, 
discard the supernatant. 
•  Resuspend the pelleted cells in 300 μ l  of T-solution. Incubate on ice for 5 min. 
•  Centrifuge for 1 min at 6000 RPM in a microcentrifuge, discard the supernatant. 
•  Resuspend pelleted cells in 120 μ l  of T-solution. Incubate 5 min on ice. 
•  The ligation mixture is now added ina volume of 2.5 μ l  (containing 14 ng vector DNA) or 
1 μ l  of supercoiled Control DNA (10-100 pg) into new microcentrifuge tubes. Chill on 
ice for 2 min. 
•  Add 50 μ l  of the prepared cells that are on ice to each tube containing DNA, mix and 
incubate again on ice for 5 min. 
•  Plate immediately on pre-warmed LB-ampicill in X-Gal/IPTG agar plates. Incubate 
overnight at 37°C. 
•  Document the plates and controls by doing colony counts and taking photographs on 
the GeneDoc 
 
Transformation Using Chemically Competent Cells 
•  Pre-chill  Eppendorf tubes on ice. (Some tubes are for the experimental transformations 
and one tube is for the pTZ57R positive control). Preheat SOC medium to 42°C. 
•  Thaw the chemically competent cells on ice. When thawed, gently mix and aliquot 100 
µ l  of cells into each of the two pre-chilled tubes. Add 1.7 µ l  of β-mercaptoethanol to 
each aliquot of cells. Gently swirl the tubes to mix. Incubate the cells on ice for 10 
minutes, swirling gently every 2 minutes. 
•  Add 0.1–50 ng of the experimental DNA (see Quantity and Volume of DNA, reverse 
page, for guidelines) to one aliquot of cells and add 1 µ l  of the pUC18 control DNA to 
the other aliquot. Swirl the tubes gently. 
•  Incubate the tubes on ice for 30 minutes. 
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•  Heat-pulse the tubes in a 42°C water bath for 45 seconds. The duration of the heat 
pulse is c r i t i c a l  for maximum efficiency. 
•  Incubate the tubes on ice for 2 minutes. 
•  If  the antibiotic resistance gene is anything other than ampicill in, add 0.9 ml of 
preheated SOC medium and incubate the tubes at 37°C for 1 hour with shaking at 225–
250 rpm, to allow time for antibiotic expression. 
•  Plate ≤200 µ l  of the transformation mixture on LB agar plates containing the 
appropriate antibiotic‡ (and containing IPTG and X-gal if colour screening is desired). 
For the pTZ57R control transformation, plate 200 µ l  of the transformation on LB–
ampicill in agar plates. 
 
Note: Cells may be concentrated by centrifuging at 1000 RPM for 10 minutes. Resuspend 
the pellet in 200 µ l  of SOC medium. If plating <100 µ l  of cells, pipet the cells into a 200 µ l  
pool of SOC medium and then spread the mixture with a sterile spreader. If plating ≥100 µ l ,  
the cells can be spread on the plates directly. Tilt and tap the spreader to remove the last 
drop of cells. Some β-galactosidase fusion proteins are toxic to the host bacteria. If an 
insert is suspected to be toxic, plate the cells on media without X-gal and IPTG. Color 
screening will be eliminated, but lower levels of the potentially toxic protein will be 
expressed. 
•  Incubate the plates at 37°C overnight (at least 17 hours for blue-white color screening). 
Colonies containing plasmids with inserts will remain white, while colonies containing 
plasmids without inserts will be blue. The blue color can be enhanced by incubating the 
plates for two hours at 4°C following the overnight incubation at 37°C. 
•  For the pUC18 control, expect 100 colonies (≥5 °— 106 CFU/µg pUC18 DNA). For the 
experimental DNA, the number of colonies will vary according to the size and form of 
the transforming DNA, with larger and non-supercoiled DNA producing fewer colonies. 
 
5.1.5 Cracking 
•  An aliquot of 500 µ l  of the bacterial culture was placed into a sterile 1.5 ml Eppendorf 
tube, and centrifuged at 12 000 RPM for 1 minute, then the supernatant was discarded.  
•  The pellet was resuspended in 100 µ l  of Cracking Buffer (Appendix B) and vortexed. The 
resuspended bacterial cells were centrifuged at 12 000 RPM for 20 minutes. 
•  The bands resulting from the cracking reaction were visualised on a 1% agarose gel by 
loading 30 µ l  of the supernatant. 5 µ l  1 kb DNA Ladder was run alongside. Importantly 
samples had to be loaded onto a “dry” 1% (w/v) agarose gel, meaning the running 
buffer in the tank was lower than the top edge of the agarose gel but not covering the 
wells, to prevent the sample from floating out of the well. After the samples had run 
into the gel, the entire gel was submerged in running buffer, and electrophoresis for 
1.5 hours at 75 V. 
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5.1.6 Plasmid Mini Preparation 
Sigma Solution Mini Prep with no columns. 
Procedure: 
•  8ml of cells were grown overnight with shaking at 120 RPM and 37oC, transfer 2ml of 
culture into Cryo tube for glycerol stocks 
•  Pellet the remaining 6ml of culture by microfuging for 5 min at 8 000 RPM, discard 
supernatant 
•  Resuspend the pellet in 200 µl Solution I  
•  Add 200 µl Solution II, invert gently to mix and leave at room temperature for 5min 
•  Add 350 µl Solution III,  shake to mix and incubate on ice for 10 min 
•  Microfuge to pellet the cell debris at room temperature for 10 min at 13 000 RPM 
•  Decant the supernatant in to a sterile Eppendorf with a pipette 
•  Add 600 µl Isopropanol and microfuge at room temperature for 30 min (13 000 RPM) to 
precipitate the DNA, pour off the supernatant 
•  Wash with 1 ml 70 % ethanol, microfuge at room temperature for 15 minutes (13 000 
RPM), pour off ethanol supernatant 
•  Dry isolates overnight at 37oC 
•  Resuspend in 40µl of sterile water 
•  Do NanoDrop spectrophotometry on a number of the samples to check DNA 
concentration 
•  Store at -20oC until further use 
 
5.1.7 Ethanol Precipitation of DNA 
•  To 180 µl of resuspended plasmid isolate add 18 µl of 3M Sodium Acetate (pH 5.2) and 
mix 
•  Add 600 µl of -20⁰C 100% ethanol, mix and centrifuge at 13 000 RPM for 20 minutes, 
pour off supernatant 
•  Add 1 ml of 70% ethanol and centrifuge at 13 000 RPM for 10 mins, pour off supernatant 
•  Dry pellet in the stationary 37°C Incubator and then resuspend in 50µl 
•  DNA concentration was estimated using the NanoDrop spectrophotometer and running 
some linearised sample on a 1% Agarose gel 
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5.1.8 Ligation  
Using the InsTAclone Kit: 
The InsTAclone Kit recommends that for DNA amplicons of 2000 bp in length 350 ng of 
DNA should be added to the ligation mixture. Thus the appropriate amount of DNA would 
be calculated from the concentration established by NanoDrop spectrophotometry. Table 
5.4 below shows the components of a l igation reaction. All reactions were carefully mixed 
and then placed first on the bench at room temperature for 30 minutes and then in the 
thermocycler at 4°C overnight. Controls always included: 
1. Positive control (vector with a control PCR fragment) – to test efficiency of the 
ligation reaction 
2. Second positive control (supercoiled circular DNA vector)  
3. Empty vector control (where the open vector was added with no insert) - to test 
whether the enzyme was working 
4. No DNA control – which would show no contamination of competent cells once they 
are transformed 
Note:  pTZ57R – closed circular supercoiled vector 
  pTZ57R/T - l inearized cloning vector with single 3’-ddT overhangs 
 
Table 5.4: Components of Ligation Reaction using the InsTAclone Kit 
Component: Quantity (volume in μ l ) :  
 Ligation 
Reaction 
Positive 
Control 
pTZ57R pTZ57R/T 
(Empty 
Vector 
control) 
No T4-
DNA 
Ligase 
No DNA 
Control 
Vector 
pTZ57R/T 3 7 7 3 7 0 
10x Ligation 
Buffer 3 3 3 3 3 3 
Purified PCR 
Product 
1-15 
depending on 
concentration 
0 0 0 0 0 
Control PCR 
Fragment 0 4 0 0 4 0 
Best Quality 
Water 
(Nuclease 
Free) 
8-23 
depending on 
concentration 
15 19 23 15 27 
T4 DNA 
Ligase 1 1 1 1 0 1 
Total Volume 30 30 30 30 30 30 
 
 
 131 
Using T4-DNA Ligase: 
The DNA concentration of all DNA to be ligated was determined first by NanoDrop 
Spectrophotometry. For l igations the optimal insert/vector ratio is 3:1, however to be safe, 
a 1:1 ratio was included as well.  
Controls included: 
•  A pTZ57R (circular) positive control 
•  A cut and ligate control (vector only control) 
•  A no T4-DNA Ligase control  
•  A no DNA negative control 
Once reactions were set up contents were carefully mixed and then placed at 4°C in the 
thermocycler overnight. 
 
Table 5.5: Typical Contents of a Ligation Reaction 
Component: Quantity (volume in μ l )  
 
pTZ57R 
positive 
control 
Experimental 
Ligation 
Cut 
+Ligate 
Control 
No T4-
DNA 
Ligase 
control 
No DNA 
Control 
Insert 
 
0 μ l  
1-20 μ l  
depending on 
concentration 
0 μ l  10 μ l  0 μ l  
Vector 
 
6 μ l  1 μ l  1 μ l  1 μ l  0 μ l  
Best Quality 
Water 
18 μ l  
1-10 μ l 
depending on 
concentration  
23 μ l  16 μ l  24 μ l  
10x ligation 
buffer 
3 μ l  3 μ l  
 
3 μ l  3 μ l  3 μ l  
T4-DNA 
Ligase 
3 μ l  3 μ l  
 
3 μ l  0 μ l  3 μ l  
Total Volume 30 μ l  30 μ l  
 
30 μ l  30 μ l  30 μ l  
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5.1.9 Restriction Digestion 
Before setting up any Restriction reaction the concentration of the DNA was determines by 
NanoDrop spectrophotometry. This is because 1 μ l  of Enzyme solution is sufficient to digest 
up to 1 μg of lambda DNA. Thus the between 800 ng – 1 μg of DNA was added to each 
restriction digestion reaction. 
Table 5.6: Typical Contents of a Restriction Digest Reaction 
Content: Experimental Digest No DNA Control 
Plasmid DNA 1 – 8 μ l   
depending on concentration 
(always aim to digest 800-1000 
ng/ μ l )  
0 μ l  
Appropriate Buffer 1 μ l  1 μ l  
Enzyme 1 μ l  1 μ l  
Best Quality Water 1 – 7 μ l   
depending on concentration 
8 μ l  
Total Volume 10 μ l  10 μ l  
 
All restriction digestions were mixed and then incubated at 37°C for one hour unless the 
Enzyme used required a different temperature. After restriction loading dye was added 
(typically 5 μ l )  to stop the reaction, and together were loaded onto a 1% (w/v) Agarose Gel 
and ran at 75V for 1.5 hours. 5 μ l  1 kb DNA Ladder was run alongside. The results were 
visualised and images captured on the GelDoc System. 
 
5.1.10 Plasmid Maxi Preparation 
Qiagen Protocol for DNA Maxi Prep from Bacterial Culture for Cloning Purposes: 
•  Cells were harvested from culture by centrifuging at 5 500 RPM for 15 minutes at 4⁰C 
•  Cells were then resuspended thoroughly by aspirating with a pipette in 10 ml of Buffer 
P1 (check that RNase has been added) 
•  Cells were then lysed by adding 10 ml of Buffer P2 incubate at room temp for 5 min and 
then add 10 ml of Buffer P3, incubate on ice for 15min 
•  The lysate was then cleared by centrifuging at 11 000 RPM for 30 minutes at 4⁰C, 
transfer supernatant to a fresh Nunc tube and centrifuging again at 11 000 RPM for 15 
minutes at 4⁰C 
•  A Qiagen column was then equilibrated by adding 4 ml of Buffer QBT, the flow through 
is discarded 
•  The cleared lysate was then loaded onto the column with the aid of an inoculation loop 
to prevent the flocculant from blocking the column, flow through was discarded 
•  The column was then washed twice with 30 ml of Buffer QC and the flow through was 
discarded 
•  The plasmid DNA was then eluted into a fresh tube using 15 ml of buffer QF 
•  Then 10.5 ml of isopropanol was added to the tube to precipitate the DNA, this was 
then carefully mixed and then centrifuged at 4⁰C for 30 minutes at a speed of 12 000 
RPM, after which the supernatant was carefully poured off 
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•  Added 5 ml of 70% ethanol to each tube, mixed carefully and centrifuged for 15 
minutes at 12 000 RPM at room temperature, again supernatant was carefully poured off 
•  The pellet was dried until pellet was translucent 
•  The pellet was resuspended in 50-100 µl of sterile preheated TE buffer 
•  Each tube was tapped vigourously, incubated at 60⁰C for a few minutes, then again at 
37⁰C for a few minutes and then spun briefly 
•  The DNA concentration was estimated by NanoDrop, and DNA was stored at -20°C 
 
Qiagen Protocol for DNA Endo Free Maxi Prep from Bacterial Culture for Transfection 
Purposes: 
•  Cells were harvested from culture by centrifuging at 5 500 RPM for 15 minutes at 4°C 
•  Cells were then completely resuspended by aspirating with a pipette in 10 ml of Buffer 
P1 (check that RNase has been added) 
•  Cells were then lysed by adding 10 ml of Buffer P2 incubate at room temp for 5 min and 
then add 10 ml of Buffer P3, incubate on ice for 15 minutes 
•  During the incubation, prepare QIAfilter cartridge  
•  Pour the lysate into the QIAfilter Cartridge. Incubate at room temperature for 10 minutes, 
do not insert the plunger yet. Remove the cap from the QIAfilter Cartridge outlet nozzle. 
Gently insert the plunger into the QIAfilter Cartridge and filter the cell lysate into a 50 
ml tube. 
•  Add 2.5 ml Buffer ER to the fi ltered lysate, mix by inverting the tube approximately 10 
times, and incubate on ice for 30 minutes. 
•  Equilibrate a QIAGEN-tip 500 by applying 10 ml Buffer QBT, and allow the column to 
empty by gravity flow. 
•  Apply the fi ltered lysate from step 7 to the QIAGEN-tip column and allow it to flow 
through the tip. Flow through was discarded. 
•  The column was then washed twice with 30 ml of Buffer QC and the flow through was 
discarded 
•  The plasmid DNA was then eluted into a fresh tube using 15 ml of buffer QF 
•  Then 10.5 ml of isopropanol was added to the tube to precipitate the DNA, this was then 
carefully mixed and then centrifuged at 4°C for 30 minutes at a speed of 12 000 RPM, 
after which the supernatant was carefully poured off 
•  Added 5 ml of 70% ethanol to each tube, mixed carefully and centrifuged for 15 minutes 
at 12 000 RPM at room temperature, again supernatant was carefully poured off 
•  The pellet was dried until pellet was translucent 
•  The pellet was resuspended in 50-100 µl of sterile preheated TE buffer 
•  Each tube was tapped vigorously, incubated at 60°C for a few minutes, then again at 
37°C for a few minutes and then spun briefly 
•  The DNA concentration was estimated by NanoDrop 
 
 
 134 
5.1.11 Cell Culture Techniques 
The UV lights (in hood and on tissue culture room ceiling) were switched on for 30 mins 
prior to starting any work in the tissue culture room, and again after completing work. The 
water bath was switched on to 37°C. All elements that go into the hood were sprayed with 
70% ethanol before placing them inside the hood. 
 
Thawing Cells: 
Cells should be thawed rapidly, i .e. not on ice, and then slowly (dropwise) thawed in 10 ml 
of warm medium. Add cells to a 75 ml culture flask to avoid osmotic shock. 
 
Passaging/Splitting Cells: 
After 2 days of growth (or more depending on confluency), remove media with a pipette.  
Wash cells twice with 5-7 ml of Sodium Chloride or 1% EDTA Sodium Chloride Solution, 
incubating at room temperature for 5 mins each time. Remove the solution after each wash.  
Add 1,5 ml of Trypsin to the cells, and incubate at 37°C for 2 mins (or less). Neutralise the 
Trypsin by adding 4-5 ml of Complete Medium, resuspend the cells gently and transfer to a 
15 ml Falcon tube. Spin cells down (at 50% for 5 minutes). Resuspend in the desired amount 
and split into as many flasks as is required usually 2 x 75 cm2 flasks).   
Incubate at 37°C with 5% CO2 for as 2 days before changing medium or splitting again. 
 
Freezing Cells: 
It is recommended to freeze rapidly growing cells. 
Wash cells twice with 5-7 ml of Sodium Chloride or 10% EDTA Sodium Chloride Solution, 
incubating at room temperature for 5 mins each time. Remove the solution after each wash.  
Add 1,5 ml of Trypsin to the cells, and incubate at 37°C for 2 mins (or less). 
Neutralise the Trypsin by adding 4-5 ml of Complete Medium, resuspend the cells gently 
and transfer to a 15 ml Falcon tube. Spin cells down (at 50% for 5 minutes). 
Resuspend them in Freezing Solution 1 (F1) (20% Serum) to half the desired final volume 
(i.e. if you want to freeze 6 mls of cells resuspend in 3 ml), place the tubes in an ice bucket 
and allow cells to cool. 
Once cells are cool add Freezing Solution 2 (F2) (20% Serum, 20% DMSO) dropwise (same 
volume as F1). Chill the cells on ice for exactly 30 mins, then transfer to pre chilled vials for 
freezing (rack should be chilled as well), use 1 ml per vial.   
Place vials in a well insulate box and place in the -70°C freezer overnight for slow cooling. 
Place samples in liquid nitrogen and store at -70°C indefinitely. 
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Seeding Protocol: 
Grow Huh7 cells to the desired confluency in a 75 cm flask, here we use 100% confluency.  
First trypsinise cells and spin them down, resuspend in 10ml of complete media. 
 
For seeding at 80% 
100% confluent 
1 well is 3.6 cm 
 seed 10 wells 
1 x 75 cm flask 
(100 x 75) / (80 x3.6) = 7500 / 288 = 26.04 
10 / 26.04 = 0.38 % 
Therefore 380 μ l  per well. 
Thus add 3.8 ml of resuspended cells to 6.2 ml of complete media, mix thoroughly and seed 
1 ml per well. Always rock the plate gently to distribute cells evenly. 
 
Similarly: 
For seeding at 70% 
(100 x 75) / (70 x3.6) = 7500 / 252 = 29.76 
10 / 29.76 = 0.33 % 
Therefore 330 µ l  per well. 
Thus add 3.3 ml of resuspended cells to 6.7 ml of complete media, mix thoroughly and seed 
1 ml per well. 
 
For seeding at 60% 
(100 x 75) / (60 x3.6) = 7500 / 216 = 34.7 
10 / 34.7 = 0.28 % 
Therefore 280 µ l  per well. 
Thus add 2.8 ml of resuspended cells to 7.2 ml of complete media, mix thoroughly and seed 
1 ml per well.  
 
For seeding at 50% 
(100 x 75) / (50 x 3.6) = 7500 / 180 = 42.6 
10 / 42.6 = 0.22 % 
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Therefore 230 µ l  per well. 
Thus add 2.3 ml of resuspended cells to 7.7 ml of complete media, mix thoroughly and seed 
1 ml per well.  
 
For seeding at 40% 
(100 x 75) / (40 x 3.6) = 7500 / 144 = 52.08 
10 / 52.08 = 0.11 % 
Therefore 110 µ l  per well. 
Thus add 1.1 ml of resuspended cells to 8.9 ml of complete media, mix thoroughly and seed 
1 ml per well. 
 
Cell Transfection: 
D a y  1  
Wash cells twice with 5-7 ml of Sodium Chloride or 10% EDTA Sodium Chloride Solution, 
incubating at room temperature for 5 mins each time. Remove the solution after each wash. 
Add 1,5 ml of Trypsin to the cells, and incubate at 37°C for 2 mins (or less). Neutralise the 
Trypsin by adding 4-5 ml of Complete Medium, resuspend the cells gently and transfer to a 
15 ml Falcon tube. Spin cells down (at 50% for 5 minutes). 
Resuspend in 10ml (preferably in a 50 ml Nunc Tube) 
Use the seeding protocol described above to seed at 80%, thus cells should be at 90% 
confluency on the day or transfection. 
 
D a y  2  
Reagents and equipment necessary for PEI transfection include: 
•  10 ×  PEI 
•  300 mM NaCl 
•  1.5 mL sterile microfuge tubes 
•  1 mL, 200 µL and 10 µL pipette and tips 
•  Ultrapure Sabax distil led water 
•  Vortex mixer 
•  Incubator at 37°C with 5% CO2 
 
To prepare 10 ×  PEI mix (1 mg/mL) dissolve 50 mg of PEI (Polyethyeneimine unbranched) in 
50 mL of water and heating the mixture to 80°C for a few hours with periodic mixing. Filter 
steril ise, aliquot and store at ‐20°C. 
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PEI Transfection Procedure: 
•  Seed cells (one day before transfection or on day of transfection and wait 4 hours).  
Check that cells have grown to 90% confluency 
•  Remove and replace the complete medium on cells before transfection. 
•  Bring all reagents to room temperature. 
•  Prepare DNA solution. Dilute DNA to be 2,5 μg in 5 μ l .  Prepare PEI solution. Mix 
DNA and PEI solutions. Add the PEI solution to the DNA solution (not the other way 
around). See table below for ratios. Transfection mix (PEI mix + DNA in 150 mM 
NaCl) should be 10% of medium ie 100 μ l  transfection mix in 900 μ l  of medium. 
•  Incubate 10 minutes at room temperature (not longer). 
•  Add transfection mix to cells (drop wise). 
•  Change transfection medium after 8‐12 hours (or next morning). 
 
Figure 5.2: DNA and PEI ratios for Transfection 
 
Table 5.7: Optimised Transfection Contents 
Plate Format 12 Well Plate (Content Per Well)  
Volume of Medium 900 μ l  
Volume of Transfection Mix 100 μ l  
Total Volume 1 ml 
DNA Mix: 
DNA (mass) 
Volume of 300nM NaCl  
Volume of Best Quality Water 
 
2 μg 
25 μ l  
To 50 μ l  
PEI Mix: 
Volume of 10 x PEI 
Volume of 300nM NaCl  
Volume of Best Quality Water 
 
5 μ l  
25 μ l  
20 μ l  
PEI :  DNA Ratio 5 μ l  :  2 μg 
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D a y  3  
Check Transfection Efficiency of the well containing the eGFP plasmid under the fluorescent 
microscope. Count total amount of cells in your field, then count how many are fluorescent 
(x/y x100 = % efficiency). 
Harvest supernatant and lysates on days 1, 3 and 5 post transfection.  
Add Protease Inhibitor Cocktail Tablets cOmplete mini solution (Roche) to a final 
concentration of 50X to the serum and stored at -70°C until further use. 
 
5.1.12 ELISA for HBsAg  
The Murex® HBsAg Version 3 (DiaSorin) ELISA is designed specifically to determine 
presence of HBsAg with high sensitivity. The 96 well ELISA plate is coated in mouse 
monoclonals that are specific for different epitopes on the ‘a’ determinant of HBsAg. 
Therefore this kit should be sensitive even for some mutant strains of HBV. 
•  Supernatant that was stored at -70°C was thawed on ice until f luid. Supernatant was 
diluted 1:20 with neat cell culture media (DMEM GlutaMAX™ media without foetal 
bovine serum) 
•  The plates were taken from the fridge, and allowed to reach room temperature, and 
then only removed from protective bag. Also allow all reagents to come to room 
temperature. 
•  Determine which samples go on the plate, their positioning, and the positioning of the 
controls. Only use the wells required for your number of samples and controls. For all 
experimental samples, three biological replicates and two technical replicates were 
loaded onto the plate. 
 
Figure 5.3: Plate Layout for HBsAg ELISA 
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The blank contains no incubation buffer, and no serum ie substrate only. The Negative 
control (Neg) is human serum/plasma non-reactive for HBsAg. The Positive control (Pos) is 
deactivated human serum that is reactive/positive for HBsAg.  
 
•  Prepare the Substrate and Wash Solutions 
o  To the Substrate Solution add a volume of colourless Substrate Diluent to an 
equal volume of pink Substrate Concentrate in either a clean glass or plastic 
vessel. Prepare this solution just prior to use. It is important that this order of 
addition is followed and that any pipettes and glassware used to prepare 
Substrate Solution are clean. Alternatively, the Substrate Solution may be 
made by pouring the entire contents of the bottle of Substrate Diluent into 
the bottle of Substrate Concentrate. One bottle of Substrate Solution 
provides sufficient reagent for at least five plates. The Substrate Solution 
should be pink; if it is purple before being used, it should be discarded and 
fresh Substrate Solution prepared.  
o  For the Wash Solution - Add one volume of Concentrated Wash Fluid 
(Glycine/Borate wit 0.2% Bronidox) to 19 volumes of distil led or deionised 
water (best quality water) to give the required volume. 
•  To each well add, first 25 μ l  of Sample Diluent (mix by shaking before use) and then 75 μ l  
of sample/control. Do not add any Sample Diluent or sample to the blank well. Controls 
and samples were aliquoted in duplicate (i.e. two wells each) onto the plate. Add 
samples first and then controls, which include:  
o  Positive Control – included in Kit, contains human sera positive for HBsAg 
o  Negative Control – included in Kit, contains human sera that is non-reactive 
for HBsAg 
•  Cover the plate with provided lid and allow to incubate at 37°C for 1 hour 
•  Add 50 μ l  of Conjugate (invert bottle to mix before use) to each well except the blank 
well, add the lid, and shake the plate on a shaker for 10 seconds 
•  Incubate for 30 minutes at 37°C 
•  Wash the plate 5 times by fi l l ing (±500 μ l )  all active wells with the Wash Solution, 
aspirate the liquid and allow to soak (±30 seconds). After the last round of washing invert 
the plate onto absorbent paper (blot), taking particular care on the last wash to tap out 
any residual Wash Solution. 
•  Immediately add 100 μ l  Substrate Solution to each active well, cover plate with lid and 
incubate at 37°C for 30 minutes while colour develops. Reactive wells should have a 
purple colour. 
•  After the incubation add 50 μ l  of Stop Solution to each well, reactive wells should have a 
yellow colour.  
•  Blank the plate reader on air (no plate in cartridge). Within 15 minutes of adding the 
Stop Solution, place the plate in the plate reader, and measure the absorbance of each 
active well at 450 nm. Use 620 nm to 690 nm as a reference wavelength.  
 
CALCULATION OF RESULTS 
Each plate must be considered separately when calculating and interpreting results of the 
assay. Approved software may be used for calculation and interpretation of results. 
Quality Control 
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The absorbance of the negative control (or average of the negative controls) must be less 
than 0.2. The absorbance of the positive controls must be above the average of the 
negative controls plus 0.8 (i .e. the absorbance of the positive control is more than 0.8 
above the absorbance of the negative control) 
The assay is only valid if these criteria are met. 
 
Negative Control 
Calculate the mean absorbance of the replicates of the Negative Control.  
If  one of the Negative Control wells has an absorbance more than 0.03 above the other 
discard the higher value. 
Cut-off Value 
Calculate the cut-off Value by adding 0.05 to the mean of the Negative  
Control replicates. 
Example 
Negative Control absorbance: well 1 = 0.071, well 2 = 0.075 
Mean Negative Control = (0.071 + 0.075)/2 = 0.073 
Cut-off Value = 0.073 + 0.05 = 0.123 
 
Note:  
The term biological replicates describes three separate samples of the same construct that 
were treated with the exact same experimental conditions but independently of one 
another. Whereas, technical replicates are when the exact same sample, collected after all 
experimental techniques are complete is analysed multiple times. 
 
5.1.13 ELISA for HBeAg  
The ETI-EBK PLUS (HBeAg) (DiaSorin) ELISA kit is designed specifically to determine 
presence of HBeAg with high sensitivity. The 96 well ELISA plate is coated in mouse 
monoclonals that are specific for the HBeAg. 
•  Supernatant that was stored at -70°C was thawed on ice until f luid. Supernatant was 
diluted 1:20 with neat cell culture media (DMEM GlutaMAX™ media without foetal 
bovine serum) 
•  The plates were taken from the fridge, and allowed to reach room temperature, and 
then only removed from protective bag. Also allow all reagents to come to room 
temperature. 
•  Determine which samples go on the plate, their positioning, and the positioning of the 
controls. Only use the wells required for your number of samples and controls. For all 
experimental samples, three biological replicates and two technical replicates were 
loaded onto the plate. 
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Figure 5.4: Plate Layout for HBeAg ELISA 
The blank contains no incubation buffer, and no serum ie substrate only. The three 
calibrators (Cal 1, 2 and 3) are three replicates of a human serum/plasma non-reactive for 
HBeAg. The Negative control (Neg) is human serum/plasma non-reactive for HBeAg. The 
Positive control (Pos) is recombinant HBeAg expressed in E. coli.  
•  To each well add, first 50 μ l  of Incubation Buffer, except for the blank well (mix by 
shaking before use) and then add 100 μ l  of sample/calibrator/control. The Positive and 
Negative Controls are loaded in singlicate. Calibrators were loaded in triplicate and 
samples were aliquoted in duplicate (i.e. two wells each) onto the plate. Add samples 
first and then controls and calibrators. Incubation buffer should turn green upon adding 
the sample/calibrator/control.   
•  Cover the plate with provided cardboard sealer, tap the plate gently to get rid of air 
bubbles and mix (can put on shaker for 30 seconds), and allow to incubate at 37°C for 2 
hours. 
•  Just before the end of this incubation step prepare the Enzyme Tracer Solution (or 
Conjugate), prepare by diluting 1:50 with tracer diluent (i.e. add about 100 μ l  conjugate 
+ 4.9 ml tracer diluent). 
•  Remove the cardboard sealer and discard it, wash the plate 5 times by fi l l ing (±300 μ l )  all 
active wells with the Wash Solution, aspirate the liquid and allow to soak (±30 seconds). 
After the last round of washing invert the plate onto absorbent paper (blot), taking 
particular care on the last wash to tap out any residual Wash Solution. 
•  Add 100 μ l  of Enzyme Tracer Solution to each well except the blank well, add a new the 
cardboard sealing lid, and shake the plate on a shaker for 10 seconds. Incubate for 1 
hour at 37°C 
•  Remove the cardboard sealer and discard it, wash the plate 5 times by fi l l ing (±300 μ l )  all 
active wells with the Wash Solution, aspirate the liquid and allow to soak (±30 seconds). 
After the last round of washing invert the plate onto absorbent paper (blot), taking 
particular care on the last wash to tap out any residual Wash Solution. 
•  Add 100 μ l  chromogen/substrate solution into all active wells, and incubate for 30 
minutes at room temperature (but protect from light. 
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•  Add 100 μ l  Stop Solution to each well 
•  Measure absorbance immediately after adding Stop Solution at 450/630 nm, subtract 
the 630 nm reading from the 450 nm reading.  
 
CALCULATION OF RESULTS 
Each plate must be considered separately when calculating and interpreting results of the 
assay. Approved software may be used for calculation and interpretation of results. 
 
Quality Control 
•  Blank absorbance must be between 0.0000 and 0.150 
•  The Mean absorbance for the calibrator must be less than 0.120 and greater than -
0.020 nm 
•  The absorbance of the negative control must be less than 0.120 and greater than -
0.020 nm 
•  The absorbance of the positive control must be less than 2.500 and greater than 
0.500 nm 
•  The difference between the positive control absorbance and negative control 
absorbance must be greater than 0.450 nm (PC – NC > 0.450). If not the run is invalid 
and should be repeated. 
 
Cut-off Value 
Calculate the cut-off Value by adding 0.060 to the mean of the calibrator replicates. 
Cut-off Value = Mean (Cal) + 0.060  
Example 
Calibrators: Cal 1 = 0.071, Cal 2 = 0.075, Cal 3 = 0.069 
Mean Negative Control = (0.071 + 0.075 + 0.069)/3 = 0.072 
Cut-off Value = 0.072 + 0.05 = 0.122 
 
Note:  
The term biological replicates describes three separate samples of the same construct that 
were treated with the exact same experimental conditions but independently of one 
another. Whereas, technical replicates are when the exact same sample, collected after all 
experimental techniques are complete is analysed multiple times. 
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5.1.14 Supernatant and Cell Lysate Harvesting Protocol 
For Supernatants: 
Collect the supernatant, add to an equal volume of proteinase inhibitor buffer (which was 
made up as 1 tablet per 25 ml ultra pure water, i .e. f inal concentration is 1X PIC Buffer) in a 
Eppendorf tube. Transfer to -70°C for storage until DNA Removal Protocol was executed 
For Cell Lysates: 
Pre-cool the centrifuge to 4°C. Add 500 μ l  1% EDTA Sodium Chloride Solution and 75 μ l  
Trypsin EDTA to each of the 12 wells on the transfection plates, after supernatant has been 
removed. Incubate at 37°C for 5 minutes, then neutralise the trypsin by adding 600 μ l  of 
complete DMEM media. Transfer to a clean Eppendorf tube. Pellet the cells by centrifuging 
for 5 mins 800 RPM at 4°C. Wash 3 times with 1 ml of ice-cold Phosphate Buffered Saline 
(PBS). Add 200 μ l  of chilled RIPA buffer with 200 μ l  of PIC Buffer, incubate on ice for mins. 
Sonicate for 1 min the samples to break cells in rounds of 10 seconds, keep the samples on 
ice during sonication. Centrifuge at 12 000 RPM for 12 mins at 4° to pellet cell debris, 
transfer supernatant to a fresh Eppendorf tube without disturbing the pellet. Transfer to -
70°C for storage until DNA Removal Protocol was executed 
 
5.1.15 Pre Real-Time PCR Plasmid DNA Removal Protocol 
Thaw supernatants or cell lysates on ice for 30 minutes. Centrifuge at 22 000g or 12 000 
RPM for 5 minutes at 4°C, resuspend in best quality water (130 μ l ) .  Treat the supernatant 
with DNase I recombinant RNase-free Nuclease to remove double stranded plasmid DNA, 
and Mung Bean Nuclease to degrade single stranded DNA as indicated in Tables 5.8 and 
5.9. 
Tables 5.8 and 5.9: Components of Nuclease Digestion Reactions 
Component Quantity in μ l  
Supernatant 130 
10x Incubation Buffer 7,5 
10U/ul DNase I 1,5 
10x Mung Bean Buffer 7,5 
80U/μ l  RNase A (Mung Bean Nuclease) 1,5 
Nuclease Free Water (Best Quality Water) 2 
Total Volume in μ l  1 5 0  
 
Alternatively when using NEB Mung Bean Nuclease and DNase I: 
Component Quantity in μ l  
Supernatant 175 
NEB Mung Bean Nuclease Buffer 10  
NEB Mung Bean Nuclease 4 (1 μ l  for every 1 μg of DNA) 
10x DNase I Reaction Buffer 10  
NEB DNase I 1  (2 units for every 5 μg of DNA) 
Nuclease Free Water (Best Quality 
Water) 
0  
Total Volume 2 0 0   
 
 144 
Mix thoroughly and incubate at 37°C for 20 minutes. Stop the reaction by adding % 5 μ l  of 
0.2 M EDTA pH 8.0 (to a final concentration of 5mM) and incubate at 75°C for 10 minutes. 
Proceed with the Qiagen NucleoSpin® Tissue Extraction protocol (see above in section 
1.1.1) 
 
5.1.16 Imunnocapture Protocol to collect Secreted Viral DNA 
This protocol was developed by Samal et al., for the quantitation of HBV DNA in secreted 
virions in cell culture methods [207]. Supernatants collected on the third day post 
transfection were collected as outlined in 1.1.15. The supernatants were subjected to 
DNAseI and RNaseA for plasmid DNA removal as outlined above in 5.1.16.  
Add 100 μ l  of supernatant to the Monolisa™ HBsAg ULTRA plate, along with 50 μ l  of the 
conjugate solution (which is made up of kit solutions R6 and R7 and mixed thoroughly to 
homogenise the conjugate which is lyophilised).  
To allow binding this mixture was incubated at 37°C for 90 mins, and then washed 5 times 
with PBS. 
Treat the bound material with 10 μ l  Proteinase K and 100 μ l  of Lysis Buffer from the Qiagen 
NucleoSpin® Tissue Extraction Kit.  
Proceed with the Qiagen NucleoSpin® Tissue Extraction protocol (see above in section 
5.1.1) 
 
5.1.17 Real-Time PCR for Determining Viral Load 
Real-Time PCR Quantitation was carried out using a SYBR Green method. 
 Table 5.10: Real-Time Probes and Primers 
 
The standard curve was prepared using the pCH-9/3091 plasmid, which using 3 916 154.16 
g/mol as the molecular weight, 6.503 ng equates to 109 copies. Thus diluted the plasmid to 
6.503 ng/µl and made serial dilutions to get 108, 107, 106, 105, 104, 103, 102, 101 and 100. Then 
diluted these 1:5 to get these copy numbers per 5 µl [222].  
First both the PCR hood and the DNA hoods are treated with bleach, then distil led water 
and then 70% ethanol, followed by at least 30 minutes of UV light, in order to 
decontaminate the hoods. 
All components for were defrosted on ice, thawed primers, SsoFast™ EvaGreen® Supermix, 
extracted DNA and plasmid serial dilutions were kept on ice. 
The Master Mix was prepared as outlined in Table 5.11 
In each case, the controls included 
Primer: Sequence: 
HBVs F 5’- tgcacctgtattcccatc -3’ 
HBVs R 5’- ctgaaagccaaacagtgg -3’ 
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•  A positive control – Eurohep standard, a 106 HBV U/ml standard from the National 
Standards International Bank 
•  A negative control – extraction negative samples  
•  A reagent blank – no DNA template 
 
Table 5.11: Real-Time PCR Master Mix Contents 
R e a g e n t  I n i t i a l  
C o n c e n t r a t i o n  
V o l u m e  P e r  
r e a c t i o n  ( i n  μ l  p e r  
2 0  μ l  r e a c t i o n )  
F i n a l  
C o n c e n t r a t i o n  
SsoFast™ EvaGreen® 
Supermix 
2x 10  1x 
HBVs F and R 10 μM 1  0.5 μM 
Best Quality Water  0   
DNA  9   
Total  2 0    
F o r  S t a n d a r d s     
DNA  5   
Best Quality Water  4   
Total  2 0    
 
After adding all the contents of the Master Mix to a 2ml Eppendorf tube, the mixture was 
thoroughly mixed, and then 11 μ l  was aliquoted into the 96 well plate. Standards were 
loaded onto the plate in triplicate, 5 μ l  into each well. Extracted DNA samples were loaded 
in duplicate, 9 μ l  into each well. For all experimental samples, three biological replicates 
and three technical replicates were loaded onto the plate. 
 
 
Figure 5.5: Real-Time PCR Cycling Conditions 
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Note that a Melting Curve was added at the end of the run to confirm that primer binding 
was specific.  Reactions were placed in the CFX96™ Real-Time System with C100™ Thermal 
Cycler with the aforementioned conditions. Data was analysed on the CFX 96 BioRad Real-
Time System, and then exported into an Excel document for further statistical analysis. 
Sample results are reported in HBV U/ml, only values with an R2 value of 0.92 and above 
were considered significant. Also it was ensure that only runs with efficiency between 95 
and 105% were considered valid.   
 
Note:  
Biological replicates describes three separate samples of the same construct that were 
treated with the exact same experimental conditions but independently of one another. 
Whereas, technical replicates are when the exact same sample, collected after all 
experimental techniques are complete is analysed multiple times. 
 
 
 
  
 147 
5.2  Appendix B – Composition of Reagents and Solutions 
 
100x TAE Buffer (for gel electrophoresis) 
Dissolved 484 g of Tris buffer in 100 ml in ddH2O. Added 500 ml 0.5 M Na2 EDTA (pH 8.0) 
and 57.1 ml glacial acetic acid.  Adjusted volume to 1 L with ddH2O. Autoclaved at 121°C 
for 30 minutes, and allowed to cool. Stored at room temperature. Diluted to a 1×  working 
solution for gel electrophoresis by adding 10 ml of 100x TAE to 1 litres of ddH2O. 
 
PIPES Transformation Buffer: 
Add 1,47 g of CaCl2 (final concentration should be 100 nmol/l),  0.3g of PIPES.HCL power, 
15 ml of 100% glycerol to a 200 ml Schotts Glass. Add 50 ml of best quality distil led water, 
and pH to 7.0 using 1 M NaOH solution. Make up to 100 ml with best quality distil led water. 
Autoclave at 121 °C for 30 minutes, allow to cool. Store at - 20°C in the dark until use. 
 
NaOH Solutions 
For a 1 M solution add 4 g NaOH in 100 ml best quality water 
For a 10 M solution add 40 g NaOH in 100 ml best quality water 
Can be stored at room temperature 
 
Cracking buffer: 
Add 1% (w/v) SDS (2.5 g), 2 mM EDTA Disodium Salt (0.19 g), 400 mM Sucrose  (34.22 g), 50 
mM Tris-HCl, pH 6.8 (125 ml), 100 µg/ml RNase A, DNase- and Protease-Free (2.5 µ l ) ,  0.01% 
(w/v) Bromophenol Blue Sodium Salt for Electrophoresis (0.025 g), 0.01% (w/v) Xylene 
Cyanol FF (0.025 g).  
Use Best quality distil led water, add to make up to a final volume of 250 ml, after which it 
was stored at room temperature until use. 
 
Ampicil l in (100 mg/ml) 
Dissolve 1g ampicil l in powder in 10ml of best quality distil led water 
Filter steril ize into aliquots of 1 ml and store at –20oC 
 
Kanamycin (100 mg/ml) 
Dissolve 1g kanamycin powder in 10 ml of best quality distil led water 
Filter steril ise into aliquots of 1 ml and store at -20°C 
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0.2 M EDTA pH 8.0 Solution 
Add 7.44 g EDTA-2Na + 80 ml dH20  
Adjusted to pH 8.0 using 1M NaOH (10 ml of NaOH) 
Bring volume to 100 ml with dH2O 
Stir vigorously on a magnetic stirrer* 
Steril ize by autoclaving 
Store at room temperature 
*The disodium salt of EDTA will not dissolve until the pH of the solution is adjusted to 8.0 
by the addition of NaOH 
 
10% (0.5M) EDTA Solution 
Add 186.1 g of disodium EDTA (Na2EDTA) to 800 mL of dH2O 
Adjust the pH to 8.0 with 1M NaOH (~50 ml of NaOH) 
Bring volume to 1 L with dH2O 
Stir vigorously on a magnetic stirrer* 
Steril ize by autoclaving 
Store at room temperature 
*The disodium salt of EDTA will not dissolve until the pH of the solution is adjusted to 8.0 
by the addition of NaOH 
 
 
10% EDTA Sodium Chloride 
1 ml of 10% EDTA to 1L of Sodium Chloride Solution 
 
DMEM 
6.69 g of DMEM Powder 
1.85 g of Sodium Hydrogen Carbonate 
500 ml of SABAX or sdH20 
Mix all ingredients thoroughly and then filter steril ize 
Store at 4°C until use 
 
Foetal Calf Serum (FCS) 
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Filter steril ize as needed (8 ml at a time usually works) 
 
Complete Medium (10% Serum, 2x Streptomycin) 
For 50 ml of medium: 
44 ml of DMEM 
5 ml FCS (fi lter steril ized) 
1 ml 100x Streptomycin 
 
Huh7 Freezing Solution 1 (F1) (20% Serum) 
8 ml DMEM 
2 ml FCS 
Huh7 Freezing Solution 2 (F2) (20% Serum, 20% DMSO) 
6 ml DMEM 
2 ml FCS 
2 ml DMSO (sterile) 
 
100x cOmplete PIC solution 
Dissolve 1 tablet in 25 ml of sdH20, vortex til l  tablet is completely dissolved.  
Store at 4°C 
 
1x PBS Buffer 
For 1000 ml 
1.42 g of 10 mM Na2HPO4 
0.22 g of 1.8 mM NaH2PO4  
8.19 g of 140 mM NaCl 
Adjust to pH 7.4  
Make up to 1000 ml 
 
Ripa Buffer 
For 1000 ml: 
50 ml of 50 mM Tris-HCl, pH 7.4 
 150 
8.76 g of 150 mM NaCl 
10 ml of 1% Triton X-100 or NP-40 
5 g of 0.5% Sodium deoxylcholate   
1 g of 0.1% SDS 
2 ml of 1 mM EDTA (0.5M stock) 
0.42 g of 10mM NaF 
Make up to 1000 ml 
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5.3  Appendix C – Complete Plasmid Maps  
 
Figure 5.6: The pIDT-Blue Plasmid with Synthesized SHH011A Fragment 
A 709 bp fragment was synthesized by IDT and placed within the pIDT-Blue backbone for 
subcloning purposes. This is after multiple attempts to amplify the S region from this 
patient serum failed. Note that the fragment is flanked by two XbaI sites for ease of 
subcloning. 
 
Figure 5.7: The pIDT-Blue Plasmid with Synthesized SHH045A Fragment 
A 772 bp fragment was synthesized by IDT and placed within the pIDT-Blue backbone for 
subcloning purposes. This is after multiple attempts to amplify the S region from this 
patient serum failed. Note that the fragment is flanked by two XbaI sites for ease of 
subcloning. 
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Figure 5.8: The pIDT-Blue Plasmid Without Insert 
This is the plasmid that was used as the backbone for the synthesized genes. It is a high 
copy vector of 2951 bp in size, with an ampicill in resistance gene.  
 
 
Figure 5.9: The pEGFP-C3 Plasmid with Green Fluorescent Protein Gene 
Green Fluorescent Protein is and inherently fluorescent protein that is used here as a 
reporter in order to calculate transfection efficiency. Huh7 cells successfully transfected 
with this protein can be visualised directly using a fluorescent microscope. Transfection 
efficiency is then calculated, depending on the amount of GFP fluorescence.   
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Figure 5.10: The pTZ57RT Cloning Vector 
Shown here as a closed circular vector, which is how it was used and a positive 
transformation control. However, in the InsTAclone kit, it is also available as a linearised 
vector (pTZ57R/T) which is used for direct insertion of a PCR amplicon with TA ends. 
 
Figure 5.11: The pcDNA™ 4/TO Cloning Vector 
This plasmid was used as the backbone for the overlength clone constructs.  
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Figure 5.12: The A12C15_OL A1WTSA 1.28 MER Overlength Clone 
This clone has a 1.28 MER overlength Subgenotype A1 wild type HBV within the pcDNA™ 
4/TO backbone. The 1.28 MER HBV segment contains a full Polymerase, full S gene, as well 
as two times PreCore, Core and X Open Reading Frames (ORFs). Please note there are three 
XbaI sites. 
 
 
Figure 5.13: The A12C15_OL A1WTSA 1.28 MER Altered 9.3 Clone 
This clone stil l  contains an unaltered 1.28 MER overlength Subgenotype A1 wild type HBV 
within the pcDNA™ 4/TO backbone. However the backbone was restricted with ApaI and 
NotI, and the resulting ends were blunted. After re-ligating this construct the undesired 
XbaI site in the vector was removed. 
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Figure 5.14: OL_DELMUT SHH011A-F Clone 
In this construct a portion of the SHH011A S gene (pink arrow) was inserted using the two 
remaining XbaI sites. Here SHH011A is in the correct orientation. 
 
 
Figure 5.15: OL_DELMUT SHH011A-R Clone 
In this construct a portion of the SHH011A S gene (purple arrow) was inserted using the two 
remaining XbaI sites. Here SHH011A is in the incorrect orientation. 
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Figure 5.16: OL_DELMUT SHH045A-F Clone 
In this construct a portion of the SHH045A S gene (purple arrow) was inserted using the two 
remaining XbaI sites. Here SHH045A is in the correct orientation. 
 
 
Figure 5.17: OL_DELMUT SHH045A-R Clone 
In this construct a portion of the SHH045A S gene (purple arrow) was inserted using the two 
remaining XbaI sites. Here SHH045A is in the incorrect orientation. 
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Figure 5.18: OL_DELMUT SHH167A-F Clone 
In this construct a portion of the SHH167A S gene (pink arrow) was inserted using the two 
remaining XbaI sites. Here SHH167A is in the correct orientation. 
 
 
Figure 5.19: OL_DELMUT SHH167A-R Clone 
In this construct a portion of the SHH167A S gene (purple arrow) was inserted using the two 
remaining XbaI sites. Here SHH167A is in the incorrect orientation. 
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Figure 5.20: OL_DELMUT SHH193A-F Clone 
In this construct a portion of the SHH193A S gene (pink arrow) was inserted using the two 
remaining XbaI sites. Here SHH193A is in the correct orientation. SHH193A contained no 
deletions and was thus used as a wild type control. 
 
 
 
Figure 5.21: OL_DELMUT SHH193A-R Clone 
In this construct a portion of the SHH193A S gene (purple arrow) was inserted using the two 
remaining XbaI sites. Here SHH193A is in the incorrect orientation. SHH193A contained no 
deletions and was thus used as a wild type control. 
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5.4  Appendix D – Ethics Clearance Certificate 
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5.5  Appendix E – Molecular Weight Markers 
 
Figure 5.22: DNA Molecular Weight Markers Used for this Study 
The 1kb Promega Ladder (A) was used for to determine the size of the products of the 
initial HotStart and some high fidelity PCR reactions. The GeneRuler™ 1 kb DNA Ladder (B) 
was used for most high fidelity PCR reactions, all cracking, digestion reactions and ligations, 
as well as for most restriction mapping. The GeneRuler™ DNA Ladder Mix (C) was used to 
determine concentration after Gel purification and after restriction mapping (prior to 
ligations) in addition to NanoDrop spectrophotometry. The 1kb Plus DNA GeneRuler™ (A) 
was used for some of the restriction maps. 
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5.6  Appendix F – Protocols for Phylogenetic Tree Production 
 
Standard Operating Procedures for Phylogenetic Analysis using Neighbor-Joining Methods 
with Bootstrapping 
1.Multiple Sequence Alignment (MSA) 
Prepare a multiple sequence alignment of all sequences for analysis using a program of 
your choice (ClustalW, Muscle, MEGA, BioEdit, CLC Main Workbench). Check the alignment 
by visualising it in a multiple sequence alignment viewer (AliView, SeaView, GeneDoc, 
BioEdit, MEGA, CLC Main Workbench), and curate sequences as necessary (verify INDELS 
and wobble bases). 
 
2.Create a Phylip fi le 
Use either GeneDoc, Mega or CLC Main Workbench to export your MSA as a phylip fi le with 
the extension .phy 
 
3.Run the Tree through Pipeline: TreeMail 
Submit the phylip fi le you just created to Pipeline: TreeMail online at 
http://hvdr.bioinf.wits.ac.za/treemail/). Select Neighbor-Joining 1000 bootstrapping 
replicates and press Run TreeMail. The result is emailed to you. 
 
4.Creating a Publication Ready Tree 
Open the final tree (output from Pipeline: TreeMail, a .tre fi le) in FigTree (or TreeView). For 
correct display of your tree select Node and under Node Labels, set display to posterior, 
and make sure the scale bar reads 0.02 (2% divergence), Your Order must be decreasing. 
 
Standard Operating Procedures for Bayesian Analysis using BEAUti and BEAST – Procedure 
for producing a Maximum Clade Credibility Tree: 
 
1.Multiple Sequence Alignment (MSA) 
Prepare a multiple sequence alignment of all sequences for analysis using a program of 
your choice (ClustalW, Muscle, MEGA, BioEdit, CLC Main Workbench). Check the alignment 
by visualising it in a multiple sequence alignment viewer (AliView, SeaView, GeneDoc, 
BioEdit, MEGA, CLC Main Workbench), and curate sequences as necessary (verify INDELS 
and wobble bases). 
 
2.Quick Check using Maximum Likelihood Tree 
Run the MSA (FASTA, Phylip or Nexus/PAUP) through Garli to check the tree. Garli 
produces a Maximum Likelihood (ML) tree. Open this tree in FigTree or TreeView. Garli 
does not accept Nexus fi les from CLC Main Workbench. All l ines in a Nexus fi le, which 
contain square brackets, must be deleted. This should be done in a standard text editor, 
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such as Notepad (Windows) or TextEdit (Mac). Check that the ML tree looks “reasonable” 
and that all sequences, which should appear on this tree, are included. 
Note: Garli does not accept long sequence names, thus edit sequences names to be 
Genotype, Accession number and country only eg. A1_AY233090_SA 
Note: On Mac to Run Garli… 
Set up your Garli bin folder which should contain your FASTA/Nexus fi le of your MSA, make 
sure the fi le name and output name is correct in your config fi le 
Open Terminal and direct to the correct cd to run your Garli  
 
3.Create a Nexus File 
Open the MSA FASTA file in MEGA, export it as a Nexus/PAUP file (.nxs or .nex or .nexus). 
CLC Main Workbench does not export a valid Nexus fi le, so use MEGA instead. Open the 
Nexus fi le in Notepad (Windows) or TextEdit (Mac) and delete all l ines containing square 
brackets. 
 
4.Model Test 
At this stage you can run a Model Test using either a FASTA or Nexus fi le of your alignment, 
a Model Test allows one to carry out statistical selection of best-fit models of nucleotide 
substitution JModelTest or PAUP* are two of the software packages that can be used for 
this purpose. Import your fi le, select l ikelihood calculations, and then run/execute the 
model test. This will tell you which statistical model is best applied to your data set. 
However it has been shown in the past that the generalised time-reversible (GTR) model is 
best suited to HBV. 
 
5.Create a BEAUti fi le 
This is the most important step, as this dictates the Bayesian analysis parameters, such as 
the evolutionary model, the log normal and exponent settings. Open BEAUti, go to File è  
Import Data è  Select your Nexus fi le. 
Choose appropriate settings: 
Under Sites, select the GTR evolutionary model, for Base Frequencies select Estimated, and 
under Site Heterogeneity Model select Gamma + Invariant Sites  
(Thus the model is GTR + I + G) 
Under MCMC select length of chains (10 000 000 is usually acceptable) 
You will run BEAUti twice, 1st to establish your log normal .xml fi le (Select Clocks and under 
Model select log normal relaxed clock) and the 2nd time to establish your exponential .xml 
fi le (Select Clocks, and under model select exponential relaxed clock) 
At this stage you can save this BEAUti fi le, and it will  save your settings, so you can save 
one for log normal and one for exponential if you wish. It may also be useful to save the log 
normal fi les into one folder and exponential f i les into another folder.  
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6.Run BEAST 
This programme will create many possible trees. Later, Tree Annotator is used to select the 
best tree (most supported tree). You will run BEAST twice, once with your log normal fi le 
and then again with your exponential f i le. 
Open BEAST è  Select XML file è  Run. The input for BEAST is the XML file created by 
BEAUti. BEAST takes around 5.5 hours to process 10 mill ion chains for 225 samples. 
Copy or rename the “log” and “tree” files from the first BEAST run, and then run BEAST 
again with the second XML file. (Or put your log and exponential f i les in separate folders) 
 
7.Use Tracer to Identify the best Model  
Import the .log fi les of both the log normal and the exponential runs from BEAST. Select 
the posterior statistic. 
Under the Marginal Probability Distribution tab, make sure your distribution is a normal 
distribution (i.e. not skewed). Under the trace tab, make sure your trace/hairy caterpillar is 
relatively level (not uneven in height or density). The burn in should appear as grey. 
Under the Estimates tab, check the effective sample size (ESS), an acceptable ESS is > 100 
however an ESS ≥  200 is desirable. 
Compare the two files’ AICM values by selecting both, click on analysis, and select Model 
Comparison [103], this may take some time  
Ultimately you should choose the fi le with the option (log normal or exponential) with the 
highest ESS and the lowest AICM to be the fi le you work on for your final tree. You should 
also identify you HPD percentage and include this in the legend under your tree. 
 
8.Find the ‘Best’ Tree or Single Target Tree 
Open Tree Annotator è  Select Burn-in as 10 (%) i.e. 1000 trees and set posterior 
probability as 0.5%. Choose the input fi le (which will be the BEST result, either the log 
normal or exponential .trees fi le, depending on which one scored best in step 7). Create a 
name for your output fi le, and select a destination for the result. Press Run 
 
9.Creating an Publication Ready Tree 
Open the final tree (out put from Tree Annotator) in FigTree (or TreeView). 
For correct display of your tree select Node and under Node Labels, set display to posterior, 
and make sure the scale bar reads 0.02 (2% divergence), Your Order must be decreasing. 
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5.7  Appendix G – Complete List of Sequences Used for 
Phylogenetic Trees 
Other than the sequences or the quasispecies and their parental strains, the 
PreS1/PreS2/Surface section of sequences from all 9 genotypes were used as reference 
sequences. 
Table 5.12: Reference and Genotype Sequences Used for Phylogenetic Trees 
 
 GenBank 
Accession 
Number  
Country of  
Origin 
  GenBank 
Accession 
Number  
Country of  
Origin 
Subgenotype A1 AY233288 South Afr ica Genotype C JN315779 Korean Mummy 
AY233284 South Afr ica AB014376 Japan 
AY233281 South Afr ica AY066028 China 
AY233277 South Afr ica AF458664 China 
AY233279 South Afr ica AY057947 Tibet 
AY233276 South Afr ica AB117758 Cambodia 
AY233287 South Afr ica AB112066 Myanmar 
AY233278 South Afr ica AY167099 Taiwan 
AY233289 South Afr ica AB112065 Vietnam 
AY233283 South Afr ica AB112472 Thai land 
AY233282 South Afr ica AP011107 Indonesia 
AY233285 South Afr ica HM011493 Indonesia 
AY233288 South Afr ica AP011108 Indonesia 
AY233290 South Afr ica X75656  Polynesia 
AY233275 South Afr ica X75665 New Caledonia 
AY233274 South Afr ica AB493842 Indonesia 
AB246336 South Afr ica AB554020 Indonesia 
AY903452 South Afr ica AB554018 Indonesia 
AB116085 Bangladesh AB644287 Indonesia 
JQ023661 Colombia AB540583 Indonesia 
KJ854687 Brazi l  AB241109 Phi l ippines 
AB453988 Japan AB048704 Austral ia  
AF043560 Argentina Genotype D FJ386590 China 
AY934771 Somalia FJ904415 Tunis ia 
AB116094 Phi l l ipines JN642129 Lebanon 
AB076678 Malawi GU456684 Iran 
FJ692592 Hait i  JF754629 Turkey 
FM199974 Rwanda AY233296 South Afr ica 
Subgenotype A2 AY233286 South Afr ica X85254 Ita ly 
Z35717 Poland GQ922000 Canada 
Z72478 Germany AB048701 Austral ia  
AF537371 USA FJ692532 Hait i  
AJ344115 France FJ904438 Tunis ia 
Subgenotype A3 FJ692554 Nigeria FJ904394 Tunis ia 
GQ161813 Guinea AB03358 Japan 
AM180624 Cameroon GQ205378 India 
Genotype B AB073831 Thai land Genotype E X75664 Senegal 
AF282918 China AB091255 Cote d’ Ivoire 
AB073836 Taiwan Genotype F DQ823092 Argentina 
AB115551 Cambodia X69798 Brazi l  
AB073835 Vietnam AY090455 Nicaragua 
AB033555 Sumatra AF223965 Argentina 
M54923 Indonesia X75658 France 
AB241117 Phi l l ippines AY090461 El  Salvador 
AB010291 Japan AY090458 Costa Rica 
DQ463797 Canada Genotype I  EU833891 Canada 
DQ463801 Canada FJ023666 Laos 
 DQ463799 Canada AF241407 Vietnam 
   EU835241 India 
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